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Thesis Summary 
In the first chapter of this thesis an investigation of the influence of cellulose type II in the 
drug release from a coated tablet is presented. The cellulose II product can be obtained by 
mercerization (chemical treatment with sodium hydroxide) from cellulose I (e.g. Avicel 
PH102) and is suitable to be used in tableting as a multipurpose excipient. Once organic 
solvents have been avoided in the pharmaceutical industry it was decided to apply an 
aqueous coating dispersion. As this polymorphic form of cellulose also acts as a super 
disintegrant, carrying out an aqueous coating process could be a challenge. The model 
drug used was the poor water-soluble proquazone, a BCS class II drug.  
First of all, the manufacture of the tablet core was already a challenge in itself due to the 
powder mixture being not flowable enough to be used in a rotary tablet press, in which the 
feed system is basically a simple hopper. To overcome this undesirable situation a wet 
granulation process was executed, and for monitoring the process, as well to study the 
powder agglomeration behavior, power consumption method was applied. The decision of 
to use this method as a monitoring tool during the wet granulation process originated further 
studies, that are shown and compose the second chapter of this thesis. The power 
consumption showed to be a very useful tool to monitor and control the granulation in real-
time. Complete powder and granules characterization was done and is presented. 
Compaction studies were not the focus of this work.  Nevertheless, they had been executed 
in other prior studies cited in the references. The tablet cores manufactured were 
characterized and showed to be robust enough to surpass the coating process. The initial 
idea of use a pan coating (a process that is known to be gentler and causes less damage to 
the cores) was shifted to a lab scale fluidized bed because of the load of tablets necessary 
to pan coating be much larger than for the fluidized bed. Tablet cores composed of high 
amounts of cellulose II were sensitive to the aqueous coating, which could be identified by 
the coating defects found. However, the process could be optimized and the source of 
defects eliminated adjusting parameters such as the sprayed droplets size, spray rate, bed 
temperature, and total solids content in coating suspension, for example. Those actions 
reduced the contact time between the core and water, minimizing water penetration, and 
thus avoiding some damage on the core surface and/or premature core disintegration. In 
principle, different aqueous coating systems were used: Eudragit® RS and RL and 
Aquacoat® ECD. The drug release studies showed that methacrylic copolymers were more 
flexible and kept the integrity of the reservoir, promoting a more sustained drug release 
through the pores. On the other hand, the ethylcellulose polymer was brittle and did rupture, 
promoting a burst drug release. After these results, the decision of continue further studies 
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with Aquacoat® ECD was taken, in order to investigate the application of the cellulose type II 
as a hygroscopic and expansive agent for pulsatile drug-release systems.  
Many coating levels were applied in cores of three formulations (composed of different 
ratios of drug:excipient). The presence of a pore former (hydroxyproprylmethylcellulose) in 
the coating layer was also analyzed. The lag time before coating rupture was shown to be 
directly proportional to the coating thickness and inversely proportional to the amount of 
pore former. It showed also to be directly dependent to the level of cellulose type II present 
in the cores. Higher ratios of the multifunctional excipient promoted faster, and probably 
larger, water uptake leading to an increase of internal osmotic pressure responsible for the 
separation of the coating from the core and for the core erosion. Except for a delay, the 
release kinetics of the drug contained in the core was not significantly influenced by the 
presence of the rupturable barrier, but instead for the erosion and disintegration of the core. 
Using model-independent approaches it could be confirmed that the release of the drug 
after coating rupture happened fast, in a single pulse. According to percolation theory, the 
tablet core consists of clusters of particles which form a network. This theory provided 
useful explanations to describe the composition and formation of the tablet and the 
distribution of the pores and particles within it. It could be concluded that use of cellulose II 
polymorph can be a good opportunity to develop a simple modified-drug-delivery-system, 
able to facilitate a rapid drug release after a lag time, and based on approved and well 
known excipients and also applying conventional and non-expensive processes. 
 
On the second chapter of this thesis an investigation of the influence of drug load, liquid 
addition rate and batch size on the power consumption profile recorded during a high shear 
mixer granulation is presented. In the pharmaceutical industry the moist agglomeration 
process by high-shear mixing is a critical unit operation that remains more of ‘an art’ than a 
science-based approach. Because of the difficulties associated with the direct measurement 
of particle characteristics, such as particle size distribution, moisture contents and 
deformability, some indirect monitoring parameters have been adopted as the indicators of 
particle characteristics. A commonly accepted monitoring parameter in the pharmaceutical 
industry is the equipment power consumption technique.  
The materials used in this study were the wide-spread filling microcrystalline cellulose and 
the poor water-soluble drug paracetamol. In all formulations hydroxypropylmethylcellulose 
was added as a dry binder into the mixture, and distilled water as the granulation liquid. The 
equipment was a lab scale high-shear mixer with 10 liters of volume. The power 
consumption of the mixer motor (i.e. main impeller) was measured by a transducer, 
converted into an electric potential signal, sampled by a multifunction card to a laptop 
computer, and displayed graphically by an “in process” computer calculation program.  
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In order to investigate the influence of drug load three formulations were designed 
containing different ratios of drug:excipients. For the liquid addition rate comparison, the 
granulation liquid was added using a peristaltic pump under constant addition speeds, two 
main ones, until the powder mixture become a slurry. Finally, the influence of working 
vessel filling in the powder agglomeration, and thereafter in energy consumption profile, 
was studied loading the equipment with different batch sizes.  A complete starting material 
characterization is presented as well as a granule size analysis comparing formulations and 
the influence of the different compounds ratio in the behaviour of agglomerates growth 
kinetics. Also here, percolation theory could be applied to describe the growth behaviour 
and granules properties. The mass liquid saturation, expressed by the amount of liquid (pi2) 
and the degree of saturation (pi), were calculated for the entire process and used to 
compare different moments of the granulation and also facilitate the comparison among 
formulations. For better understanding of the process the dimensionless Power Number 
(pi1) which is applied to analyze process similarities between different scales was calculated 
too.  
It was found that the powder physicochemical properties strongly affect the liquid saturation, 
by influencing the amount of liquid penetration and the free surface liquid which is 
necessary for the coalescence of primary particles and/or agglomerates, and consequently 
affecting the power consumption profile. Those influences also affect the rate of granule 
breakage wherefore affecting the energy consumption too. Thus the drug load showed to be 
the most influential factor on power consumption measurement. The measurement of power 
as defined by the parameters S3, S4, S5 was practically independent of the batch size. The 
granulation liquid requirement was linearly dependent of the mass loaded. The liquid 
addition rate made a slight impact on the total amount of water used in the process, and in 
the granulate growth kinetics. The granules cumulative weight fractions of the three binary-
mixtures at a fixed pi-value presented similarity but it was dependent of the proportion of the 
compounds. The “in process” measurement of power consumption showed to be a reliable 
analytical tool for monitoring the moisture content and particles agglomeration growth, thus 
making it a science-based real-time control.  
 
From the data generated in the granulation studies another question arose: Would be 
possible to predict the power consumption curve? The conclusion is given in the third 
chapter of this thesis.  
In a collaboration project with University of Belgrade the use of an Artificial Neural Network - 
ANN software to predict the characteristics of a wet granulation process was studied. The 
initial aim of using an expert system was to try directly predict the profile of power 
consumed during a granulation process; using as inputs (data used to supply the system 
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with information)  properties of the starting material as well as process variables. After some 
weeks learning how to work with the artificial intelligence software, an extra time was 
dedicated in the first step of building a network: the data mining. In the so called 
‘preprocessing’ step data preparation is carried out. That is a fundamental and very 
important step once that the software will learn by observation of the data presented to it. 
Which data and how to input it will make big differences in the resulted output (feature(s) 
that you want to predict). As inputs six formulation and process parameters were chosen, 
named Time (in minutes), Drug concentration, MCC concentration, HPMC concentration (all 
in % by weight of total formulation), Batch Size (grams) and Granulation-Liquid Added 
(grams). The output was the absolute power value (watts). Each of those features 
represents one column and the data/values were arranged in the rows and sorted in an 
ascending order, i.e. in a time sequence. All experiments were collated in a single excel 
sheet and converted to a CVS file. From the overall data an amount equivalent to 14.25% 
was selected for validation of the system, it corresponded to 3 experiments. As the 
experimental values were a time series, i.e. they are in time sequence, the order of the data 
is important to avoid that the software when taking a value doesn’t break the sequence, 
leading to a misunderstanding/misinterpretation of the data. Other 3 experiments (one for 
each formulation) were kept out of the inputted data set in order to be used to test the 
trained system.  After to input the data into the system evaluations over the raw data itself 
were carried out such as linear correlation between features, frequency histograms, 
clustering visualizer (Self-Organizing Map), values plotted versus samples as well as ƒ(x)=y 
plots. From these tools of data mining was decided to remove the HPMC concentration as 
an input, once that it showed to have no influence over the output. It was due this excipient 
be present at the same concentration in all experiments. As the data is a time series 
sequence of values, in the network design step a dynamic network was selected from the 
software snippet library. After properly connecting all the blocks creating the network 
topology, the system was trained in different ways looking for the most suitable training 
parameters for that specific data set and specific network. The more relevant changes were 
found to be in the choice of how many samples to take in to account for each update of the 
system parameters, i.e. the batch length. Preferably the batch length should be chosen so 
that the full length is a multiple of the batch length. Failing to have it can result in samples 
being cropped. In order to avoid the samples being cut a batch length of 1 was chosen. This 
choice could result in slowing down the system as it results in more updates per epoch, 
however it can help to avoid local minima and make up the lack of precision. Another 
relevant point during training was the amount of times that the collection of all available 
samples (rows) enters the system, called epoch, and is the same as iteration (repetition). 
When one epoch has passed, the adaptive system has been presented with the available 
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data once. Many epochs are usually required to fully train the system. However for small 
amount of samples the system can become over-trained easily and hence not being able to 
execute reliable generalizations. The number of epochs was kept small. Different snippets 
(that are fragments of networks) were analyzed and the one that showed reduced error and 
better predictions was a so called Gamma-Recurrent Hybrid network (after be optimized 
using a genetic algorithm). After training, the system was tested using the 3 experiments left 
out of the inputted data set. The resulted predictions showed that the aforementioned 
network was able to satisfactory predict the power consumption curve of formulations 
containing higher amounts of excipients. For the formulation with higher drug load (90% w/w 
of paracetamol) the predictions were unsatisfactory. It was not possible to predict the 
accentuated slope, plateau and faster drop in the power consumption for that formulation. 
The experimental granulation process executed for the higher drug load formulation 
generated more irregular power consumption curves/profiles and that wide variability among 
the inputted samples could result in a difficult learning from the system, and can be the 
reason for the lack of network precision in predicting the behaviour of this formulation. Post-
processing tools were also used to evaluate the system performance. The absolute error for 
the prediction of the power consumption value was 76,35; relatively small compared with 
other systems tested. The output prediction accuracy of +/- 201.34 was within the desired 
95% confidence. A sensitivity analysis, i.e. how much the output changes if an input feature 
is changed at certain percentage, was done and is discussed in the results. Another way to 
work with the granulation power consumption using an ANN was tested. Submitting as 
inputs some formulation properties as drug concentration, excipient concentration, bulk 
density and residual moisture of the power mixture, batch size and equipment filling fraction 
as well as the granulation liquid addition rate, it was tested the ability of an adaptive system 
to predict the relevant S2, S3, S4 and S5 points of a typical Leuenberger power 
consumption profile. The networks that resulted in higher values in the R2 coefficient are the 
generalized one layer and generalized two layer. They are extensions of the standard Multi-
Layer Perceptron, a basic static feedforward backpropagation neural network. The systems 
were trained for a very short time and using small batches. No optimization was necessary.  
Predicting the future output of very complex systems is a difficult task. Adaptive systems 
however have shown themselves, trained on the right data, quite capable of producing good 
predictions. They perform consistently better than more traditional methods. 
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First Chapter 
Application of cellulose type II in a pulsatile drug delivery system. 
 
Abstract 
Microcrystalline Cellulose, and its modifications, is a well known and widely used excipient in the 
pharmaceutical industry. Cellulose II product, that is obtained by mercerization from cellulose I 
polymorph, shows to behave as a multifunctional excipient, working as both a filler and super 
disintegrant. The objective of the presented work was to investigate the possibility to create a 
Pulsatile Drug Delivery System based on Rupturable Coating using the cellulose II polymorph as a 
hydration agent, as well as to check the behavior of this super disintegrant during an aqueous 
coating process. Three binary mixtures containing cellulose II and proquazone, a poor water soluble 
drug, were produced in different proportions. The amounts of cellulose II in the mixtures were 08, 48 
and 88 percent (w/w). In all formulations 2% of Hydroxypropylmethylcellulose was added as a dry 
binder into the mixture. Granules in a range of 125 - 710µm of particle size were collected after the 
wet granulation of the powder mixtures using a lab scale high shear mixer and distilled water as the 
granulation liquid. Power Consumption method was used to monitor the granulation process. 
Granules were compacted into tablets using a Korsch® rotary press. The deep concaved tablet cores 
were coated in a bottom spray lab scale fluidized bed coater with Eudragit RS® 30D, Eudragit RL® 
30D and Aquacoat ECD® 30%. Subsequently the drug release profile was analyzed. The results 
showed that an aqueous-based coating process is possible even in a core composed of high loads of 
a super disintegrant when the proper parameters are set. Special care must be taken regarding the 
inlet air temperature, atomizing air pressure and spray rate. The release of the drug showed to be 
dependent on the coating polymer type, the thickness of the coating layer and tablet core 
composition. A sustained drug release with no lag time was obtained using different mixtures of 
Eudragit® polymers. A delayed drug release, with a sigmoidal curve, and presenting different lag 
times according to the coating thickness, was obtained with Aquacoat. With thinner coating layers the 
lag time (between the tablets containing 48 and 88 percent of cellulose II) were similar, showing the 
influence of this excipient in the core swelling and coating disruption. These findings highlight 
cellulose II to be used in the development of a pulsatile drug delivery system, based on approved 
and well known excipients while continuing to use conventional processes. 
 
Keywords  
Cellulose type II, multifunctional excipient, super-disintegrant, aqueous coating, pulsatile drug 
delivery system, chronotherapy.  
 
C H A P T E R  I  – T H E O R E T I C A L  S E C T I O N  
 
Elaine Darronqui 
 
- 16 -
1 Theoretical Section 
“A drug is not given to man. What is given is a preparation containing the drug” (A.H. Beckett). 
 
1.1 Pharmaceutical powders – Excipients 
Excipients are components of a finished drug product other than the active pharmaceutical 
ingredient (API) and are added during formulation for a specific purpose. Although listed as 
inactive ingredients by FDA (Food and Drug Administration), excipients generally have well-
defined functions in a drug product. As with active ingredients, they may be small molecule 
or complex and may vary in terms of degree of characterization. They may be chemically 
synthesized or may be either natural source or biotechnology-derived (recombinant). In 
contrast to active ingredients, minor components of an excipient may have significant 
impact on its pharmaceutical performance (U.S. Pharmacopeia, 2007). The term ‘inert’, 
used alone, is not suitable anymore to describe pharmaceutical excipients.  
 
Pharmaceutical excipients are a very diverse group of materials. They cover all the states of 
matter: gas, liquid, semi-solid and solid. According to Baldrick (2002) excipients include 
diluents, fillers and bulking agents, binders and adhesives, propellants, disintegrants, 
lubricants and glidants, colours, flavours, coating agents, polishing agents, fragrances, 
sweetening agents, polymers, and waxes. A review of the literature indicates approximately 
1300 excipients used in the pharmaceutical industry. They can be used in a variety of 
dosage forms, and some may be used for more than one route of administration. Excipients 
provide a wide variety of functions, such as: to improve processability of APIs into dosage 
forms, tablet binding and disintegration, better API stability, solubility and bioavailability. 
 
A large proportion of pharmaceutical API and excipients are in the powder form. The 
manufacture of such products involves processes such as crystallisation and size reduction 
followed by formulation, agglomeration, compaction and tabletting. It is well-known in 
practice that these processes can greatly influence the chemical activity and physical 
properties of the final product. Thus, pharmaceutical powder technology plays a major role 
in the manufacturing process. 
 
The solid-handling properties of a bulk mass are influenced by any factor that can have an 
effect on the particle–particle interactions of constituent particles. Factors associated with 
the nature of the particles and their surfaces such as size, shape, surface morphology, 
packing conditions, and interparticle forces must therefore be considered. To make the 
situation more complex, the interparticle forces can be of a number of types: mechanical 
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forces, surface tension, electrostatic forces, van der Waals forces, solid-bridge forces, or 
plastic welding forces; none of these can be readily quantified (Howard, 2002). 
 
Two of the most common processes that a powder, or more often a mixture of different 
powders, undergoes in the pharmaceutical field, are the ones involved in the manufacturing 
of solid dosage forms, e.g., granulation and compaction. More detailed explanation about 
wet granulation process is given in the second chapter of this thesis, as well as Power 
Consumption method as a granulation process monitoring tool. 
 
The process of compaction involves subjecting the materials to stresses causing them to 
undergo deformation. The reaction of a material to a deformation stress is dependent on 
both the mode of deformation and the mechanical properties of the material (Rowe and 
Roberts, 1996). 
 
That all excipients are neither truly inert nor inactive is shown by the fact that drug-excipient 
interactions can considerably affect the physiological availability of many drug products 
(Monkhouse, 1972; Jackson et al, 2000). By either accelerating or retarding the release of 
the active ingredients, excipients can affect the therapeutic performance of the drug by 
increasing or reducing bioavailability. Indeed, the properties of the final dosage form (i.e. its 
bioavailability and stability) are, for the most part, highly dependent on the excipients 
chosen, their concentration and interaction with both the active compound and each other. 
No longer can excipients be regarded simply as inert or inactive ingredients, and a detailed 
knowledge not only of the physical and chemical properties but also of the safety, handling 
and regulatory status of these materials is essential for formulators throughout the world. In 
addition, the growth of novel forms of delivery has resulted in an increase in the number of 
the excipients being used, and suppliers of excipients have developed novel excipient 
mixtures and new physical forms to improve their properties (Rowe et al, 2006). 
 
Such roles may reflect the definition of an excipient in the U.K. legislation on medicines as 
“any substance which does not contribute directly to the pharmacological action of the 
medicinal product otherwise than by regulation of the release of the active ingredients” 
(Medicines Order, 1997). 
 
1.2 Multifunctional Excipients and disintegrant aids 
 
Functionality of an excipient refers to desirable properties that aid manufacturing and 
improves the quality and performance of a medicinal product, according to the International 
Pharmaceutical Excipients Council of the Americas and U.S. Pharmacopeia. In another 
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words, excipients are included in the formulation because they possess properties that, in 
conjunction with the processing, allow the medicine to be manufactured and to meet the 
required specification. 
 
Following this thinking, “multifunctional” excipients are the ones that combine two or more 
functions inside a formulation usually provided by single ingredients, such as glidants, 
lubricants, antiadherents, binders, or disintegrants. The terms multifunctional and high-
functionality excipients are quite often misused, according to Moreton. For example, a 
material suitable for multiple processes is not the same as saying it is multifunctional in a 
formulation (Rios, 2006).  
 
Defining the functionality of an excipient may not be as easy as it seems. Many excipients 
are by nature multifunctional and produced in various grades. Microcrystalline cellulose 
(MCC) is compactable, it also wicks water and can aid disintegration without aiding 
compaction (Rios, 2006). It is known that its performance may change as the source of the 
wood pulp, the pulping process, and other factors are altered.  Other typical examples are 
lactose, which is not only a filler but makes at the same time the formulation more 
hydrophilic, which is important issue concerning disintegration and dissolution of a solid 
dosage form; and starch that can be used in low concentrations as a disintegrant and in 
high concentrations as a matrix for hydrophilic long acting drug release dosage forms 
(Leuenberger, 2006). 
 
There are successful histories of formulators that replaced two or more different excipients 
for one single multifunctional excipient, leading to a less complex formulation, fewer 
processing steps and lower costs (Labella and McDougal, 2006). 
 
Excipient functionality can only be assessed in the context of a particular formulation and 
manufacturing process. Because functionality is linked inextricably to the formulation and 
process, and all formulations are different, functionality per se is a matter for the excipient 
user and supplier. However, certain excipient properties may relate to functionality in a 
more general sense and can be measured and limits can be set (Moreton, 2004 and 2006). 
The need for functionality tests, procedures, and acceptance criteria in an excipient 
monograph is generally limited, given that they are dosage form related (U.S. 
Pharmacopeia, 2007). 
 
Drug bioavailability from conventional solid dosage forms is only reached when the dosage 
form breaks apart releasing the pharmacological active ingredient. Water penetration is a 
necessary first step for disintegration and the ability of some adjuvants to draw water into 
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the porous network of a tablet is essential for effective disintegration. Most of the adjuvants 
with that characteristic are called disintegrants. They help in the tablet breakup by inducing 
the process of desegregation of constituent particles. 
 
Since the USP first established a disintegration standard in 1948, the search for good 
disintegrating agents for tablet formulations has intensified. And also the recognition of the 
importance of bioavailability and compendial dissolution test requirements spurred the 
search for new disintegrants (Chien et al, 1981).  
 
“Superdisintegrants” (Shangraw et al., 1980) are disintegrant agents with efficient 
disintegrating properties at relatively low concentrations, used to promote rapid breakdown 
of oral solid dosage forms. Generally used at levels typically 1-10% by weight relative to the 
total weight of the dosage unit. Examples of superdisintegrants are sodium starch glycolate 
(cross-linked starch), croscarmellose sodium (cross-linked cellulose) and crospovidone 
(cross-linked polymer). Their disintegration efficacy is correlated with their different ability to 
disintegrate, i.e. a combination of various properties, including particle size, hydration 
capacity, swelling behaviour, swelling pressure and volume (Quadir and Kolter, 2006) and 
differences in the particle size generated in the disintegrated tablet (Zhao and Augsburger, 
2005). 
 
Peppas et al. (1989) attribute the difference in disintegration rate between soluble and 
insoluble matrices to two proposed phenomena: an interface-controlled mechanism and a 
diffusion-controlled mechanism. The interface-controlled phenomenon involves tablet 
particles breaking apart from the interface of the tablet and the diffusion-controlled 
phenomenon involves particles diffusing away. Although it is thought that both happen 
simultaneously, the degree to which disintegration depends on each system can differ. 
Since super disintegrants are highly hydrophilic yet insoluble in water, they would be 
expected to be more effective in breaking the tablet apart interfacially than controlling the 
diffusion per se (Augsburger et al, 2002). 
 
The study of the effect of disintegrating agents in tablets, prepared by wet granulation is 
more complicated because of the action of more variables, such as the method of 
incorporation and position, intra- and extra-granular, of the agent in the tablet. Best 
compromise had been obtained by using both intra- and extra-granular agents together, so 
that the extra-granular agents break up the tablet rapidly to the original granules and intra-
granular agent then reduces the granules into the original particles (Van Kamp et al., 1983). 
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In addition, during the dissolving process, soluble materials that tend to swell can form 
viscous barriers, which may impede further penetration of moisture into the matrix, 
hindering dissolution. Thus the use of multifunctional filler, that can also works as a 
disintegrant, and is an insoluble material can be an advantage for fast disintegration tablets.  
 
1.3 Cellulose derivates: Cellulose type II 
 
Cellulose forms the backbone of many excipients used in marketed drug products. 
Cellulose is the primary constituent of wood, paper and cotton. It is a carbohydrate made up 
of glucose units (Figure 1.3.1); these have an empirical formula C6H12O6 and can be given a 
cyclic structure, sometimes designated as a beta-D-glucopyranose or anhydroglucose unit 
(AGU). Cellulose is built up of repeating glucose units joined by β-1,4-glucosidic bonds. 
 
 
Figure 1.3.1: Cellulose Structure and Hydrolysis Challenges (Genomics: GTL 
Roadmap, U.S. Department of Energy Office of Science, August 2005, 
http://genomicscience.energy.gov/roadmap/) 
 
Chain-length determination is very difficult, and average values are given, referred to the 
average degree of polymerization (DP), that is customarily designated as the number of 
AGUs in the chain. Attached to carbon atoms 2, 3 and 6 of each anhydroglucose unit is a 
hydroxyl group capable of undergoing chemical reactions (Bolhuis and Chowhan, 1996). 
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The cellulose fibres in the starting material are composed of millions of microfibers (Figure 
1.3.1). In the microfibers, two different regions can be distinguished: a paracrystalline 
region, which is an amorphous and flexible mass of cellulose chains, and a crystalline 
region, which is composed of tight bundles of cellulose chains in a rigid linear arrangement 
(Bolhuis and Chowhan, 1996). 
 
Whereas inorganic compounds often crystallize in one particular crystal system, organic 
compounds have the capability of crystallizing in several different (poly) forms (morphs), 
and this phenomenon is denoted polymorphism. The molecules may be in different lattices, 
because their orientation is different in the two different polymorphs (Cartensen, 2001). 
 
As different polymorphic forms display diverse physicochemical properties (solubility, 
wettability, melting point etc.), the polymorphic form can play an important role in the quality 
of a drug product (bioavailability and stability, shelf life). In contrast with the polymorphism 
of drugs, little attention is dedicated in the study of polymorphism of excipients, despite the 
impact of this variable on the quality of the drug product.  
 
It is known that cellulose can exists in four polymorphic forms, namely cellulose I, II, III and 
IV. The polymorphic forms can be interconverted according to Figure 1.3.2 mostly by certain 
chemical and thermal treatments. Among the allomorphs of cellulose, the major forms are 
cellulose I (native cellulose) and cellulose II (most regenerated or mercerized from native 
cellulose) (Zugenmaier, 2001). 
 
 
Figure 1.3.2: Polymorphy of cellulose and their 
conversions (from Kono, 2004) 
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Native cellulose can exist in a crystalline or non-crystalline state, as described above. 
Crystalline cellulose has at least two distinct allomorphs, the cellulose I and II. Both are 
found naturally synthesized in nature; however, the metastable cellulose I is by far the most 
prevalent. There are two known suballomorphs of cellulose I (cellulose Iα and cellulose Iβ) 
and usually they coexist together within a given microfibril. Cellulose II is the most 
thermodynamically stable form, which has an additional hydrogen bond per glucose 
residue. Cellulose which has undergone solubilization, then re-precipitation (e.g. 
mercerization) is cellulose II. Cellulose I can be converted directly to cellulose II; however, 
the opposite cannot happen (Brown, 1999, 2004).  
 
Microcrystalline cellulose (MCC), cellulose I powder, is widely used in pharmaceuticals, 
primarily as a binder/diluent in oral tablet and capsule formulations where it is used in both 
wet-granulation and direct-compression processes. In addition to its use as a binder/diluent, 
microcrystalline cellulose also has some lubricant and disintegrant properties that make it 
useful in tableting. It is also used in cosmetics and food products. Microcrystalline cellulose 
is a purified, partially depolymerized cellulose that occurs as a white, odourless, tasteless, 
crystalline powder composed of porous particles. It is commercially available in different 
particle sizes and moisture grades that have different properties and applications. 
Microcrystalline cellulose is manufactured by controlled hydrolysis with dilute mineral acid 
solutions of α-cellulose, obtained as a pulp from fibrous plant materials. Following 
hydrolysis, the hydrocellulose is purified by filtration and the aqueous slurry is spray-dried to 
form dry, porous particles of a broad size distribution. Several different grades of 
microcrystalline cellulose are commercially available that differ in their method of 
manufacture, particle size, moisture, flow, and other physical properties (Galichet, 2006). As 
an effect of controlled hydrolysis (in MCC manufacture), the amorphous fraction has largely 
been removed, yielding aggregates of the more crystalline portions of cellulose fibres 
(Bolhuis and Chowhan, 1996). 
 
Kumar et al. (2002) had investigated, for the first time, the use of sodium hydroxide treated 
cellulose powder as a direct compression excipient. They found that cellulose-derived 
powders (e.g. MCC, powdered cellulose (PC) and low crystallinity powdered cellulose 
(LCPC)), when soaked in an aqueous solution of sodium hydroxide (conc. ≥ 5N) and 
subsequently precipitated by ethanol, result in a material (hereinafter referred to as UICEL – 
University of Iowa Cellulose), that can be compressed into a tablet, with or without the aid of 
a binder. The resulting tablet rapidly disintegrates in water, suggesting that UICEL can be 
used as a direct compression excipient, especially in the design and development of fast-
disintegrating tablets due its highly effective disintegrant activity. The powder X-ray 
diffractogram peaks, as well as the FT-IR (Fourier-transform infrared) spectra, of UICEL are 
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indicative of the presence of the cellulose II lattice and low crystallinity. The degree of 
crystallinity of UICEL ranged between about 47 and 57% (Kumar et al., 2002).  
 
Lower degree of crystallinity causes more hydroxyl groups to be accessible for interaction 
with water molecules. The cellulose chain arrangements, and consequently, the hydrogen 
bonding network, in UICEL compared to Avicel® PH-102 may also contribute to its 
increased affinity for water molecules (Kumar et al., 2002).    
 
In further comparative evaluations of powder properties and compression behaviour of 
cellulose type II (referred as UICEL, UICEL-A/102, MCC Sanaq Rapid) and cellulose type I 
(most cases Avicel® PH-102) it was concluded that cellulose II lattice has lower degree of 
polymerization and lower crystallinity, however shows higher true density, bulk density, tap 
density, Carr’s index and Hausner ratio values. Compared to Avicel® the cellulose II 
powders were denser, shows improved flow, less ductile and more elastic; while showed 
much faster disintegrating properties (Kumar et al., 2002; Reus-Medina et al., 2004; Reus-
Medina and Kumar, 2007b; Rumman, 2009).  Ishikawa and co-workers also found that 
cellulose II is more hydrophilic and with a larger internal surface area of the fibres compared 
with other cellulose polymorphs (Ishikawa et al., 1997). 
 
A modified cellulose type II was also prepared and investigated in order to improve its 
binder properties, without adversely affecting the rapid disintegration characteristics. After 
reaction of UICEL-A/102 with glutaraldehyde the product (referred as UICEL-XL) had a 
lower degree of polymerization, higher crystallinity, lower bulk and tapped density, higher 
porosity, less elastic, and it is more compressible and compactable, keeping similar fast 
disintegration, compared with the starting UICEL-A/102 (Reus-Medina and Kumar, 2007a). 
 
The original idea proposed by Iowa group (Reus-Medina and Kumar, 2006) of the 
application of cellulose II polymorph as a multifunctional excipient for direct compression, 
acting as an all-in-one filler/binder/disintegrant, was supported by other investigations 
(Lanz, 2006; Müller, 2008; Rumman, 2009; Balzano, 2009). 
 
1.4 Percolation Theory in Pharmaceutical Technology 
 
In general the starting material for tablets is a mixture of particulate material consisting of a 
certain amount of fine drug powder and of appropriate amounts of excipients. A tablet 
formulation can be considered a complex system and percolation theory is a tool to a better 
understanding the behaviour of such a system.  
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Percolation theory (Stauffer, 1994) deals with the random occupation of a chosen (one-, 
two-, three-dimensional, n-dimensional) lattice, real or virtual, by different items (e.g. trees 
of a forest, atoms, molecules, nanoparticles, coarse particles, etc.). Generally, it deals with 
the number and properties of clusters. It is assumed that the spaces/sites are randomly 
occupied by the particles, of a drug for example, thus the unoccupied sites may be empty, 
i.e. pores, or may be occupied by an other material, e.g. an excipient. This random 
occupation of particles forms clusters (Leuenberger, 1999; Leuenberger et al, 1996). Such a 
system can be described in general as a binary one, i.e. for a better understanding, a drug 
formulation can be analysed as a two-component, i.e. drug/matrix carrier-system (Holmann 
and Leuenberger, 1980; Leuenberger, 2006). 
 
It is generally accepted that an oil-in-water (O/W) emulsion has totally different properties to 
a water-in-oil emulsion (W/O), as we have either water or oil as a continuous phase. It is 
astonishing that many people do not make a distinction between a drug-in-excipient (D/E) 
and an excipient-in-drug (E/D) powder system. In the case of a poorly wettable drug and a 
hydrophilic filler such as lactose the formulation becomes non-robust close to the critical 
concentration, where the component starts to percolate (Leuenberger, 2005). 
 
It is possible to distinguish between random site and bond percolation phenomena. In the 
case of bond-percolation, a group of particles is considered to belong to the same cluster 
only when bonds are formed between neighbouring particles. The bond probability pb can 
play an important role, and can assume values between 0 and 1. When pb = 1, all possible 
bonds are formed and the tablet strength is at its maximum. In order to form a stable 
compact it is necessary that the bonds percolate to form an ‘infinite’ cluster within the 
ensemble of powder particles filled in a die.  
 
In site-percolation a cluster may be considered as a single particle or a group of similar 
particles which occupy bordering sites. The formation of clusters is a function of the 
occupation probability p of the lattice. In a square lattice, Figures 1.4.1 and 1.4.2, can be 
found an occupation probability below (Fig. 1.4.1) and above (Fig. 1.4.2) a critical 
concentration pc, i.e. the percolation threshold, point where a continuous network is formed. 
Below pc only isolated clusters exist, however, exactly at the critical concentration an 
‘infinite cluster’ is formed spanning the whole lattice from left to right and from top to bottom. 
Thus in a two-dimensional lattice only one component can percolate.  
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Figure 1.4.1 (at left): Square lattice (site-percolation, i.e. random occupation of lattice sites) with 
an occupation probability p below the critical concentration, i.e. percolation threshold pc. The points 
represent occupied sites, empty sites are ignored. Two clusters are marked by lines. Figure 1.4.2 
(at right): Square lattice (site-percolation) with an occupation probability p above the critical 
concentration, i.e. percolation threshold pc. An ‘infinite cluster’ is marked by lines. 
 
In a three-dimensional lattice two components can percolate at the same time, and two 
percolation thresholds, pc, can be defined: a lower threshold, pc1, where one of the 
components just begins to percolate, and an upper threshold, pc2, where the other 
component ceases to have an infinite cluster. Below the lower or above the upper 
percolation threshold, the clusters of the corresponding components are finite and 
isolated. In site percolation of a binary powder mixture, pc, corresponds to a critical 
concentration ratio of the two components. The critical volume-to-volume ratios depend on 
the type of percolation and the type of lattice. In the case of a real powder system the 
geometrical packing is a function of the particles size, shape and distribution. At a 
percolation threshold some property of a system may change abruptly or may suddenly 
become evident (Leuenberger, 1999; Leuenberger et al, 1996).  
 
When the formation of a tablet inside a die, the granules represent clusters of primary 
particles and primary particles are considered as clusters of molecules. 
 
Holman (1991) also shown that the percolation theory, in combination with the principles of 
mechanics, adequately describes the relationships between resistance to volume change 
and the area of interparticulate contact below and above the percolation threshold, in other 
words, the mechanical properties of the material under compression. Among others, he 
identified the percolation threshold of the pores, pca, which signifies the transition from a 
particulate system to a continuum one (Holman, 1991).  
 
The percolation theory was successfully used to interpret water uptake, disintegration time 
and intrinsic dissolution rate of tablets consisting of binary mixtures (Luginbühl and 
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Leuenberger, 1994), as well as to describe the percolation effects in matrix-type controlled 
drug release systems allowing a more rational design of such systems (Leuenberger et al., 
1995). 
 
Caraballo et al. (1996) studied for the first time the existence and behavior of the 
percolation thresholds in ternary pharmaceutical tablets. They demonstrated that a 
multicomponent system can be reduced to a binary one by using a discriminating property 
and the percolation theory is able to be applied to an increasing number of pharmaceutical 
systems giving a better explanation of these systems than ‘classical theories’ (Caraballo et 
al., 1996). 
 
1.5 Modified (oral) Drug-Delivery Systems and the coating process 
 
The term drug delivery covers a very broad range of techniques used to get therapeutic 
agents into the human body.  
 
In recent years there has been great interest in the development and use of tablets which 
should be swallowed and thereafter slowly release the drug in the gastrointestinal tract. 
Such tablets are denominated in various ways, such as slow release, extended release, 
sustained release and prolonged release. They are often also referred to as controlled-
release preparations. This latter term is somewhat misleading, as all tablets, irrespective of 
their formulation and use, should release the drug in a controlled and reproducible way (The 
nomenclature for prolonged-release preparations is subject to some debate and no 
harmonized worldwide system exists) (Alderborn, 2007). 
 
According to FDA definition, Modified Release (MR) Dosage Forms are dosage forms 
whose drug-release characteristics of time course and/or location are chosen to accomplish 
therapeutic or convenience objectives not offered by conventional dosage forms such as a 
solution or an immediate release dosage form. Modified release solid oral dosage forms 
include both delayed and extended release drug products (FDA, 1997). 
 
From an extended release, also known as sustained release system, the drug is released 
slowly at a nearly constant rate (or alternatively as a series of pulses). If the rate of release 
is constant during a substantial period of time, a zero-order type of release is obtained, i.e. 
M = kt (where M is the cumulative amount of drug release and t is the release time). For 
delayed release tablets the drug is liberated only some time after administration. After this 
period, of lag time, the release is normally rapid (Alderborn, 2007). 
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These techniques for drug delivery are capable of regulating the rate of drug delivery, 
sustaining the duration of therapeutic action, and/or targeting the delivery of drug to a 
specific tissue. These advancements have already led to the development of several novel 
drug delivery systems that could provide one or more of the following benefits (Chien and 
Lin, 2002): 
 
1. Controlled administration of a therapeutic dose at a desirable rate of delivery. 
2. Maintenance of drug concentration within an optimal therapeutic range for prolonged 
duration of treatment. 
3. Maximization of efficacy-dose relationship. 
4. Reduction of adverse side effects. 
5. Minimization of the needs for frequent dose intake. 
6. Enhancement of patient compliance.  
 
Oral modified release forms most commonly involve either dispersing the drug into a 
polymeric matrix, or encapsulating the drug containing core or granules with a rate-
controlling membrane. Film coating is a popular technique to modify the release of a drug 
from the dosage form. As shown in figure 1.5.1, it involves the deposition, usually by a 
spraying method, of a thin film of a polymer formulation surrounding the surface of a tablet 
core, capsule or multiparticulate core.  
 
 
 
Figure 1.5.1: Schematic representation of the stages in spray 
film coating (Aulton and Twitchell, 1995). 
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Modified-release film coatings, also known as ‘functional’ coatings, can be categorized as 
either for delayed-release or extended-release coatings, according to the design or polymer 
applied.  
 
Currently, the majority of film-coating processes involve the application of a liquid coating 
formulation where the major component (the solvent/vehicle) is removed by means of a 
drying process that is concurrent with the application of that coating solution/suspension. 
Film-coating formulations typically comprise of polymer, plasticizer, solvent/vehicle, pore 
former (when necessary), and colourants. 
  
In general, film coatings have two main functions. Coatings intended to be applied on 
immediate-release products should have good solubility in aqueous fluids to facilitate fast 
release and dissolution of the drug. However, film coatings used to modify the rate of drug 
release tend to have limited or no solubility in aqueous media. Polymers solubility, viscosity, 
permeability and mechanical properties are imperative factors in the choice of the polymer 
to be used. The same factors can also be applied to the plasticizer choice.  
 
For many years, the liquid component of coatings was a volatile solvent, such as alcohol or 
other quick-drying substances like methylene chloride. While solvent-based coatings 
performed well in many respects, they presented problems in handling, operator safety, 
recovery, and odour. They could even make the finished tablets smell like solvent, which is 
not a desirable property. Solvent-based coatings are still used in some applications, but 
water-based, or aqueous, coatings have largely replaced them. It does not present all that 
troubles and it is environmentally friendly as well. As a result, coating has become much 
more challenging, because water-based coatings are much less forgiving. The coating must 
be applied and the water removed before it can jeopardize the integrity of the tablet. The 
key to tablet coating is to get the surface slightly wet and immediately dry (Tousey, 2005). 
 
The water penetration into the core depends on a complex set of interacting factors related 
to the coating process, the formulation of the coating liquid and the tablet core. Most 
pharmaceutical solid dosage formulations contain disintegrants. Modern disintegrants, often 
referred to as superdisintegrants, act by rapid uptake of water followed by rapid and, for 
some, enormous swelling up. Superdisintegrant particles compressed into the surface of the 
tablet may get activated prematurely on contact with droplets of aqueous film coating 
solution resulting in very fast and excessive water penetration into the core and uneven 
surface of the coated product (Levina and Cunningham, 2005).  
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1.6 Delayed Drug Release and Chronotherapy 
 
Another alternative terms used to describe delayed release are pulsatile or sigmoidal 
release. Ideally, with a pulsatile release system, the drug is released rapidly and completely 
after a defined lag time of no drug release (Figure 1.6.1). In recent years, pulsatile release 
systems have gained increasing interest. 
 
 
 
Figure 1.6.1: Drug release profiles: (A) 
pulsatile, (B) and (C) conventional extended 
release. 
 
The application of pulsatile release systems can be advantageous to adapt a drug therapy 
to chronopharmacological needs or to target a drug to a specific site in the gastrointestinal 
tract (GIT), e.g., to the colon. Besides one-pulse systems, can be done multipulse systems 
that release the drug in subsequent pulses.  
 
These drug delivery systems (DDS) can be classified in site-specific and time-controlled 
systems. Drug release from site-specific systems depends on the environment in the GIT, 
e.g., on pH, presence of enzymes, and the pressure in the GIT. In contrast, time-controlled 
DDS are independent of the biological environment. The drug release is controlled only by 
the system. Time-controlled pulsatile delivery has been achieved mainly with drug-
containing cores, which are covered with release-controlling layers. The cores serve as 
reservoirs, which protect the core from the environment, e.g., water, acidic pH, and 
enzymes, until the drug is released after the lag phase. The coatings can erode/dissolve, 
rupture, or alter their permeability at the required time (Bussemer and Bodmeier, 2003).  
When the integrity of the coating is destroyed, the core then disintegrates immediately and 
burst releasing all or most of the drug at a specific site. By controlling parameters in the 
device, such as the core composition, carrier material in the coating, film thickness and 
particulate matter, the location and time of release of the drug can be carefully controlled. 
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A well time-controlled pulse, or series of pulses, is currently attracting great interest and 
several investigations have been done. Some examples of pulsatile DDS are Pulsincaps 
and hydrophilic sandwich (Stevens, 2003 and Nayak et al., 2009), modified pulsincap 
systems (Patel and Patel, 2009), systems containing a swellable core material (Lerner and 
Penhasi, 2003), multiple-unit formulations (Roy and Shahiwala, 2009), press-coated tablets 
(Conte, 1993), rupturable coated hard gelatin capsules (Bussemer et al., 2003), self-
exploding microcapsules (De Geest et al., 2009), multitude of multicoated particulates 
(Percel et al., 2006), magnetic hydrogel nanocomposites for remote control (Satarkar and 
Hilt, 2008), “tablets in capsule” device (Li et al., 2008), incorporation of disintegrants in pH-
responsive polymer coatings (Schellekens et al., 2008), system based on swelling and 
osmotic pumping mechanism (Zhang et al., 2003), among others.  
 
Very few products are already found in the market, e.g. Verelan® PM XL release capsule 
(hypertension treatment), InnoPran® XL tablet (hypertension treatment), MoxatagTM tablet 
(infections treatment), Covera® HS (hypertension treatment), Uniphyl® (bronchodilator), 
Ritalin® LA (psychostimulant drug). 
 
A challenge in the development of pulsatile drug delivery system is to achieve a rapid drug 
release after the lag time. Often, the drug is released over an extended period of time. 
Pulsatile drug delivery offers advantages such as extended day-time or night-time activity, 
reduced side-effects, reduced dosing frequency and dose size, improved patient 
compliance and lower treatment costs.  
 
Many individuals take their medications at times of the day that are convenient or easy to 
remember (in the morning, at lunchtime, or before bed, for example). Instead, an approach 
called Chronotherapy takes into account your body’s rhythms to tailor the timing and 
dosage of your drugs so that they work better and produce fewer side effects. The term 
“chrono” basically refers to the observation that metabolic events undergo rhythmic changes 
with time. And chronotherapeutics refers to a treatment method in which in vivo availability 
is timed to match rhythms of disease. 
 
If a multiple dosage regimen requires a dose to be administered ‘four times a day’ it is 
unlikely that a dose will be administered at exactly 6-hourly intervals around the clock. 
Instead, the four doses are likely to be administered during the ‘waking’ hours of each day. 
The significance feature of both these dosing schedules is that the patient will experience 
an overnight no-dose period of 12 hours. Such periods will result in substantial decrease in 
the amount of drug in the plasma and body, and may also cause problems in maintaining 
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therapeutic steady-state plasma concentrations of drug in the body after the first overnight 
no-dose period (unless the therapeutic range of the drug is sufficiently large to 
accommodate the fluctuations in drug concentration associated with overnight no-dose 
periods). The potential problems associated with overnight no-dose periods are even further 
complicated by patients who forget to take one of their daytime doses (Collett, 2007). 
 
The human body follows multiple natural rhythms to regulate physiological functions and 
behaviour. The most important one for chronotherapy is circadian rhythm, your body's daily 
biological clock that follows the sun's 24-hour cycle and regulates sleeping and waking. 
Circadian rhythm also affects important biological processes such as hormone secretion, 
cell growth, and metabolism. Scientists have also discovered that biological rhythms 
(chronobiology) play a role in disease and its treatment, since these rhythms cause 
symptoms to vary throughout the day. Consequently, chronotherapy times administration of 
a drug so that its peak concentration in the blood occurs around the time of day when the 
symptoms are worst, not necessarily because the drug works any better at that time. For 
example, symptoms of allergic rhinitis, a condition that affects the mucus membranes of the 
nose and includes seasonal allergies (hay fever), are often worst in the morning when 
histamine levels in the body are elevated. That is why some allergists recommend that 
individuals take a long-acting antihistamine drug at bedtime so it will be in their systems 
when they wake up (Johns Hopkins Health Alert, 2009).  Chronoterapeutic diseases include 
asthma, cardiovascular diseases, glaucoma, rheumatoid arthritis and cancers (Khan et al., 
2009) 
 
If symptoms of a disease display circadian variation, drug release should also vary over 
time. Drug pharmacokinetics can also be time-dependent; therefore, variations both in a 
disease state and in drug plasma concentration need to be taken into consideration in 
developing drug delivery systems intended for the treatment of disease with adequate dose 
at appropriate time. Various technologies such as time-controlled, pulsed, triggered and 
programmed drug delivery devices have been developed and extensively studied in recent 
years for chronopharmaceutical drug delivery. Time-controlled or pulsed-release 
formulations are preferable, especially in the treatment of early morning symptoms (Sajan et 
al., 2009). Conventional controlled release drug delivery systems are not designed to 
complement the circadian rhythm. In order to achieve optimal success, drug release should 
coincide with the body’s circadian rhythm and ought to occur after predetermined time 
delays. 
 
While it seems logical to simply change dosing schedules to account for the chronobiology 
of disease states, patient time structure, and chronokinetics and dynamics of medications 
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as a means to improve therapeutic impact and safety, this approach requires faithful patient 
adherence. This can be difficult, especially in poorly motivated or uneducated patients, or 
patients requiring treatment with many different medications for co-existing morbid 
conditions (Smolensky and Peppas, 2007). Thus the common theme underlying these 
delivery modes is increased therapeutic efficiency as well as increased patient compliance. 
 
It can be concluded that pulsatile drug delivery systems offer a solution for delivery of drugs 
exhibiting chronopharmacological behaviour, extensive first-pass metabolism, necessity of 
night-time dosing, or absorption window in GIT. A variety of systems based on single or 
multiple units are developed for pulsatile release of drug. Most systems perform quite well in 
vitro; their performance in vivo has often not been tested. One major challenge will be to 
obtain a better understanding of the influence of the biological environment on the release 
performance of pulsatile delivery systems in order to develop simple systems based on 
approved excipients with a good in vitro-in vivo correlation (Gothoskar et al., 2004). 
 
Thus, despite of the potential therapeutic benefits of the modified drug delivery systems, still 
remaining a lack of manufacturing reproducibility and efficacy mainly due to their 
complicated manufacturing procedures and the large number of process variables caused 
by multiple formulation steps. Added to that is the use of new or expensive excipients what 
has been strongly limiting the number of marketed products. All major components of the 
modified drug delivery systems should have a pharmacopeia monograph or have GRAS 
status and present no regulatory issues regarding the composition of the dosage form itself. 
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2 Materials 
2.1 Model Drug 
Proquazone (1-isopropyl-7-methyl-4-phenyl-2(1H)-quinazolinone); C8H18N2O; CAS Registry 
Number: 22760-18-5; molecular weight 278.35; melting point 137-138°C; log P (octanol-
water) 3.020; pKa 1.1; presented as a yellowish powder; soluble in chloroform, insoluble in 
water; with a contact angle > 90°. Solubility in acid medium of 1.42 g/L (measured at pH 1.0 
- 0.1N HCl). It can be classified as a BCS class II drug, which is characterized by a high 
permeability and a low solubility (Lanz, 2006; Von Orelli, 2004; O'Neil, 2006; U.S. Nat. Lib. 
of Med.; NCBI). 
It has a total surface free energy of 21.0 mN/m (polar contribution: 3.7 mN/m, and non-polar 
contribution: 17.3 mN/m) according to Owens and Wendt (Owens and Wendt, 1969). 
Proquazone (PQZ) is an NSAID that had been used in musculoskeletal and joint disorders 
(Sweetman, 2007), as well as in children with juvenile rheumatoid arthritis (Lempiäinen and 
Mäkelä, 1985). The drug was kindly provided by Sandoz Ltd., Basel, Switzerland 
(nowadays Novartis Pharma AG). Batch n° 87.327. 
 
                                  Figure 2.1: Chemical formula of proquazone 
 
2.2 Excipients 
2.2.1 Cellulose Type II Polymorph 
In this study the polymorphic form type II of cellulose was used. It was kindly provided by 
Pharmatrans Sanaq, Switzerland, in two batches: MCC SANAQ Rapid Type II (Lot. no. 126-
T03) and MCC SANAQ Burst (Lot. no. 120-34). 
 
Figure 2.2: Chemical formula of cellulose 
 
Empirical formula: (C6H10O5)n 
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Manufacturing: Powdered cellulose, manufactured by mechanical processing of α-cellulose 
pulp from fibrous plant materials. 
Properties: White, odorless, tasteless powder of various finesses, ranging from a free-
flowing, dense powder to a coarse, fluffy, non-flowing material. Insoluble in water, dilute 
acids and most organic solvents. 
 
2.2.2 HPMC 
Hydroxypropylmethylcellulose is an odorless and tasteless, white or creamy white fibrous or 
granular powder. Used as coating agent; film-former; rate-controlling polymer for sustained 
release; stabilizing agent; suspending agent; tablet binder; viscosity-increasing agent. 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or dry-
granulation processes. High-viscosity grades may retard the release of drugs from a matrix 
system (Rowe et al., 2006); therefore a low-viscosity grade was used as a binder for wet 
granulation (Methocel® E5 Premium LV, Dow Chemical). 
 
2.2.3 Magnesium Stearate 
The European Pharmacopeia describes magnesium stearate as a mixture of magnesium 
salts of different fatty acids consisting mainly of stearic acid and palmitic acid and in minor 
proportions other fatty acids. Magnesium stearate is a very fine, light white, precipitated or 
milled, impalpable powder of low bulk density. Flowability: poorly flowing, cohesive powder. 
It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5.0% w/w (Rowe et al., 2006). Magnesium stearate (Lot. no. 84808), 
kindly donated by Novartis Pharma, Switzerland. 
 
2.3 Storage 
All starting materials were stored at room temperature in their original packaging, protected 
from light and humidity. 
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3 Methods 
3.1  Powder Characterization 
3.1.1 Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy pictures were taken at the Center of Microscopy from the 
University of Basel, ZMB-UniBasel. (Scanning Electron Microscopy, Philips XL 30 FEG 
ESEM. Philips, Eindhoven, Netherlands). Sample preparation was consisted of to fix the 
samples over aluminium holders and sputtering them with gold to achieve conductivity. 
 
3.1.2 Particle Size Determination 
The particle size distribution was analyzed by laser diffraction scattering (MasterSizer X 
Long Bed, Malvern Instruments, UK). The measurement was performed using the Manual 
Dry Powder Feeder for cellulose type II and the liquid sample unit for a dispersion 
(water:tween 80) of Proquazone. The process system and the resulted data analysis were 
operated by MasterSizer X Software (version 2.19, Malvern Instruments, UK). The function 
“polydispers” was activated and the “Frauenhofer” model was chosen (following Malvern 
recommendation), and obscuration value was kept between 15-25% for all measurements. 
The measurements were carried out 5 times for each sample. 
 
3.1.3 Moisture Content 
Loss on drying was determined thermogravimetrically (Mettler-Toledo LP16M, Mettler 
Instruments, Switzerland). Before and immediately after granulation, as well as right before 
compaction, specimens of 1 to 2 g were heated up at 105°C for 20 minutes. The loss of 
moisture was calculated in percent by weight. 
 
3.1.4 Densities 
True density ρt was determined using a Helium Pycnometer (AccuPyc 1330, Micromeritics 
Instruments Corporation, USA). A known weight of the samples was placed into the sample 
cell. Helium was used as a measuring gas and values were expressed as the mean of five 
parallel measurements. The apparatus determined the sample volume on the base of the 
displaced gas mass, and then it calculated the true density dividing the sample weight by 
the sample volume. The Pycnometer repeated automatically the measurement five times for 
each sample, and the final true density was calculated as an average of the five results. 
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Bulk and Tapped Density (ρbulk and ρtap, respectively) were determined according to U.S. 
Pharmacopeia 31, using the apparatus Type STAV 2003, Engelsmann AG, Germany. 100g 
of powder or granules were poured into a glass cylinder and their bulk volume (50-250ml) 
was read immediately. Then the sample was tapped 250 times, until to complete 1250 taps, 
or the difference between succeeding measurements was less than 2%, in order to check 
the respective tapped volume.  
Both bulk and tapped density were calculated using the following equation: m/V=ρ  
where:  ρ: Bulk or tapped density [g/ml] 
 m: Weight of the sample [g] 
 V: Bulk or tapped volume [ml] 
 
3.1.5 Hausner Ratio and Compressibility Index 
Hausner Ratio and Compressibility Index (also called Carr’s Index) are simple, fast, and 
popular methods of predicting powder flow* characteristics. They were calculated and 
scaled according to European Pharmacopoeia 5.3. 
 
Hausner Ratio = Tapped Density                                                     (1) 
                            Bulk Density 
 
Compressibility Index = Tap Density – Bulk Density x 100              (2) 
                                                  Tap Density 
 
*The flow through an orifice technique could not be done, because the cohesive forces 
between the relatively small particles of the starting materials perturbed its free flow. 
 
3.1.6 Packing fraction and Porosity 
The constant of proportionality, k, is known as the packing fraction or fractional solids 
content. And it is equal the proportion ρbulk/ρt (bulk density/true density). 
Powder porosity (ε) was calculated using the powder true and bulk densities, according to 
the formula: 
ε = [1 - ρbulk/ρt] x100. 
 
3.2 Granulation 
A wet granulation method was used. It has the advantage of improved uniformity of content 
for low concentration, potent drugs, and of enhanced batch to batch reproducibility of the 
process. The granulation also improves the flowability of the powder and the hardness of 
the obtained tablets.  
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3.2.1 Equipment and Preparation 
A lab scale Diosna® P10 high-shear mixer (Dierks & Söhne, Osnabrück, Germany) with a 
volume of 10L was used. Three main formulations containing the cellulose type II 
polymorph and Proquazone (PQZ) in different proportions were produced, as shown in 
Table 3.2.1. The percentage of drug was 10%, 50% and 90% (w/w). In all formulations 2% 
of Hydroxypropylmethylcellulose (HPMC) was added as a dry binder into the mixture, and 
the granulation liquid was distilled water. The granulation liquid was added using a 
peristaltic pump under constant addition speeds. The total amount of blend was mixed for 5 
minutes inside the mixer with an impeller speed of 430 rpm. After the mixing time, the liquid 
addition and the power consumption measurement were started simultaneously. The 
process was stopped when samples with the desired granules diameter were collected. 
 
Table 3.2.1:  Formulations prepared containing different proportions of drug and excipient. 
Starting materials percentage per weight (% w/w) 
Proquazone  10 50 90 
Cellulose type II 88 48 08 
HPMC 02 02 02 
 
 
3.2.2 Power Consumption Measurement 
 
An “in process” computer calculation program was used to record the power consumption 
(P.C.) profile during all granulation experiments. It was used as a monitoring tool in a way to 
facilitate the visualization of the mixture liquid saturation and powder cohesion inside the 
mixer vessel. The power consumption of the mixer motor (i.e. main impeller) is determined 
by the electric current consumption of the motor according to the equation P = U x I, where 
P is the power (W), U the electric potential (V), and I is the electric current (A). The product 
of electric potential (V) times electric current (A) is measured by a measuring transducer 
(Sineax Type PQ 502, 0–2kW, Camille Bauer AG, Switzerland). The power consumption is 
converted into an electric potential signal between 0 and 10V, 10V corresponding to 2 kW 
and sampled by an I/O Multifunction DAQ-Card, to a laptop computer and displayed 
graphically by the Recorder Software (produced in co-operation with Pharmatronic Ltd, 
Switzerland). 
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3.3  Granules Characterization 
3.3.1 Particle Size Determination 
The wet granulates were dried in a dish dryer (Heraeus Instruments) at 40°C for around 10 
hours before sieve analysis be carried out in ISO-norm sieve oscillator type equipment 
(Rietsch, Germany), using eight selected sieves ranged from 1000 µm to 90 µm mesh 
screen. A particle-size distribution was calculated by the ratio of sieves cumulative weight 
and total sample mass. In this work, the desired granules particle size used for posterior 
compression was set between 125 to 710µm (i.e., cumulative samples from sieves 125 to 
500µm) in order to keep more homogeneity among the particles and avoid the presence of 
fines. 
 
3.3.2 Moisture Content 
Determined as previously described for powder characterization in section 3.1.3. 
3.3.3 Densities 
Determined as previously described for powder characterization in section 3.1.4. 
3.3.4 Hausner Factor and Carr’s Index 
Determined as previously described for powder characterization in section 3.1.5. 
 
3.3.5 Crushing Strength of granules 
The mechanical strength of a material is associated with its resistance to fracturing, attrition 
and deformability. 
The crushing strength (hardness), of the granules produced from the three powder 
mixtures, was measured by a force tester (Programmable Universal Tester for tensile and 
compression forces, FMT-310, Alluris, Germany). The measurements were carried out in 
samples consisted of 20 to 40 isolated granules, for each formulation. An average value, 
and its standard error, was calculated. 
 
3.3.6 Scanning Electron Microscopy (SEM) 
Determined as previously described for powder characterization in section 3.1.1. 
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3.4 Tablet Compaction 
The manufacture of biconvex-faced tablets was chosen in a way to guarantee a more 
efficient and robust coating process, avoiding or minimizing tablet damage during tumbling 
inside the coating pan, and/or fluid bed container walls attrition, as well as to avoid sticking 
between tablet’s surfaces. 
 
3.4.1 Equipment and Process 
Tablets were compressed using a 6 station rotary tablet press (Phamapress PH100, 
Korsch, Germany), equipped with 8mm concave-faced punches (R= 5.5) with edge. 
Granules were mixed with 0.1% (w/w) of Magnesium Stearate for 3 minutes in a Turbula 
blender (Type T2A, W. A. Bachofen, Switzerland) before compression. No glidant was 
used, as well as very few lubricant, to prevent any interactions that could influence the drug 
release. The machine was loaded pouring the material through a steel conical hopper. 
During operation, the speed of the turret rotation was fixed at 19 rpm, and the depth of the 
filling material and the thickness of the tablets were manually adjusted for each formulation 
to keep similar tablet characteristics, such as porosity, for all tablet formulations. The tablet 
weight was fixed at 200mg. 
 
3.5 Tablet Characterization 
3.5.1 Tablet Dimensions 
The thickness (or total height), the length/height of the edge and the diameter of the 
biconvex tablets were measured by a digital caliper (Digimatic® Caliper CD-15CPX, 
Mitutoyo Corporation, Japan). The tablets weight was measured with an analytical balance 
(XS 204, Mettler Toledo, USA). The measurements were carried out from samples 
consisted of 10 tablets for each preparation. (In the Appendix of this chapter an explanatory 
figure about the biconvex tablet dimensions is presented) 
  
3.5.2 Crushing Strength (Failure Force) and Tensile Strength 
The resistance of tablets to capping, abrasion or breakage under conditions of storage, 
transportation and handling before usage depends on its mechanical properties. The 
mechanical strength of a tablet also provides a measure of the bonding potential of the 
materials. 
The crushing strength (Sc) is the compressive stress required to cause a solid to fail by 
fracture; in essence, it is the resistance of the solid to a pressure placed upon it. Using a 
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tablet hardness tester (8M, Dr. Schleuniger Pharmatron AG, Switzerland), Sc was 
measured from samples consisted of 10 tablets for each formulation. The apparatus 
measures the diametrically applied force required to break the tablet. 
 
A non-compendial method of measuring the mechanical strength of tablets that is now 
widely used is the tensile strength. The breaking load of a powder compact subjected to 
diametral loading (Sc) can be converted into a tensile strength (σt) value by the application 
of the expression:  
 
where Sc is the crushing strength (or breaking load), D is the tablet diameter, t is the total 
tablet thickness and W is the central cylindrical core thickness (edge height). The above 
expression is only valid for convex-faced tablets (Pitt et al., 1989; Haririan and Newton, 
1999; Newton et al., 2000). 
 
3.5.3 Friability 
The Sc provides a measure of tablet strength while friability (F) is a measure of tablet 
weakness. 
Friability was measured according to the standard friability test USP 31, using a friability 
tester (Erweka TAP, Erweka, USA) at the rotation speed of 25 revolutions per minute for 
100 revolutions. Each batch was consisted of not less than 6.5 g (total weight) of tablets. 
The uncoated tablet samples were carefully dedusted prior and after testing, when the 
weight loss after tumbling could be determined. 
 
3.5.4 Porosity 
It has been shown that penetration of water into a tablet is proportional to its mean pore 
diameter or porosity (Singh et al., 1968; Ganderton, 1969). Generally short disintegration 
times are associated with rapid fluid penetration (Ganderton and Shotton, 1961; Nogami et 
al., 1969). 
 
The porosity of the tablets was calculated according to the following equation: 
 
ε = [1 - ρapp/ρgran] x100. 
 
where: ε: porosity of the compact (% v/v) 
 ρ app: apparent density of the compact [g/cm3] 
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 ρ gran: true density of granules [g/cm3] used for tabletting. 
 
The apparent density of the compact was calculated dividing the weight of the tablet by its 
volume: 
ρ app = m/ V 
where:  m: weight of the tablet [mg] 
 V: geometric volume of the tablet [mm3] 
 
The apparent density of the compact was calculated using the average of the weight and 
geometric volume of 5 tablets. For the calculations of the geometric volume see Appendix. 
 
3.5.5 Scanning Electron Microscopy (SEM) 
Surface roughness and internal structure morphology of the tablets were assessed using 
SEM images. The method was previously described in the section 3.1.1. 
 
3.5.6 Disintegration 
For a drug to be absorbed after oral administration of a solid dosage form, it must first be 
dissolved, and the first important step toward this condition is usually the break-up of the 
tablet; a process known as disintegration. The disintegration test is a measure of the time 
required, under a given set of conditions, for a group of tablets to disintegrate into particles 
which will pass through a 10 mesh screen. 
 
The disintegration time was determined in a disintegration tester Sotax DT3 (Sotax, 
Allschwil/Basel, Switzerland) with a basket-rack assembly without disk. The disintegration 
medium was consisted of 900 ml of distilled water and hydrochloric acid 0.1N, maintained at 
37°C ±1. The tablets were considered disintegrated when no residue of the units remained 
in the basket, except for fragments of coating layers. For each formulation six tablets were 
tested and the time taken to complete the disintegration was recorded. The results were 
expressed as average of the six measurements. 
 
3.5.7 Dissolution 
Dissolution is the process by which a solid solute enters a solution. In the pharmaceutical 
industry, it may be defined as the amount of drug substance that goes into solution per unit 
time under standardized conditions of liquid/solid interface, temperature and solvent 
composition. Dissolution behaviour of drugs has a significant effect on their pharmacological 
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activity. Solid dosage forms may or may not disintegrate when they interact with 
gastrointestinal fluid following oral administration, depending on their design (Figure 3.5.1). 
For disintegrating solid oral dosage forms, disintegration usually plays a vital role in the 
dissolution process since it determines to a large extent the area of contact between the 
solid and liquid. However it is well known that considerable dissolution of the drug can take 
place before complete disintegration of the dosage form, a phenomenon which depends 
largely on the mechanism of disintegration and certain physicochemical properties of the 
drug, such as its solubility. This could be important when considering the motility of the drug 
or dosage form, and the release of the drug at specific sites, in the gastrointestinal tract 
(Amidon et al., 1995). 
 
 
Figure 3.5.1: schematic representation of disintegrant and non disintegrant tablets. 
 
No official method for the measurement of proquazone is found in the literature. Thus the 
selection of the medium was done based on the work of Lanz (2006) and Van Orelli (2004). 
The dissolution test was performed after tableting and coating (n=6), using a dissolution 
apparatus (Sotax AT7, Sotax AG, Basel) equipped with an automatic sampling unit. The 
dissolution procedure was performed with a USP Paddle (apparatus II) method. The speed 
of the paddles was set to a constant speed of 100 rpm. Different dissolution mediums were 
tested: hydrochloric acid 0.1M, phosphate buffer pH 6.8 and phosphate buffer pH 6.8 + 1% 
Sodium Lauril Sulfate, all with volume of 1000 ml, maintained at 37± 0.5°C. The 
concentration of PQZ was quantified with a UV spectrophotometer (Lambda 25, 
PerkinElmer, Inc. Fullerton, USA), using 1mm cells, at the maximum wavelengths (λmax) of 
299 nm (for HCl) and 285 nm (for the buffer), and compared to the calibration curve of PQZ 
in the same mediums. For controlled-release dissolution test, the USP Method B was 
chosen. 1000 mL of acid media was placed for 2h followed by total replacement of pH 6.8 
phosphate buffer. Sink conditions (defined in this study as the total drug concentration 
dissolved in the medium should not be significant higher than 10% of its total solubility) 
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were maintained throughout the experiments except for the formulation containing 90% 
(w/w) drug that represents 12.6% of its total solubility.   
 
3.6 Tablet Coating 
3.6.1 Coating Polymers and adjuvants 
In order to investigate the influence of cellulose type II in the drug release from a coated 
system, different polymers were tested: Eudragit® RS 30D, Eudragit® RL 30D and 
Aquacoat® ECD 30%. Afterwards Aquacoat ECD® 30% was selected for further 
experiments. 
  
3.6.1.1 Eudragit® RS 30D and RL 30D 
Eudragit® RS and RL are methacrylic copolymers with trimethylammonioethyl methacrylate 
as functional group, available in aqueous dispersion with 30% polymer content.  
They provide time-controlled release of active ingredients independently of the pH of gastric 
fluids. The drug release occurs by diffusion and is tailor-customized by varying film 
thickness and polymers ratio. Both are water insoluble, swellable film formers based on 
neutral methacrylic acid esters with a small proportion of trimethylammonioethyl 
methacrylate chloride (functional ionic group). 
 
With Eudragit® RL, the molar ratio of the quaternary ammonium groups to the neutral ester 
groups is 1:20 (corresponding to about 50 meq./100g), with Eudragit® RS this ratio is 1:40 
(corresponding to roughly 25 meq./100g). 
 
Since quaternary ammonium groups determine the swellability and the permeability of the 
films in aqueous media, Eudragit® RL, which contains more of these groups, forms more 
permeable films with little delaying action. By contrast, and owing to the reduced content in 
quaternary ammonium groups, films of Eudragit® RS swell less easily and are only slightly 
permeable to active ingredients. Given coherent film coatings and an adequate layer 
thickness, it is therefore possible to slow down drug diffusion very noticeably.  
 
Eudragit® RS and RL polymers can be mixed in any ratio to produce films with intermediate 
permeability. In order to obtain films of adequate flexibility, 20% plasticizer on dry polymer 
substance has to be added to the dispersions of Eudragit® RS and RL. 
 
During processing special attention should be given to the process temperature, it has to be 
well controlled and kept down to avoid sticking, since the Eudragit® polymers are soft. 
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Eudragit® RS 30D (Lot n° G070118011, Evonik Röhm, Germany) 
Physical properties: It is a milky-white liquid of low viscosity with a faint characteristic odour. 
Chemical structure: 
 
 
Product Form: Aqueous Dispersion 30% (w/w) 
Targeted Drug Release Area: Time controlled release, pH independent 
CAS number: 33434-24-1  
Chemical/IUPAC name: Poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl 
methacrylate chloride) 1:2:0.1  
INCI name: Acrylates / Ammonium Methacrylate Copolymer 
Monographs: 
Ph. Eur.: Ammonio Methacrylate Copolymer, Type B  
USP/NF: Ammonio Methacrylate Copolymer Dispersion, Type B - NF  
JPE: Aminoalkyl Methacrylate Copolymer RS 
GMP standard: The Joint IPEC – PQG Good Manufacturing Practice  
Guide for Bulk Pharmaceutical Excipients 2006 and  
USP-NF General Chapter <1078> 
 
Drug Master File: # 1242  
Molecular weight information: approx. 32,000 g/mol  
Alkali Value: 19,4 mg KOH/ g Polymer 
Minimum Film Forming Temperature (MFT): ~45°C  
 
 
Eudragit® RL 30D (Lot n° G070516084, Evonik Röhm, Germany) 
Physical properties: It is a milky-white liquid of low viscosity with a faint characteristic odour. 
Product Form: Aqueous Dispersion 30% (w/w) 
Targeted Drug release Area: Time controlled release, pH independent 
CAS number: 33434 – 24 – 1  
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Chemical structure: 
                                     
 
Chemical/IUPAC name: Poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl 
methacrylate chloride) 1:2:0.2  
INCI name: Acrylates / Ammonium Methacrylate Copolymer 
Monographs: 
Ph. Eur.: Ammonio Methacrylate Copolymer, Type A  
USP/NF: Ammonio Methacrylate Copolymer Dispersion, Type A - NF  
JPE: Aminoalkyl Methacrylate Copolymer RS  
GMP standard: The Joint IPEC – PQG Good Manufacturing Practice  
Guide for Bulk Pharmaceutical Excipients 2006 and  
USP-NF General Chapter <1078> 
 
Drug Master File: # 1242  
Molecular weight information: approx. 32,000 g/mol  
Alkali Value: 32,3 mg KOH/ g polymer 
Minimum Film Forming Temperature (MFT): ~ 40 °C 
 
(from Eudragit® Application guidelines) 
 
3.6.1.2 Aquacoat® ECD 30% (Ethylcellulose Aqueous Dispersion) 
Aquacoat ECD is a low viscosity, nanosized, 30 percent by weight, aqueous dispersion of 
ethylcellulose polymer. Ethylcellulose (EC) is a hydrophobic coating material used in a 
variety of coating applications.  
 
It offers dissolution rate control, stability and reproducibility, which are pH independent. 
Drug release happens by diffusion through the film layer, being a function of wall thickness 
and surface area. The drug release profile can be tailored by adjusting the coating level, 
plasticizer type, level of plasticizer, and by adding soluble polymers (pore formers) such as 
HPMC. 
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Aquacoat ECD is a solvent-free pharmacopeial coating product, low viscous and non-tacky 
features, with monographs in the US National Formulary and the book of Japanese 
Pharmaceutical Excipients (“Aqueous Ethylcellulose Dispersion” NF/JPE). 
 
For sustained release applications, additional heating is necessary to cure the polymer 
coating. This is a necessary step for aqueous polymer coatings to ensure that the film 
coating is fully coalesced, resulting in reproducible release profiles. It is recommended 
curing at 60°C for two hours. 
 
Aquacoat® ECD 30% (Lot n° JN06817063, FMC BioPolymer, USA) 
Chemical structure: 
                         
Ethylcellulose is derived from cellulose, and like cellulose, the backbone of its molecule is 
based on repeating β-anhydroglucose units. Specific properties of the various ethylcellulose 
polymers are determined by the number of anhydroglucose units in the polymer chain and 
the degree of ethoxyl substitution. 
 
Product Specifications  
CAS number: 9004-57-3 
Ethylcellulose: 24.5 - 29.5% 
Sodium lauryl sulfate: 0.9 - 1.7% 
Cetyl alcohol: 1.7 - 3.3% 
Total solids: 29-32% 
Loss on drying: 68.0 - 71.0% 
pH: 4.0 - 7.0 
Hydrogen peroxide: NMT 50 ppm 
Heavy metals: 0.001% 
Viscosity: NMT 150 cP* 
Specific gravity: 1.025 - 1.040 
Particle size: Submicron, 85% of particles < 0.5 µm 
Total aerobic microbial count/gm: NMT 100 cfu/g**  
Total yeast and mold count/gm: NMT 20 cfu/g** 
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Glass Transition Temperature: 129-133°C (ethylcellulose powder) 
Minimum Film Forming Temperature (MFT): ~ 40 °C 
Properties: Odorless, tasteless, white to light tan-colored. No ammonia used. 
* centipoise 
**colony-forming units-granulocyte 
(from Aquacoat® Application guidelines) 
 
3.6.1.3 Triethyl Citrate - TEC 
TEC is used to plasticize polymers in formulated pharmaceutical coatings. It has hydrophilic 
characteristics. 
Plasticizers are non-volatile, high-boiling liquids used to impart flexibility to otherwise hard 
or brittle polymeric materials. They are high-boiling to avoid loss from the polymers by 
volatilization. Plasticizers produce partial neutralization of the secondary valence bonds of 
the polymer molecules which become less strongly bound to each other, changing its 
physical properties, e.g., tensile strength is lowered, elongation and flexibility are increased, 
and softening temperature and brittle temperature are lowered (Citroflex, 2005). 
 
Plasticizers soften and swell the polymer latex spheres which aid deformation and 
coalescence, and lower the film forming and glass transition temperatures. The glass 
transition temperature, Tg, is the temperature at which the polymer undergoes marked 
changes in physical properties. Higher amounts of plasticizer will even accelerate film 
formation. 
 
For most of applications, excluding specific tailored ones, it is recommended that 
plasticizers be added at 20-25 percent of the latex solids level (grams plasticizer/grams 
solid x 100 = 25%) (FMC guidelines). 
 
As a general rule it can be stated that the use of hydrophilic plasticizers produces coatings 
with higher permeability and faster dissolution, whereas lipophilic ones reduce permeability 
and dissolution speed (Eudragit guidelines). 
 
Citoflex® 2  (Lot n° N86154, Morflex, Inc., USA) 
 
Chemical Name: 2-Hydroxy-1,2,3-propanetricarboxylic acid; triethyl ester. 
CAS number: 77-93-0 
Triethyl citrate is a clear, odorless, practically colourless, oily liquid. 
Viscosity (dynamic): 35.2 cP at 25°C 
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Structural Formula: 
                              
 
Typical Properties: 
Acid value: 0.02 
Melting Point: -45 ºC 
Water Solubility: 5.7 g/100 ml (25 ºC) 
Boiling Point: 288 ºC 
Flash Point: 151 ºC 
Molecular Weight: 276.32 
Solubility: soluble 1 in 125 of peanut oil, 1 in 15 of water. Miscible with ethanol (95%), 
acetone, and propan-2-ol. 
 
Among others materials, TEC as a derived from citric acid, is most often chosen as 
plasticizer for its global regulatory acceptance and compatibility with most of the generally 
useful polymers. Triethyl citrate is especially recommended as a solvent plasticizer for 
cellulose acetate and other cellulosic derivates. It enhances the grease resistance of 
formulations because of its limited oil solubility (Citroflex, 2005). 
 
3.6.1.4 Hypromellose (pore former)  
Hypromellose, also known as hydroxyproprylmethylcellulose (HPMC), is water-soluble 
cellulose ether, and had been shortly described in section 2.3.2.  
Depending upon the viscosity grade, concentrations of 2-20% w/w are used for film-forming 
solutions to film-coat tablets. Lower-viscosity grades are used in aqueous film-coating 
solutions. As a hydrophilic polymer it can be used as a pore former in mixtures with 
hydrophobic polymers.  
Since it is nonionic, hypromellose will not complex with metallic salts or ionic organics to 
form insoluble precipitates. 
 
MethocelTM E3 Premium (Lot n° 850 721 1E, Dow Chemical, USA) 
Chemical Name: Cellulose hydroxypropyl methyl ether. (Hypromellose 2910) 
CAS number: 9004-65-3 
Formula Weight: 59.08708 
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Structural Formula: 
     
Typical Properties: 
Acidity/alkalinity: pH = 5.5–8.0 for a 1% w/w aqueous solution. 
Ash: 1.5–3.0%, depending upon the grade and viscosity. 
Auto-ignition temperature: 360°C 
Density (bulk): 0.341 g/cm3 
Density (tapped): 0.557 g/cm3 
Density (true): 1.326 g/cm3 
Melting point: browns at 190–200°C; chars at 225–230°C. 
Glass transition temperature: 170-180°C. 
Nominal viscosity (cP): 2.4-3.6, for Methocel E3 Premium LV (for 2% (w/v) aqueous 
solutions measured at 20°C.) 
Methoxyl content (%): 28-30 
Hydroxypropyl content (%): 7-12 
Specific gravity: 1.26 
Solubility: soluble in cold water, forming a viscous colloidal solution; practically insoluble in 
chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and 
dichloromethane, mixtures of methanol and dichloromethane, and mixtures of water and 
alcohol. 
Moisture content: hypromellose absorbs moisture from the atmosphere; the amount of 
water absorbed depends upon the initial moisture content and the temperature and relative 
humidity of the surrounding air.  
Stability: Stable material. Solid is combustible, incompatible with strong oxidizing agents. 
 
3.6.2 Equipment and Coating Process 
 
The tablet cores were coated in a bottom spray lab scale fluid bed (AerocoaterTM Strea-1TM 
Classic, Aeromatic-Fielder AG, Switzerland) equipped with a stainless steel container, an 
appropriate perforated plate and without a boost tube. 
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Tablets were preheated and gently dedusted, applying pressured air, prior the coating 
process. 
As illustrated in the figure 3.6.2, the coating solution was sprayed onto the semi-finished 
products. The solution was fed using peristaltic pump and the coating nozzle atomizes it 
inside the product container. Subsequent drying fixed the particles and generated the final 
products. 
 
Figure 3.6.2: schema of the fluid bed used for coating.     
 
A flashlight was used during the coating process to look into the container and check the 
tablets fluidization and nozzle cleanness.  
 
The composition of the spray suspensions are summarized on Table 3.6.1 and Table 3.6.2. 
 
Process parameters were optimized according to the coating polymer used, and set under 
the following parametric conditions:  
 
Coating polymer:  Eudragit® RS 30D and RL 30D 
 
Polymer combinations: Eudragit® RS was applied lonely, aiming different coating 
thickness, and also with addition of 50% Talc (anti-tacking agent). Eudragit® RL was 
applied lonely, aiming different coating thickness. Two different combinations of RS 
and RL were also tested: ratio RS:RL = 70:30 and 50:50. 
 
Plasticizer: TEC; set constant for all applications in 20% calculated on the dry 
polymer basis. 
 
Total of Solids in the Spray Suspension: 25% (mass), except for one experiment it 
was 20%. 
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Preparation: Eudragit® products were agitated for 1h (at least) before its use in the 
coating suspension preparation. All adjuvants, including the plasticizer, were first 
poured in the diluent liquid and homogenized. After, the adjuvants suspensions were 
added to the Eudragit® suspension and stirred for at least 30 minutes.  
  
Load/Mass of tablets: 50 -100 grams 
Desired weight gain: 3 – 10% 
Inlet temperature (°C): 35-45 
Bed temperature (°C): 30-40 
Atomizing Air (bar): 0.5-1 
Spray rate (g/min): 3.5-6 
Coating solution temperature: Room Temperature 
 
Fan speed (Air Flow): the air flow rate was adjusted in order to promote an accurate 
number of particles revolutions with the air turbulences. The entire charge should be 
fluidised during the entire process, to guarantee an acceptable heat and mass transfer 
between air and product. 
 
Spray Time: adjusted according to the desired load of coating to be added. 
Drying time: 3 - 6 minutes 
Curing conditions:  Enteric Eudragit formulations usually do not show curing effects. 
For the mixtures of RS and RL a curing time of at least 3h at 40°C was applied. 
 
The coating suspension was gentle stirred during the entire coating process to prevent 
sedimentation. During first experiment trials the loss of coating suspension in the container 
walls and tube connections was calculated and, afterwards, an excess was applied in the 
following experiments to compensate it. 
 
Table 3.6.1: Composition of the Eudragit® suspensions sprayed 
               Mixtures 
Substances  
Mix 1 
[% w/w] 
Mix 2*  
[% w/w] 
Mix 3  
[% w/w] 
Mix 4  
[% w/w] 
Mix 5  
[% w/w] 
Eudragit® RS 69.44 39.25 - 34.72 48.61 
Eudragit® RL - - 69.44 34.72 20.83 
TEC 4.16 2.33 4.16 4.16 4.16 
Talc - 5.90 - - - 
Water 26.40 52.52 26.40 26.40 26.40 
Total 100 100 100 100 100 
 * Total of solids in the spray suspension was 20%. 
 
After drying or curing, the coated tablets were stored in a desiccator; protected from light, 
moisture, crushing, and mechanical shocks. 
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Coating polymer:  Aquacoat ECD 30%  
 
Pore Former: Methocel E3 Premium; without (w/o), and added in concentrations of 
3% and 6% calculated considering the amount of coating polymer used on a dry basis 
(by weight). 
 
Plasticizer: TEC; set constant for all applications in 25% calculated on the dry 
polymer basis. 
Total of Solids in the Spray Suspension: 25% (mass) 
 
Preparation: Aquacoat product was mixed at least for 1h before its use in the coating 
suspension preparation. The plasticizer was then added to the Aquacoat suspension 
and mixed for at least 30 minutes before adding any other ingredients. The pore 
former was primary mixed with a portion of water until it got completely dissolved. 
After, the pore former was added to the coating suspension and stirred for plus 20 
minutes at minimum. 
   
Load/Mass of tablets: 50 -100 grams 
Desired weight gain: 3 – 10% 
Inlet temperature (°C): 65 - 85 
Bed temperature (°C): 55-70 
Atomizing Air (bar): 0.55 
Spray rate (g/min): 4.3 – 4.5 
Coating solution temperature: Room Temperature 
 
Fan speed (Air Flow): the air flow rate was adjusted in order to promote an accurate 
number of particles revolutions with the air turbulences. The entire charge should be 
fluidised during the entire process, to guarantee an acceptable heat and mass transfer 
between air and product. 
 
Spray Time: adjusted according to the desired load of coating to be added. 
Drying time: 3 - 6 minutes 
Curing conditions:  2 hours at 60°C in a tray dish dryer (according to MFT for 
Aquacoat ECD). 
 
The coating suspension was gentle stirred during the entire coating process to prevent 
sedimentation. During first experiment trials the loss of coating suspension in the container 
walls and tube connections was calculated and, afterwards, an excess was applied in the 
following experiments to compensate it. 
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Table 3.6.2: Composition of the Aquacoat® suspensions 
                Mixtures   
Substances 
 Mix 1  
[% w/w]  
 Mix 2  
[% w/w]  
 Mix 3  
[% w/w]  
Aquacoat® ECD 
30 66.66 65.09 63.60 
TEC 5.00 4.88 4.77 
Methocel E3 Prem                  - 0.59 1.16 
Water 28.34 29.44 30.47 
Total 100 100 100 
 
After curing, the tablets were stored in desiccators; protected from light, moisture, crushing, 
and mechanical shocks. 
 
3.6.3 Coating Characterization 
Visual inspection of the coated tablets surface was carefully carried out to verify the non-
existence of coating defects. A conventional lab bench microscope (Laborlux S, Leitz, 
Germany) coupled with a digital camera system (Leica DC 200, Leica Microsystems AG, 
Gemany) was also used to characterize the uncoated and coated tablet surface.  
Scanning Electron Microscopy pictures, as described in section 3.1.1, were taken from the 
whole tablet surface. A vertical fracture in the tablet was done in order to assess the 
coating-core adherence, and to verify the homogeneous distribution of the coating layer 
over the tablet surface (with special attention to the tablet edges). The thickness of the 
coating layer could be measured by the SEM pictures, and also estimated from the increase 
in tablet weight after coating (coating level in % (w/w)). The uniformity of mass, or weight 
variation, was measured using an analytical balance and selecting not less than 10 units.  
 
3.6.4 In vitro Drug Release Test 
The drug release test was performed following the procedure previously described in 
section 3.5.7 (Dissolution). 
 
3.6.4.1 Mathematical Models and other release parameters 
To study drug release mechanisms and compare drug release profiles various approaches 
are possible. The pharmaceutical industry and the registration authorities do focus, 
nowadays, on drug dissolution studies. The quantitative analysis of the values obtained in 
dissolution/release tests is easier when mathematical formulas that express the dissolution 
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results as a function of some of the dosage forms characteristics are used. In some cases, 
these mathematic models are derived from the theoretical analysis of the occurring process. 
In most of the cases the theoretical concept does not exist and some empirical equations 
have proved to be more appropriate. A water-soluble drug incorporated in a matrix is mainly 
released by diffusion, while for a low water-soluble drug the self-erosion of the matrix will be 
the principal release mechanism. To accomplish these studies the cumulative profiles of the 
dissolved drug are more commonly used in opposition to their differential profiles. To 
compare dissolution profiles between two drug products model dependent (curve fitting), 
statistic analysis and model independent methods can be used (Costa and Lobo, 2001). 
 
Model-independent methods are easy to apply but they contribute with little information to 
clarifying the release mechanism and should be associated with each other or with some 
model-dependent approach. Examples are simple statistical methods (ANOVA) and ratio 
test. The last ones are relations between parameters obtained from the release assay, 
normally used to compare two assays at the same time point, e.g. T85% and T15min.  
 
The tx% parameter corresponds to the time necessary to the release of a determined 
percentage of drug (e.g., t20%, t50%, t85%) and sampling time corresponds to the amount of 
drug dissolved in that time (e.g., t20min, t50min, t90min). Pharmacopeias and most of guidelines 
frequently use these parameters, among others, for comparisons between profiles and as 
acceptance limits. 
 
The lag time of pulsatile release tablets is defined as the time when the outer ethylcellulose 
coating starts to rupture. It was determined visually during dissolution test and also 
estimated from the drug release profiles. For the calculation of Tx% and Txmin the lag time 
was reduced from the total time, i.e., the time was counted after the coating rupture and 
beginning of the drug release. 
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4 Results and Discussion 
4.1 Characterization of Starting Materials 
The physical properties of the two main compounds and their powder mixtures, in three 
different ratios, are compiled in Table 4.1. 
  
Table 4.1: Characterization of Starting Materials 
  
cellulose 
Type II PQZ 
Powder Mix1 
(10%-wt. 
drug) 
Powder Mix2 
(50%-wt. 
drug) 
Powder Mix3 
(90%-wt. 
drug) 
Mean particle size 
(µm) 120.31 16 - - - 
D(v, 0.1)* (µm) 
  D(v, 0.9)** (µm) 
23.78 
305.60 
6.69 
27.29 - -  
Loss on Drying (%) 5.30 0.39 4.58 3.19 1.09 
True Density 
(g/cm3) 1.543 1.230 1.509 1.403 1.294 
Bulk Density (g/cm3) 0.641 0.323 0.526 0.393 0.266 
Tapped Density 
(g/cm3) 0.781 0.396 0.654 0.596 0.410 
K (packing fraction) 0.42 0.26 0.35 0.28 0.21 
Powder Porosity (%) 58 74 65 72 79 
Hausner Ratio 1.22 1.22 1.24 1.51 1.54 
Compressibility 
Index 17.95 18.55 19.47 33.98 35.11 
Other Properties                   
(Rowe et al., 2006; Lanz, 2006) hygroscopic Hydro-phobic -- -- -- 
* 10% of volume distribution is below this value. 
** 90% of volume distribution is below this value. 
 
The hydrophobic property of PQZ was confirmed by its very low residual moisture, 0.39% 
under loss on drying. Very low moisture can also hinder flow since it is more likely to 
develop electrostatic charging (Howard, 2006; Hearn, 2002). Cellulose type II presented 
much higher moisture content, 5.30%. This property can be an indicator of the cellulose 
hygroscopicity and wettability. In the powder mixtures, increased amounts of cellulose type 
II elevated the moisture content proportionally. 
 
The Compressibility Index and Hausner ratio showed that the powder mixture of 90%-wt. 
PQZ had a very poor ability to flow. The 50%-wt. PQZ formulation presented a poor 
flowability and 10%-wt. drug a passable one. For poorer flowing materials, there are 
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frequently greater interparticle friction and interactions, being more cohesive and hence less 
free-flowing powders. This phenomenon could be clearly noticed during the experiments 
execution when the powder mixtures were not able to proper flow and fill the dies in the 
press machine in an attempt of direct compaction. Consequently a granulation process was 
required to overcome the poor flow problem.  
 
The fractional solids content, k, was much higher for the cellulose powder compared with 
PQZ, and proportionally higher among the mixtures with increased amounts of cellulose. 
The opposite happened with the porosity values. The smaller particle size material, PQZ, 
showed lower densification tendency compared with larger particle size of cellulose, since it 
produced more void space in the powder bed under the same experimental conditions. The 
densities values also expressed that behaviour. Probably caused by the broad difference in 
PQZ particles size plus its static electricity, both affect its packing geometry that became 
more loosely.  
 
Figure 4.1 shows the long fibres (aggregated and non-aggregated) that provide UICEL 
particles with a high contact area. Unlike cellulose, proquazone powder is composed of 
small and very small particles, some flakes shaped and with smoother surface and edges, 
and forming a kind of aggregated structure among the very broad range of particles sizes. 
PQZ also showed to be a microfine powder (90% of particles smaller than 45µm), 
reinforcing its cohesiveness, with very high surface-to-mass ratio.  
 
    
Figure 4.1: SEM pictures of UICEL (left) and Proquazone (right). 
 
4.2 Granulation 
The physical properties of the granules produced from the different powder mixtures are 
compiled in Table 4.2. 
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Table 4.2: Granules Characterization 
 
Granules Mix1 
(10%-wt drug) 
Granules Mix2 
(50%-wt drug) 
Granules Mix3 
(90%-wt drug) 
Median particle 
diameter (µm) 282 460 555 
Loss on Drying (%) 7.95 5.24 1.20 
True Density (g/cm3) 1.483 1.389 1.287 
Bulk Density (g/cm3) 0.400 0.417 0.500 
Tapped Density 
(g/cm3) 0.435 0.444 0.546 
Porosity (%) 73.0 70.0 61.0 
Hausner Ratio 1.09 1.07 1.09 
Compressibility Index 8.00 6.25 8.50 
K (packing fraction) 0.27 0.30 0.39 
Crushing Strength (N) 
(Error - SE) 
21.08 
(1.38) 
16.78 
(1.74) 
9.40 
(1.10) 
 
The granules moisture content was increased proportionally to the amount of cellulose II in 
the formulation. The moisture content of a material can affect its mechanical properties 
generally by acting as an internal ‘lubricant’ facilitating the slippage and plastic flow (Khan et 
al, 1981; Dawoodbhai and Rhodes, 1989). 
 
The granulate porosity appeared to increase with the enlargement in the starting material 
particle size. The lower porosity of the 90%-wt. drug granulate compared with others may 
be attributed to its wider particle size distribution and the ability of the fine particles to fill in 
the voids between the larger particles. 
 
Higher bulk density and packing fraction, smaller porosity, can all be indications of more 
dense granules. The granules with high content of drug behaved exactly the opposite of the 
drug bulk powder bed. The presence of water in the environment, acting as a binder and as 
an electrostatic isolator, together with the binder itself (HPMC), probably was able to 
improve the drug interparticulate contacts and hence to improve the superficial 
interparticulate bonding; with the fine particles again filling the void spaces. 
 
Bulk and tapped densities are also correlated with particles size and shape. The median 
granules diameter was bigger for granules of higher drug concentrations, and their shape 
were more spherical with smoother surfaces, as can be seen in the figure 4.2.1. 
The compressibility index and Hausner ratio were similar among the different granulates. All 
presented excellent flow character. 
 
C H A P T E R  I  – R E S U L T S  A N D  D I S C U S S I O N  
 
Elaine Darronqui 
 
- 58 -
4.2.1 Granules visual appearance and Crushing Strength 
It is well known that the material morphology affects its flow and packing properties 
(Howard, 2002; Brittain, 1989). As well as the mechanical strength of the granules can 
affect the strength of the tablets (Alderborn et al, 1987). Figure 4.2.1 shows the surface 
roughness of the granules, which was increased with the increase in cellulose II 
concentration. In another words, increasing the particle size of the starting material, the 
surface of the granules became rougher. This granule characteristic plus its “hardness” will 
influence in the inner part of the tablet core and its surface as well. 
 
    
   
Figure 4.2.1: SEM pictures of granules with 10% drug (top left), 50% drug 
(top right) and 90% drug (bottom left and right). 
 
A high difference in the agglomerates topological ruggedness could be qualitatively 
evaluated from the SEM images. Shape, particle structure and the propensity of the 
material to fragment or deforming can change the volume reduction behaviour of the 
agglomerate (Alderborn, 1996). That could be verified by the values found for the packing 
fraction and crushing force. Comparing all granulates, granules composed of 90%-wt. PQZ 
showed to have higher packing fraction and smaller crushing strength. Increasing amounts 
of cellulose II decreased the packing fraction and increased the crushing strength, 
proportionally to the amount of cellulose fibres present in the granules. That probably 
happened due to the tendency of irregular-shaped particles to produce open structures and 
loosely packing. 
The granules produced with 90%-wt. of the very fine proquazone powder (with its flat and 
smooth surface and edges) showed to have higher propensity to fragment or deform, i.e., 
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they were weaker under an external pressure, what was revealed by the smaller values of 
the crushing strength test. This can be a result of an insufficient binder addition for that high 
drug load formulation and a brittle behaviour. Nonetheless, during the crushing strength test 
for the granules made of 90%-wt. drug, it was observed that the particles (i.e., the individual 
granules tested) did not broke apart in little pieces but instead they changed their shape 
becoming flattened ones. It had been reported by Benbow (Benbow, 1983) that when the 
particles sizes are markedly reduced, a transition from a brittle to a plastic behaviour takes 
place. In another study, the compression of sodium chloride showed that particles above 33 
µm in diameter fractured under compression, while particles below this size did not show 
any fragmentation but deformed plastically under compression (Roberts et al., 1989).  
The relative standard deviation of the crushing force measurements was approximately 9, 
16 and 20% (for the formulations of 90, 50 and 10 percent-wt. drug, respectively), which is 
very high and due to the fact that the granules themselves differ in size. 
 
4.2.2 Particle Size Distribution (PSD) 
In the figure 4.2.2 is possible to compare the cumulative particle size distribution of the 
three formulations. It is noticed that the formulation with higher content of cellulose II had a 
smaller range or spread of equivalent diameters than the other two formulations. The PSD 
of granulates made of 50%-wt. drug showed to follow the distribution of granulates made of 
90%-wt. drug more than the 10%-wt. drug ones. It can be interpreted that the influence of 
PQZ in the agglomeration process was more significant than the cellulose type II for that 
formulation. Furthermore, the volume of drug (55.48%) was bigger compared with the 
volume of cellulose II (42.46%). 
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Figure 4.2.2: Cumulative percental frequency undersize 
distribution curves. The 3 formulations are distinguished by the 
symbols in the legend (%-wt. of drug). 
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4.2.3 Power Consumption 
Monitoring tool which provides a real-time visualization of the powder liquid saturation as 
well as changes in powder agglomeration/cohesion inside the mixing vessel. Examples of 
power consumption measurements are shown in the figures 4.2.3, 4.2.4 and 4.2.5. Profiles 
were more similar in experiments of formulations with higher content of the cellulose 
material. The total amount of water applied was increased proportionally to the increasing of 
cellulose II in the mixtures (data not shown). It can be concluded that for the progressive 
liquid saturation of the system, and the agglomeration of the particles, the cellulose II 
powder was a material with high influence. The cohesion path showed to be driven by its 
hygroscopic properties. However, the final granulate characteristics, such PSD, was 
markedly influenced by the drug content, as explained above. 
 
 
Figure 4.2.3: Power consumption measured during a granulation 
of a mixture containing cellulose type II:proquazone (88:10) (w/w).  
 
 
Figure 4.2.4: Power consumption measured during a granulation 
of a mixture containing cellulose type II:proquazone (48:50) (w/w).  
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Figure 4.2.5: Power consumption measured during a granulation 
of a mixture containing cellulose type II:proquazone (08:90) (w/w).  
 
 
The maximum absolute value of energy consumed was decreased with the increase of PQZ 
in the formulation. Considering that power consumption measurement is strongly correlated 
with the fluidity of the powders inside the mixer vessel and its contact with the vessel walls 
(adhesion was not avoided) and impeller blade, the results showed that the higher drug load 
formulation presented smaller adherence and resistance to impeller movement. Looking at 
the granules SEM images can be assumed that the attrition or friction among the particles 
and against the equipment surfaces was minimized by the higher sphericity and smoother 
surface for granules of 90%-wt. drug.  A brittle or crumb behaviour for the still green 
granulates, during granulation, could had influenced the power consumption as well. 
Moreover, the true density of the 90%-wt. PQZ mixture and its resulted granulates were 
small than other formulations. 
 
For reason of data mining a plot was generated showing the correlation between the 
properties of the starting powder mixtures, their respective produced granules properties, 
with the power consumption measured during granulation (Figure 4.2.6). The blue columns 
represents a positive correlation and the red ones a negative correlation.  
From the plot can be seen that the amount of PQZ, the powder porosity, the generated 
granules size, bulk density and packing fraction had a negative influence over the power 
consumption. 
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Figure 4.2.6: correlation between powder properties, their respective produced 
granules properties, with the power consumption. Plot generated by Synapse program 
(Peltarion Synapse version 1.3.5), software for artificial neural networks. 
 
4.3 Compaction 
 
The properties of the tablets manufactured from the three different granulates are compiled 
in Table 4.3.1. 
Table 4.3.1: Tablets properties 
  
Formulation 1 
(10%wt drug) 
Formulation 2 
(50%wt drug) 
Formulation 3 
(90%wt drug) 
Weight (mg) 205 200.8 204.9 
Geometric Volume 
(mm3) 157.67 169.52 174.56 
Surface area (mm2) 153.68 159.39 162.53 
Ratio W/D*  0.17 0.19 0.22 
Density of tablet 
(mg/mm3) 1.305 1.185 1.165 
Porosity (%) 13 15.5 10.0 
Friability (%) 0.09 0.02 0.02 
Crushing Strength 
(N) 42.40 50.00 55.88 
Tensile Strength 
(N/mm2) 2.24 2.04 1.87 
Disintegration Time 
(water) 50 sec. 8 min. > 2h 
Disintegration Time        
(HCl 0.1M pH 1.2) immediately 5 min. 50 min. 
 
* (W/D is the ratio of cylinder length/disc diameter) 
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As a rule of thumb, it is normally assumed that a decreased original particle size increases 
the tablet strength (Alderborn, 1996). Besides, under the applied compression force, 
granules usually fragment along failure planes created between primary particles (Wikberg, 
1991). The result is the formation of smaller fragments during compression of granules 
made of small particles. Consequently, by this de-agglomeration, a high superficial area that 
can be available for bonding is expected. And a core with small pore volume would be 
created during compression of those granules. The tablets core made from the 90%-wt drug 
granulates held these characteristics.  
 
The friability test showed that the tablets were robust enough to resist the tumbling inside 
the coating equipment. Also the porosity of the tablets appeared to be appropriate, once 
those very high porous tablets tend to soak up the first application of solution, eroding the 
core and preventing the coating polymer from spreading uniformly across the surface of 
every tablet in the batch.  
 
In Figure 4.3.1 the crushing strength and tensile strength of the tablets are plotted as a 
function of the crushing strength of the granules. A reduction in the granules crushing 
strength (i.e., interpreted here as its fragmentation or deformation propensity) was 
correlated with an increased crushing strength and a decreased tensile strength of the 
compacts. 
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Figure 4.3.1:  Tablets tensile strength and crushing strength 
(second axis) as a function of the granules crushing strength, for 
the three formulations. The dashed line represents the trendline for 
the tablet crushing strength.  
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These findings might be explained by the phenomenon that tablets obtained from 90%-wt 
drug formulations can be described as large agglomerates consisting of a large number of 
small particles agglomerated together. 
 
Hard granulates are better able to withstand compression forces and they are less 
deformable. Thus, the harder granules of 10%-wt drug formulation were found to produce 
fragile tablets. It is known that the bonding force of the intergranular bonds and the structure 
of the intergranular pores will be significant for the tensile strength of the tablets (Alderborn, 
2007). These same granulates containing higher amounts of cellulose II generated tablets 
with stronger tensile strengths.  
From the plot, it can be assumed that probably because the poorly compactable properties 
of proquazone the tensile strength decreased with increased amounts of drug.  
 
Cellulose powders appear to exhibit little or no swelling, yet takes water into its network 
quite rapidly. Furthermore, longer fiber length could improve the efficiency of capillary 
uptake of water into the dosage form matrix, due to its greater particle size. That could be 
seen by the short disintegration times for the tablets with higher amounts of cellulose type II. 
(Further possible reasons for the fast disintegration properties of cellulose II are given in the 
theoretical section). 
 
Due to the addition of excipients have been done by dry-mixing with the drug powder, prior 
to granulation, the cellulose type II was probably incorporated intragranularly. This mode of 
incorporation promotes disintegration of the tablets in finer particles compared with 
extragranular incorporation. 
 
4.3.1 Visual Appearance of the tablets surfaces and its internal structures 
 
Irregularities in the tablet surface can interfere in the quality of the coating. Very porous 
tablet surface prevent the coating from proper adhering to it. Also consistent hardness of 
the tablet surface enables the coating to ‘lock’ into the surface. If too soft, the impingement 
of the solution can erode the tablet, and the opposite, too hard, can not allow the solution to 
adhere and the coating will peel away (Tousey, 2005). 
 
SEM images of the inner part of the tablets’ core and their surfaces are shown in the figures 
4.3.2 and 4.3.3. 
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Figure 4.3.2: SEM pictures of the tablets’ surfaces. Tablet with 90%-wt drug (top left), 
50%-wt drug (top right) and 10%-wt drug (bottom). 
 
 
As expected, due to the softness of the granules with higher amounts of PQZ, the tablets 
produced from these granules shown smoother surfaces, practically with no cracks or 
fissures. Few lumps or protuberances are noticed. As the amount of cellulose was 
increased into the formulation, the cracks or fissures appeared to spread and the primary 
granules could be easily detected on the surface, separated by dips between them.  
 
These findings were similar to the work of Narayan and Hancock, where the highly irregular 
shape and surface morphology of the MCC particles was related to the prevention of close 
packing during compression and contributed to the high roughness of the compact surface. 
They also found that ductile materials seemed to produce compacts with rough surface 
while brittle powders seemed to produce smooth compacts (Narayan and Hancock, 2003).  
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Figure 4.3.3: SEM pictures of the internal structures of the tablets. Tablet with 90%-wt 
drug (top left), 50%-wt drug (top right) and 10%-wt drug (bottom). 
 
In the internal structure of the tablets made of 90%-wt proquazone drug, the core looks like 
a totally embedded mass, originated by the deformation of the granulates, which ones are 
not anymore clearly visible. This internal view, and also the surface roughness, can be well 
correlated with the tablet physical characteristics such its hardness. Tablets with closer 
packing/arrangement of the particles showed to be harder due to the particles have no 
space for motion. 
 
In the 50%-wt drug formulation some granules still visible and channels, void spaces, 
between them are present. For the formulation of 10%-wt drug, the edges of the granules 
are clearly visible and there are many channels in all places. Granules were only partially 
deformed in the inner part of the tablet and at the surface they still visible too. The void 
spaces present in these tablets were forming channels all around inside the core, in another 
words, they were percolating through the entire system. 
 
According to Beckert et al. (1996) when compressing pellets into tablets, their deformation 
depends on their hardness. The variations found in the internal structure of the tablets 
strengthen the affirmation that hardness and deformability of the original particles are co-
dependents and inversely proportional. 
 
C H A P T E R  I  – R E S U L T S  A N D  D I S C U S S I O N  
 
Elaine Darronqui 
 
- 67 -
In all SEM images it was possible to notice that in the region of the tablets edges the 
material appears more compressed, with less noticeable granules limits and pores, 
probably a consequence of compressing using deep concave punches. 
 
It was also taken a SEM image of a tablet (direct compressed) made exclusively with 
cellulose type II powder.  Figure 4.3.4 shows very clear the long cellulose fibres that 
promote a very porous and rough surface. 
 
 
Figure 4.3.4: SEM image of the surface of a direct compressed 
tablet made of cellulose type II. 
 
4.4 Coating 
4.4.1 Monitoring of the coating application process and coating quality 
 
Since spraying, coating distribution, and drying all take place at the same time, tablet 
coating is a dynamic, complex process that is affected by many variables.  
 
In the beginning of this study, it was not sure if it would be possible to carry out an aqueous 
coating over a tablet core composed of high amounts of filler which is also considered as a 
disintegrant (the cellulose type II). The reason lies in the possibility of erosion of the tablet 
due to water absorption and/or a soft or friable tablet. Just one broken tablet inside the 
coating equipment can distribute particles to all the other tablets and spoil their appearance, 
as well as jeopardize the function of the coating. A special attention was taken in order to 
avoid the over-wetting of the cores.  
 
Thin coatings, with percentage of weight gain not bigger than 10%, were chosen in order to 
reduce the application time and core exposure to water. Coating solutions must be 
formulated to have a sprayable solution viscosity. To maintain that condition, a low viscosity 
HPMC grade, in small concentrations, was successful used. The low viscosity of Methocel 
E3 Premium permits high solids content in the coating solution, thus less water can be used 
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and later on be removed. The goal was to enable the coating equipment to evaporate the 
water at the same rate as it is introduced into the process. 
 
Figure 4.4.1 shows coating defects found during the experimental trials done during the 
optimization of the coating process. Some of the possible causes of these defects could be 
the overwetting of the core, high atomization pressure, low bed temperature, high 
percentage of solids, high loading volume, and weak cores. The reason could also be an 
inadequate coating solution.  
 
In some cases the coating solution penetrates the surface of the tablet, often at the crown 
where the surface is more porous, causing localized disintegration of the core and 
disruption of the coating. The defect is often alleviated by increasing the drying (inlet air) 
temperature and decreasing the spray application rate, although in a minority of cases 
increasing the viscosity of the coating solution by increasing polymer concentration may be 
necessary to slow the rate of penetration of the solution into the tablet surface (Rowe, 
1997). 
 
As shown in the Figure 4.4.2, the defects mentioned above could be overcome taking the 
following actions: reducing the spray rate at the beginning of application; the bed 
temperature was increased in other to reduce the time for water evaporation (bed 
temperature is a critical step in coating process, and should be adjusted according to the 
coating formulation. Some polymers, as Eudragit® ones, are soft polymers and can 
‘over’melt after application, consequently causing tablets sticking); the atomized air 
pressure was reduced as well as the loading volume of tablets. The spray pattern was 
optimized in order to enhance the fineness of the scattering by the proper adjustment of the 
nozzle aperture. Even with the reduction in the initial spray rate, the total time of spraying 
was kept as shorter as possible, followed by the drying step (with increased air flow 
ventilation to promote higher fluidization).  
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 (a)    (b)  
 
    
 (c)    (d)  
 
    
 (e)    (f)  
 
Figure 4.4.1:  Coating defects found during trial experiments. (a) and (b) different views of 
orange peel defect with high roughness; (c) cratering and/or blistering; (d) particulate 
contamination; and (e) and (f) fissures and cracks are visible. 
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4.4.2 Visual appearance of the coated surfaces, its homogeneous distribution and 
thickness 
 
Figure 4.4.2 shows examples of surfaces of coated tablets, after the coating process 
optimization. The cross section images of the film-coated tablets, shown in Figure 4.4.4, 
where taken to assess the homogeneous distribution of the coating over the entire tablet 
surface, as well as its thickness, specially in the edges of the tablets where the chance of 
defects are higher. 
 
     
 
 
 
Figure 4.4.2: SEM pictures of coated tablets surface. Tablet with 90%-wt drug and 
coating of 3% P.F. with 3.29% w.g. (top left); tablet of 50%-wt drug, 3% P.F., 5.70% 
w.g. (top right) and tablet of 10%-wt drug, 6% P.F., 9.39% w.g (bottom). 
 
 
Defects in the tablet core, as fissures or dips, could be overcome by the application of the 
coating polymer, as shown in the Figure 4.4.3. 
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Figure 4.4.3: SEM image of a fissure in the surface of the 
tablet totally coated by the polymer. 
 
 
     
 
     
 
Figure 4.4.4: cross section SEM images of the film-coated tablets showing the 
homogeneous distribution of the coating layer. Tablet with 90%-wt drug (top left); 50%-wt 
drug (top right) and 10%-wt drug (bottom left). All coatings have 3% P.F. and 5.70% w.g. 
Detail of a tablet edge (bottom right).  
 
In addition to check the coating distribution, the SEM photos enabled to measure the 
thickness of the coating layers. The thickness did not show be reduced on the edges, but it 
was homogeneous all around the tablet surface. 
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Almost all coating experiments, using ethylcellulose, had their SEM images taken. For those 
experiments without SEM photos the coating thickness was estimated by weight variation, 
i.e., the weight gained after coating. The results are compiled on table 4.4. The values in 
micrometers represent an average of at least 10 measurements taken from different points 
of the coating layer. The values showed a good connection between gained weights and 
layer width.  
Table 4.4: Coating thickness expressed in percentage 
of tablet weight gain and by micrometers (µm) 
measured from the SEM images. 
 
Tablet weight gain 
after coating (%) 
Coating 
thickness (µm) 
9.39 99.38 
9.00 118.30 
8.07 97.00 
6.57 77.42 
5.75 88.23 
5.70 52.48 
3.80 44.20 
3.29 44.55 
 
 
4.5 Drug Release Studies 
The dissolution profile of the uncoated cores, for the three formulations, can be seen in the 
Figures 4.5.1.a, b and c. Different dissolutions media were tested in order to find the most 
discriminatory one: HCl 0.1N, phosphate buffer pH 6.8 and phosphate buffer pH 6.8 + 1% 
surfactant (sodium lauryl sulfate - SLS).  
 
 
Figure 4.5.1 a) Dissolution profiles of uncoated tablets 
composed of 10%-wt drug in different mediums. (Mean ± 
SD, n= 6) 
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Figure 4.5.1 b) Dissolution profiles of uncoated tablets 
composed of 50%-wt drug in different mediums. (Mean ± 
SD, n= 6) 
 
 
Figure 4.5.1 c) Dissolution profiles of uncoated tablets 
composed of 90%-wt drug in different mediums. (Mean ± 
SD, n= 6) 
 
Proquazone solubility was considered an important variable influencing the drug dissolution 
in the three dissolution media. Hydrochloric acid 0,1N showed to represent better the drug 
release after core disintegration. A proper solubilisation of PQZ in the buffer medium was 
only possible with the addition of surfactant. The presence of a surfactant in the aqueous 
media enhances the wetting of particles by lowering the advancing contact angle. 
Ethylcellulose is known to be pH-independent, however it was shown (Bodmeier and 
Paeratakul, 1991) that the commercial available ethylcellulose pseudolatex, Aquacoat®, 
presented a pH-dependent drug release in coated beads; having an increased release in 
simulated intestinal fluids, caused by the presence of the anionic surfactant that gets 
complete ionized at increased pH’s.  
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Thus, looking for the most discriminative way to show the fast release of the drug from the 
inner parts of the tablet (i.e. the rupture of the coating membrane and the burst 
disintegration of the core, caused by the cellulose type II) with fewer variables that could 
possibly influence it, the HCl media was chosen for further tests.  
The delayed-release (DR) dissolution testing, according to USP Method B, was carried out 
and compared with the acidic media 0.1N HCl. The results are plotted in the Figures 4.5.2.a 
and 4.5.2.b. The tablets tested belong to the same formulation and manufacturing batch.  
 
 
Figure 4.5.2.a: Dissolution profiles of tablets composed of 10%-
wt. drug and 9.39% of weight gain after coating with Aquacoat® 
ECD + 6% of Pore Former (Mean ± SD, n= 6). The two 
mediums are named in the legend.  
 
 
 
Figure 4.5.2.b: Dissolution profiles of tablets composed of 10%-
wt. drug and 6.57% of weight gain after coating with Aquacoat® 
ECD + 6% of Pore Former (Mean ± SD, n= 6). The two 
mediums are named in the legend.  
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The drug release profiles were in agreement with Bodmeier and Paeratakul (1991), showing 
a pH-relation for the commercial available ethylcellulose pseudolatex, Aquacoat® ECD. The 
premature rupture of the coating layer in the buffer media compared to the acidic one, 
probably happened due to the presence of the ionized surfactant, enhancing the water 
permeation throughout the membrane. The neutral pH media showed again not to be 
adequate for proquazone dissolution test once the drug takes very long time to achieve total 
dissolution. The aim was to choose a medium that shows the functionality of the delivery 
system in release all the drug in a short time. 
 
Tablets coated with Eudragit® polymers showed a dissolution profile absent of lag time and 
with a prolonged release, examples are in the figure 4.5.3. When Eudragit® RS was applied 
alone the drug release was smaller than 5%, therefore is not shown.  
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Figure 4.5.3: Dissolution profiles of tablets composed of 50%-
wt. drug and different weight gains (w.g.) after coating with 
Eudragit® Polymers in different proportions (Mean ± SD, n= 6). 
 
A water-insoluble, but water-permeable, polymeric membrane resists the environmental 
degradation according to its thickness. Once in contact with the fluids the soluble 
component present in the layer starts to be dissolved away. This produces a microporous 
membrane and the drug can be delivered in a controlled manner by a combination of drug 
dissolution in the core and diffusion through the pore channels. This mechanism of release 
could be noticed when Eudragit® polymers were applied as coating membrane. With the 
water permeation through the membrane into the reservoir the system became 
swollen/turgid and the coating membrane was flexible, swellable, enough to keep the 
integrity of the reservoir and the drug was released through the pores without the rupture of 
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the system. In this case the membrane served as a rate-controlling barrier to modulate the 
release of drug from the system. 
 
Almost no drug release was noticed from tablets coated exclusively with Eudragit® RS. 
Because quaternary ammonium groups determine the swellability and the permeability of 
the film in aqueous media, Eudragit® RL (which contains more of these groups) forms more 
permeable films with little delaying action. By contrast, films of Eudragit® RS (with reduced 
content in quaternary ammonium groups) swell less easily and are only slightly permeable 
to active ingredients (as explained in the materials and methods section). 
For Eudragit® coatings the penetration of the dissolution media into the core, causing the 
tumescence of the system, could be clearly visualized and measured using an analytical 
balance and a calliper (see table 4.5.1). 
 
Table 4.5.1: Percentage of weight gain and dimensional changes caused by water wicking 
(after 5h exposure) from the tablet core coated exclusively with Eudragit RS 30D (5% of 
weight gain). 
Tablet 
Composition  
(% by 
weight) 
Original 
Weight 
(g) 
Final 
Weight 
(g) 
% in 
weight 
increase 
Original 
Thickness 
(mm) 
Final 
Thickness 
(mm) 
Original 
Diameter 
(mm) 
Final 
Diameter 
(mm) 
10% PQZ 212.1 515.8 143.19 4.78 8.60 8.12 10 
50% PQZ 211.2 357.5 69.27 4.80 6.64 8.13 9.35 
90% PQZ 207.4 214.4 3.38 4.94 5.03 8.20 8.27 
 
 
Films prepared from ethylcellulose dispersions resulted in very weak and brittle films when 
compared to the acrylic films. Pseudolatex-cast ethylcellulose films showed lower puncture 
strength and elongation values when compared to those of the solvent-cast films. Curing of 
the pseudolatex-cast ethylcellulose films had minimal effects on their mechanical properties 
(O’Donnell and McGinity, 1997). 
 
For the tablets coated with ethylcellulose polymer, see Figures 4.5.4.a, b and c, the coating 
layer was burst/broken by the expanding core. These cores developed an internal osmotic 
pressure, leading to a fast separation from the coating; what could be noticed visually 
during the disintegration and dissolution tests. The drug was released from the core after 
the rupture of the surrounding polymer layer, caused by a pressure build-up within the 
system. This pressure necessary to rupture the coating was achieved by the presence in 
the core of the hygroscopic super-disintegrant. Thus, resulting the film rupture followed by a 
rapid drug release.  
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Figure 4.5.4.a) Summary of drug release profiles from tablets containing the ratio 10:88 (w/w) 
of drug:cellulose II. Coated with different rates of Aquacoat® ECD, expressed in percentage of 
weight gain (w.g.); and in the presence, or absence, of pore former (PF). (Mean, +/- SD). 
 
 
The rupture of the coating membrane strongly depended on the mechanical properties of 
the coating layer: highly flexible films, such as Eudragit® RS and RL, with high elongation 
were not ruptured in this study (Figure 4.5.3), and as consequence the drug release was 
prolonged without a lag time. Using the mechanically weaker and nonflexible film, such as 
ethylcellulose, the drug release profile was sigmoid and reproducible (Figures 4.5.4.a and 
b).  
A deeper study about the mechanical properties of ethylcellulose and Eudragit® was done 
by Bussemer et al. (2003).  
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Figure 4.5.4.b) Summary of drug release profiles from tablet containing the ratio 50:48 (w/w) 
of drug:cellulose II. Coated with different rates of Aquacoat® ECD, expressed in percentage 
of weight gain (w.g.); and in the presence, or absence, of a pore former (PF). (Mean, +/- SD). 
 
 
In the figure 4.5.4.c can be noticed that the drug release profile from formulations containing 
08%-wt of cellulose type II showed to be less sigmoidal. In these formulations the decrease 
in the drug release rate can be attributed to a decreased internal osmotic pressure, 
probably a consequence of the small amount of osmotic agent in the tablet core. This 
suggests that the level of cellulose type II used in this formulation (08%-wt, i.e. 6.5% in 
volume) may not be adequate to, alone, promote the fast water uptake that drives to the 
coating rupture (and improve the release and dissolution of the proquazone drug); 
especially after had passed through a wet granulation process and aqueous coating. The 
influence of granulation process on super disintegrants performance had been studied 
(Zhao and Augsburger, 2006) and it was demonstrated a negative impact on the 
functionality of the disintegrants tested, probably caused by the particle size enlargement. 
 
C H A P T E R  I  – R E S U L T S  A N D  D I S C U S S I O N  
 
Elaine Darronqui 
 
- 79 -
0
10
20
30
40
50
60
70
80
90
0 50 10
0
15
0
20
0
25
0
30
0
35
0
40
0
45
0
50
0
55
0
60
0
65
0
70
0
75
0
80
0
85
0
90
0
95
0
10
00
10
50
11
00
11
50
12
00
12
50
13
00
13
50
14
00
Time (min)
%
 
Dr
u
g 
Di
ss
o
lv
ed
2.66% w.g. (n=5)
4.35% w.g. (n=6)
6.72% w.g. (n=2)
7.42% w.g. (n=2)
3.80% w.g. (n=3)
5.70% w.g. + 3% PF (n=1)
3.29% w.g. + 3% PF (n=4)
5.40% w.g. + 6% PF (n=6)
 
Figure 4.5.4.c) Summary of drug release profiles from tablets containing the ratio 90:08 
(w/w) of drug:cellulose II. Coated with different rates of Aquacoat® ECD, expressed in 
percentage of weight gain (w.g.); and in the presence, or absence, of a pore former (PF). 
(Mean, +/- SD). 
 
 
It could be also interesting to question the possibility of chemical interaction between drug 
and excipient that may occur and consequently affect drug dissolution. Interesting work had 
been published by Chien et al. (1981), Gary Hollenbeck et al. (1983) and Balasubramaniam 
et al. (2008) regarding the effect of drug-excipient or drug-disintegrant interactions. In this 
study, the formulation 55.5:42.5 (% v/v) proquazone:cellulose type II did not reach 100% of 
drug dissolution in most of tests. Considering the test was under sink conditions, it could be 
due to a lack of uniformity in the drug content causing variation among samples and/or 
batches, or a drug-excipient interaction favored at these proportions of the two compounds. 
 
 
Lag time was plotted as a function of the coating thickness in the Figures 4.5.5.a and b. The 
results show that the lag time was direct proportional to the coating thickness; it was 
increased with the increasing of coating level. 
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Figure 4.5.5.a: Effect of coating level on the lag time (min) of tablets made 
of 10%-wt. drug. Coating levels (in % of tablet weight gain) are shown in the 
data label values. Each point represents the mean ± SE (n ≥ 4). 
 
 
  
 
Figure 4.5.5.b: Effect of coating level on the lag time (min) of tablets made of 50%-wt drug 
(at left) and tablets of 90%-wt drug (at right). Coating levels (in % of tablet weight gain) are 
shown in the data labels. Full background markers represent coatings without pore former 
(PF). Star and + are 3% PF and empty markers 6% PF. Each point represents the mean ± 
SE (n ≥ 3). 
 
 
The influence of the amount of cellulose type II present in the core over the release lag time 
is shown in the figure 4.5.6. 
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Figure 4.5.6: Effect of core composition (% w/w of cellulose type II) 
on the lag time of tablets with different coating levels (in % of weight 
gain). Each point represents the mean ± SE (n ≥ 3). 
 
Cores containing three ratios of cellulose II were tested: 6.5, 42.5 and 85.5% in volume of 
the total formulation. As expected, increased amounts of cellulose type II in the tablets core 
reduced the lag time. The high affinity of cellulose II for water molecules promoted a fast 
hydration of the core, which with the generated high pressure burst the coating layer. That 
process showed to be dependent of the cellulose II level present in the core.  
 
The water-soluble polymer (HPMC) served as a channel-former controlling the water 
penetration and its presence increased the permeability and therefore reduced the lag time, 
see Figure 4.5.7. 
 
Figure 4.5.7: Effect of the pore former level, incorporated in the 
coating layer, on the lag time of tablets with similar coating levels 
(shown in % of weight gain in the data label values). Each point 
represents the mean ± SE (n ≥ 5). 
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The water penetration into the system could also be affected by the type of pore former. 
According to Dürig et al. (2006), decreasing the molecular weight grade of pore forming has 
a markedly reductive effect in drug release. Increased swelling of high molecular weight 
polymers allows faster diffusion through hydrophilic domains of the film. Also for poor 
soluble drugs an addition in the pore former levels should be adequate. This could be an 
important aspect affecting the drug release profile, especially for the tablets comprised of 
higher proquazone content, once that the HPMC used in this study was of low molecular 
weight. Also in some experiments the amount of pore former applied showed to be 
insufficient to generate significant lag time differences.  
 
Except for the time-lag, the release kinetics of the drug retained in the tablet core was not 
significantly influenced by the presence of the rupturable barrier (but could be widely 
modulated using an elastic polymeric shell, e.g. Eudragit polymers). Extracted from the 
release profiles, the T50% and T85% values are plotted on the Figure 4.5.8.a and b. 
 
 
 
Figure 4.5.8.a) Time spent on the release of 50 and 85 percent of PQZ, after coating 
rupture, from the tablets composed of 85.5% (in volume) of cellulose type II. The brick 
columns represent the T50% and the full coloured ones T85%. The different coating levels 
are shown in the x-axis.  
 
For delayed release products the FDA advocates that at least 80% of the drug should be 
released to guarantee a robust formulation (FDA, 1997). Also by FDA a drug product is 
considered rapidly dissolving when no less than 85% of the labelled amount of drug 
dissolves within 30 minutes, using USP dissolution tests (FDA, 2000). For the tablets 
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containing 85.5% (v/v) cellulose II in the core, the time necessary to the release of 50% and 
85% of proquazone (T50% and T85%) was < 15 minutes (in most cases) and < 30 minutes, 
respectively. These values confirm that the release of the drug from the system, after the 
lag time, was done fast in a single pulse. Once that no drug was released before coating 
rupture, it can be concluded that what control the drug release was the rate of de-
aggregation of the system, i.e. bulk erosion of the core followed by de-aggregation of the 
granules. And both can happen simultaneously. Nevertheless, the coating rupture was 
controlled by the coating thickness and the amount of osmotic agent present in the core. 
 
 
 
 
Figure 4.5.8.b) Time spent on the release of 50 and 80 percent of PQZ, after coating 
rupture, from the tablets composed of 42.5% (left) and 6.5% (right) of cellulose type II (v/v). 
The different coating levels are shown in the x-axis.  
 
Distinctly, for tablets containing 42.5% (v/v) cellulose II in the core (Figure 1.5.8.b) the time 
to reach 50% of PQZ dissolved was smaller than 20 minutes, in most cases. But 80% of 
drug release was reached after 1 or 2h.  
 
 
For cores containing only 6.5% (v/v) of cellulose II, the time necessary to release 50% of 
drug was more divergent among the experiments (with shorter times for thinner coatings, 
which coincidently had the shorter lag times too). In many experiments it was not possible 
to determine T80% for that formulation. These results are in disagreement with the drug 
release from the uncoated cores, where 80% of drug was released before 50 minutes. This 
can be an indication of some modification(s) on the core properties after the coating 
process and/or during the long exposition to the dissolution medium. 
 
 
 
C H A P T E R  I  – R E S U L T S  A N D  D I S C U S S I O N  
 
Elaine Darronqui 
 
- 84 -
The release medium permeated through the coating, penetrated into the tablet through the 
hydrophilic pores and the continuous cellulosic network, which conveyed water from one 
particle to the next, imparting a significant hydrostatic pressure, thereby breaking the forces 
that held the tablet together, and resulting in the disintegration of the tablet. Below pca (pore 
percolation threshold) the rate of fluid penetration into a tablet would be drastically reduced, 
since the pore clusters are isolated.  
 
In addition, as the amount of cellulose type II was increased, the size and number of 
clusters increased. This happened until a level of cellulose II was reached, at which the 
finite clusters became connected and start to percolate the entire system. The proquazone 
finite clusters become more and more insulated and this continues until the percolation 
threshold where the cellulose II predominates in the system by completely surrounding the 
drug, what enables dissolution of the poorly water-soluble drug within the clusters very fast. 
 
At 6.5% (v/v) level of cellulose II, it formed only disconnected finite clusters which are 
surrounded by the infinite proquazone clusters (91.6% v/v). The drug clusters, being 
hydrophobic, limit the water penetration and thus core disintegration. At this low level the 
cellulose II was enough to help in the rupture of the coating layer but not enough for 
keeping fast and complete self-erosion of the matrix core, what could be seen by the partial 
drug release during dissolution tests. However, is important to highlight that before coating 
the drug release from this formulation tablets was complete.  
  
Considering both the porosity of the core before the coating process (approx. 10%, for the 
formulation of 90%-wt. drug) and the true density of compounds, that tablets had 83.26% (in 
volume) of PQZ and 17.62% (in volume) of other: cellulose II, HPMC and porous. Except for 
the drug, all the other components are facilitators in the water permeation and thus core 
disintegration. Analyzing the tablet product as a two-component, i.e. drug/matrix-carrier-
system, the percentage of matrix was probably sufficient to span through the system, 
surrounding the big PQZ clusters and promoting the fast erosion of the core for the 
uncoated tablets. However, after aqueous coating process a change in the matrix-carrier-
system probably happened; that could be a reduction of porosity, caused by HPMC gel 
formation in contact with the aqueous coating solution (and hence blocking/reducing the 
pores), as well as a loss in water uptake capacity by the disintegrant. 
 
Three critical percolation thresholds should be considered: the cellulose type II, the drug 
and the pore percolation. For a precise determination of them further experiments with more 
ratios of compounds should be necessary. 
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4.6 Conclusion 
As discussed above, the tablets must have the proper porosity, surface roughness, 
hardness, and moisture content. One can not have consistent coating without consistent 
tablet quality. Good adhesion between a polymeric film and a surface of the core is a 
fundamental requirement to guarantee a good result. For that, the atomized droplets, to a 
certain degree, have to penetrate into the substrate. The presence of cellulose type II 
showed to be beneficial for that and to surpass all the difficulties in the process steps, also 
adding good mechanical and functional properties to the final product. 
 
Rupturable pulsatile systems can release the drug after rupture of the outer polymeric 
coating. Rupture is generally induced by the development of high pressure within the 
system. The mechanical properties of the coating polymer are therefore very important for 
the performance of rupturable pulsatile drug delivery systems. Eudragit® films were very 
flexible, an advantage for conventional extended release systems. In contrast, 
ethylcellulose films were more brittle and showed complete film rupture. 
 
The lag time prior to drug release, for ethylcellulose coatings, was controlled by coating 
layer thickness and its HPMC content. The time of drug release was inversely proportional 
to the membrane thickness, however, directly related to the level of pore former present in 
the membrane.  
 
The system probably works better for poorly water-soluble drugs, particularly the ones that 
cannot be released by diffusion through a porous membrane. Highly water-soluble drugs 
could possibly diffuse through the open pores prior to complete coating rupture and core 
erosion.  
 
Following Bussemer and Bodmeier (2003) definitions, the drug delivery system presented in 
this study can be classified as a rupturable system (a class of reservoir-type pulsatile 
system based on rupturable coating) with a sigmoidal drug release. The main advantage of 
the system presented in this work is its simple and inexpensive manufacturing process and 
using well-known and approved excipient, which not only supports very well the coating 
rupture but also provides good compressibility and core mechanical properties. Being a 
good pharmaceutical aid to all manufacturing steps and process, the cellulose type II acts 
as a real multi-functional excipient. 
 
In addition, experts forecast a continuously rising demand for dosage forms with pulsatile 
drug release, since circadian rhythms have been extensively described for many diseases. 
In such a way, delayed release systems offer “convenience functionality” for the patient. 
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4.7 Appendix 
 
Calculation of the Tablet Geometric Volume 
The geometric volume (mm3) of the tablets was computed according to the following 
formula: 
 
 
For a biconvex tablet the variables h, a and b stands for height of the spherical caps (mm), 
radius of the tablet (mm) and height of the central cylinder (mm) respectively (Räde and 
Westergren, 1992). 
 
These variables can be clearly observed in Figure 4.7.1. 
 
 
 
 
Figure 4.7.1: Biconvex tablet dimensions. 
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Second Chapter 
Influence of the drug load, liquid addition rate and batch size on the 
power consumption profile during wet granulation process. 
 
Abstract 
Granulation is one of the fundamental operations in particulate processing and has a very ancient 
history and widespread use. In the pharmaceutical industry the moist agglomeration process by high-
shear mixing is a critical unit operation that remains more of ‘an art’ than a science-based approach. 
This study was performed to investigate the influence of drug load, liquid addition rate and batch size 
over the power consumption profile recorded during a high shear mixer granulation. The powder 
liquid saturation and particles agglomeration behaviour was compared between three formulations, 
containing 10%, 50% and 90% (w/w) drug. In all formulations the binder was added dry to the 
mixture, with the granulation liquid being distilled water. The experiments were carried out in a lab 
scale high shear mixer with batches sizes of approximately 30%, 50% and 70% of filling capacity of 
the working vessel,  and two main liquid addition rates were set constants at 38 and 50g.min-1. The 
load of a drug with poor water solubility showed to be the most influential factor in both, the kinetics 
of granule growth and hence the power consumption profile. The maximum power consumption 
values were directly proportional to the batch size but inversely proportional to the amount of drug in 
the formulation. The amount of liquid needed to reach the MAX in the power consumption, as well as 
the particles liquid saturation, was found to be dependent of drug concentration, mainly due to the 
poor water solubility of the drug chemical and physical properties. The agglomeration of high load 
drug formulations began at very low liquid saturations (pi < 25%) in contrast to the agglomeration of 
high MCC content mixtures (pi about 59%). For formulations containing 90% (w/w) of drug the 
targeted/desired granules size were found at 42.37% of system saturation, in average; and the value 
was 50.64% and 62.24% for 50% and 10% drug formulations, respectively. Phase I of a typical PC 
profile could briefly be seen in high drug load formulations, followed by a long plateau phase. In the 
mixtures with similar volume between drug and excipients, the second showed to predominate in the 
growth kinetics and agglomeration behaviour. The batch size did slightly deviate in the relevant 
points of the PC profile (more noticeable in the power values), as well did the liquid addition rate. The 
“in process” measurement of power consumption showed to be a reliable analytical tool for 
monitoring the moisture content and particle agglomeration. Understanding and controlling the 
granulation process is a key factor in robust dosage form design. The latter is the goal of the PAT 
(Process Analytical Technology) Initiative emphasizing “Quality by Design”. 
 
Keywords 
Wet granulation; high-shear mixer; power consumption; in process control; process and formulation 
design. 
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6 Introduction 
Control and optimization of the granulation process by the pharmaceutical industry is a 
fundamental requirement to guarantee a constant product quality. Nevertheless, this 
process still is very unsettled and troublesome, mostly employing operator practice rather 
than a science-based approach. More accurate methods need to be developed in order to 
better control granulation and stop the process when higher percentages of the desired 
granules size is reached, since the particle size distribution is usually wider than the one 
specified. 
 
Cameron et al. (2005) pointed out that one of the most important issues for the effective 
control of granulation processes is the development of fast and reliable measurement 
techniques for the characterization of particulate systems. Because of the difficulties 
associated with the direct measurement of particle characteristics, such as particle size 
distribution, moisture contents and deformability, some indirect monitoring parameters have 
been adopted. A commonly accepted monitoring parameter in the pharmaceutical industry 
is the power consumption. 
 
A series of investigations carried out by Leuenberger et al. (1979, 1982, 1986) 
demonstrated that granulation power consumption, liquid saturation level and granule 
particle size are inter-related, providing a technical basis for the use of power consumption 
as a monitoring tool for the characterization of particles within a high-shear mixer. A more 
detailed description of this control strategy is also provided in Leuenberger (1994). 
 
Betz et al. (2003) made a correlation between power consumption and tensile strength, 
showing that power consumption measurements are capable of determining the 
cohesiveness of powder particles, expressed by the resistance to flow of the powder 
mixture inside the mixer vessel. Holm et al. (1985b) has also correlated granule growth and 
power consumption measurement. 
 
The uptake of granulation liquid by the powder mixture is also an important factor, either 
driving particle interactions to agglomerate growth or to the formation of a slurry mass. The 
liquid saturation is claimed to be the major controlling factor for the granule growth process. 
High loads of less hydrophilic compounds, what today corresponds to approximately 40% of 
new active entities, can strongly affect the agglomeration process and therefore the power 
consumption profile. 
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Although many parameters can be set constant during process design, variations during 
production occur due to the variable nature of the powder feed. The power consumption 
profile depends on the nature of the mixture constituents and its proportions, since 
components differ tremendously in their physical-chemical properties and, as a result, in 
their processing and output features. 
 
The use of power consumption measurement to monitor the granulation process is a 
relatively simple and inexpensive method because of the absence of specialized or 
expensive equipment. It gives the operator accurate data about the moisture content and 
kinetic of agglomerate growth, making it possible to reduce batch-to-batch variability and to 
improve the production of desirable and usable granulates (Betz et al., 2004).  
 
6.1 Agglomeration process and control: background 
 
As Pietsch (2002) described in his book, humans most probably first used agglomeration 
during the making of bread by taking flour (= particulate solids including an inherent binder, 
starch) and liquid additives (= additional binder for plasticity and "green" bonding), mixing 
and forming the mass, and, finally, "curing" the product; i.e., removing of the moisture 
excess that was added during the mixing and agglomeration steps, to obtain structure and 
permanent bonding during baking. The technology of bread making combines all 
components of a complex agglomeration process including preparation of solid feed 
particles by milling (= adjustment of particle size and activation of the inherent binder, 
starch), mixing of particulate solids with additional binder(s), forming the mass into a "green" 
agglomerate, and a "post-treatment" (curing=baking=heating and cooling) to provide 
strength and texture. As a "tool" to improve powder characteristics, agglomeration was used 
by ancient "doctors" in the production of pills from medicinal powders and a binder (e.g., 
honey) or by food preparers during the making of bread from flour, with its inherent starchy 
components acting as binder (Pietsch, 2002). 
 
The cohesive forces that operate during the moist agglomeration process result from liquid 
bridges that form between solid particles, holding them together by capillary and viscous 
forces (Tardos et al., 2007).  
 
One of the primary factors controlling agglomerate growth is the degree of saturation in the 
granule structure, see figure 6.1.1. The filling of the binder in the granule pores is expressed 
as the saturation ratio, correlating the binder bridging volume between particles within the 
agglomerate to the total available pore and void space between particles. Considering the 
moisture of a bulk material independently of its origin, it can be generally said that a small 
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quantity of liquid saturation causes the formation of bridges between the individual particles 
(pendular state). By increasing the amount of liquid, we first get the funicular state, where 
both liquid bridges and pores filled with liquid are present, and then the capillary state where 
the pores are completely filled (Schubert, 1984). More growth occurs with increasing binder 
saturation, especially as the saturation approaches 100%. In the (fully-saturated) capillary 
state, rapid growth occurs by coalescence. Beyond 100% saturation, the particles are 
suspended in a continuous liquid phase (droplet) and a paste or over-wet mass results 
(Mort, 2007).  
 
 
Figure 6.1.1: the structure of granules evolves with the increasing binder 
saturation. Saturation increases by: (a) additional binder loading and/or (b) 
granular consolidation. (Extracted from Mort, 2007) 
 
Granulation mechanisms or rate processes have traditionally been described in terms of a 
number of different mechanisms (Iveson et al., 2001; Ennis, 2005). However, it is becoming 
more common to view granulation, in a modern approach, as a combination of only three 
sets of mechanisms:  
 
1. Wetting and nucleation, where the liquid binder is brought into contact with a dry powder 
bed, and is distributed through the bed to give a distribution of nuclei granules; 
2. Consolidation or coalescence and growth, where collisions between two granules, 
granules and feed powder, or a granule and the equipment lead to granule compaction and 
growth; 
3. Attrition and breakage, where wet or dried granules break due to impact, wear or 
compaction in the granulator or during subsequent product handling.  
 
Since the statement “granulation is still rather an art than a science”, in the 70’s, many 
works have been published about granulation process control; for example by Leuenberger, 
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Kristensen, Rowe, Knight, Faure, Holm and others. But unfortunately most of them still bring 
that affirmation.  
 
The aim of using instrumental methods in the control of granulation processes is to detect 
changes of the resistance of the mass against agitation, i.e., the changes of the rheological 
properties (Holm et al., 1985a).  
 
Several approaches for controlling the granulation process at one scale are available 
according to Faure et al. (2001). Those strategies can be grouped as follows: 
 
• methods based on the monitoring of one representative parameter: the 
representative parameter relates back to one or more properties of the wet mass or 
of the dry granules, e.g., power consumption of the high-shear mixing, moisture and 
vibration sensor outputs; 
• modeling the process using experimental design: once established, the models can 
estimate the quality of the granules produced when the process conditions are 
changed within the domain studied; 
• modeling the granule population balance: contrary to the previous models, some 
assumptions on the granulation regime are needed. 
 
Methods such as imaging processing by video camera (Watano and Miyanami, 1995; 
Watano et al., 2001), Acoustic Emission Signal Monitoring (Whitaker et al., 2000), Raman 
spectroscopy (Walker et al., 2009) and measurement of the stress fluctuations (Talu et al., 
2001) are also adapted for direct monitoring of granular flows and agglomerate growth. 
Acoustic chemometric monitoring is also used in fluidized beds (Halstensen et al., 2006). 
 
Nowadays, most of the mixer/granulator types offered on the market are or can be equipped 
with the option to measure the power consumption or torque profile during the moist 
agglomeration process. The relationship between power consumption, conditions of 
granulation and resulting agglomerate characteristics also have been studied (Bier et al., 
1979; Leuenberger, 1982; Leuenberger and Imanidis, 1986; Betz et al., 2003, 2004). 
  
The power consumption curve obtained by adding the binding liquid continuously to the 
powder is made up of five phases, as already described (Leuenberger and Usteri, 1989; 
Leuenberger and Betz, 2007) (Figure 6.1.2). 
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Figure 6.1.2: Division of a power consumption curve according to Leuenberger (1989). 
 
• Phase I (S1-S2): the moisture is adsorbed by powder particles to saturate the moisture 
content without any formation of liquid bridges (equilibrium moisture content at 100% 
relative humidity of the air). 
• Phase II (S2-S3): a sharp increase in power is observed due to the build-up of liquid 
bridges between the primary particles (pendular state). 
• Phase III (S3-S4): characterized by a constant power level (plateau phase), i.e., filling 
up the interparticulate void space with the granulation liquid (transition from the pendular 
to the funicular state). The liquid bridges are mobile. 
• Phase IV (S4-S5): where the funicular state is found with isolated three-dimensional 
clusters having already reached the capillary state. 
• Phase V (>S5): further addition of liquid leads to a phase transition point, S5. After that 
the whole interparticular void space is completely filled with liquid and the overwetted, 
damp mass becomes slurry. It represents the transition from the capillary state to a 
suspension. 
 
Betz et al. (2003), in order to facilitate the comparison between measurements, introduces 
the characteristic point MAX (maximum power consumption) which equals to 100% 
saturation of the particulate system and is defined as the point at which maximum power is 
taken by the motor of the mixer. After the MAX point the mixture becomes a suspension. At 
the overwetting point, the power consumption does not result from individual agglomerates 
collisions, but is a direct function of the wet mass rheology. 
 
It is important to note that the power consumption profile is different if the moisture 
equilibration (water absorption) does not take place due to the use of an organic solvent as 
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granulation liquid. If water or alcohol is used as the granulating liquid, it is important to 
check whether some of the components of the powder mix may form a hydrate or 
alcoholate, i.e., that certain molecules uptake some water or alcohol molecules in their 
crystalline structure. In such a case, the power consumption profile is different from the one 
plotted in Figure 6.1.2 (Leuenberger and Betz, 2007). The change of the type of the mixer 
also changes the profile and the absolute power consumption values (Leuenberger, 2001). 
Important rules for a successful application of the power consumption method are 
highlighted in Leuenberger et al. (2009). 
 
From the power consumption profile a distinction was made between peak and level 
detection (Leuenberger, 1982) that could be used as control signals. Also, a modified signal 
analysis system was proposed by Laicher et al. (1997) in case of active ingredients which 
react sensitive to the granulation process. 
 
In his study about different methods of monitoring the granulation process by electrical 
measurements of the drive motor, Kopcha and co-workers (1992) found that power 
consumption, direct torque and reactive torque measurements give the same general profile 
for the operation; however, direct torque is more descriptive. It has also been reported 
(Knight et al., 2001) that the torque, or power consumption, required to turn the impeller 
varies with impeller blade design, rotational speed, fill and bowl size. 
  
Ascanio et al. (2004) in his review about methods for measuring power consumption in 
stirred vessels concluded that although electrical measurements are the simplest and most 
widely used method on large scale processes, care must be taken at laboratory and bench 
scale to discount external power losses. 
 
Many are the research challenges in granulation technology, focusing on mechanical 
impeller-type mixers, also termed high shear mixers. Improvements in the quality of data 
and in data analysis have been achieved in the last 20 years. However, in order to reach 
better process control improvements in the design and operation of granulators are also 
necessary (Knight, 2004). 
 
The aim of the present study was to investigate the influence of drug load, liquid addition 
rate and batch size on the power consumption profile during moist agglomeration process in 
a high shear mixer granulator. Finally, the comparison will lead to a conclusion on how the 
formulation properties, process design parameters and the scale-up can affect the power 
consumption profile. 
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7 Experimental details 
7.1 Materials 
Microcrystalline Cellulose (MCC101, Pharmatrans Sanaq AG), Paracetamol (Mallinckrodt 
Pharmaceuticals) and Hydroxypropylmethylcellulose (Methocel K100, Dow Chemical) were 
used to prepare three different mixtures in different batch sizes.  
 
7.2 Methods 
7.2.1 Characterization of starting material 
 
The particle size distribution of the starting materials was analyzed by laser diffraction 
(MasterSizer X Long Bed, Malvern Instruments, UK). The measurement was performed 
using the Manual Dry Powder Feeder, and the obscurity was set around 20%. For the 
moisture content, ‘loss on drying’ was determined thermogravimetrically (Mettler-Toledo 
LP16M, Mettler Instruments, Switzerland). Before and after granulation, specimens of 1 to 2 
g were heated up at 105°C for 20 minutes. The loss of moisture was calculated in weight 
percent. True density ρt was determined using a Helium Pycnometer (AccuPyc 1330, 
Micromeritics Instruments Corporation, USA). Bulk and Tapped Densities (ρbulk and ρtap, 
respectively) were determined according to U.S. Pharmacopeia 31, using the apparatus 
Type STAV 2003, Engelsmann AG, Germany. Powder porosity (ε) was calculated using the 
true and bulk densities, according to the formula ε = 1 - ρbulk/ρt. The Compressibility Index of 
the three powder mixtures was calculated by the bulk and tapped volumes, according to 
U.S. Pharmacopeia 31. Scanning Electron Microscopy (SEM) pictures were taken at the 
Microscopy Center of the University of Basel, ZMB-UniBasel (Scanning Electron 
Microscopy, Philips XL 30 FEG ESEM. Philips, Eindhoven, Netherlands). Sample 
preparation consisted of fixing the samples over aluminum holders and sputtering them with 
gold to achieve conductivity. 
 
7.2.2 Granulation design and procedure  
 
Three main formulations containing Microcrystalline Cellulose (MCC) and Paracetamol 
(PCM) in different proportions were produced. The percentage of drug in the total 
formulation was zero, 10%, 50% and 90% (w/w). In all formulations 2% of 
Hydroxypropylmethylcellulose (HPMC) was added as a dry binder into the mixture, and the 
granulation liquid was distilled water. A lab scale Diosna® P10 high-shear mixer (Dierks & 
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Söhne, Osnabrück, Germany) with a volume of 10L was used. Three batch sizes were 
chosen: approximately 30, 50 and 70% in volume of the filling capacity of the mixer working 
vessel. The granulation liquid was added using a peristaltic pump under constant addition 
speeds, two main ones set at 38 and 50 g.min-1. The total amount of blend was mixed for 5 
minutes inside the mixer with an impeller speed of 452 rpm. After the mixing time, the liquid 
addition and the power consumption measurement were started simultaneously. During the 
whole process the main impeller and chopper speeds were kept constant at 430 and 3000 
rpm, respectively. The temperature inside the mixing vessel in the moment of sampling was 
also measured. 
 
7.2.3 Power consumption profile recording 
 
An “in process” computer calculation program was used to record the power consumption 
(P.C.) profile during all granulation experiments. The power consumption of the mixer motor 
(i.e. main impeller) was determined by the electric current consumption of the motor 
according to the equation P = U x I, where P is the power (W), U the electric potential (V), 
and I is the electric current (A). The product of electric potential (V) times electric current (A) 
is measured by a measuring transducer (Sineax Type PQ 502, 0–2kW, Camille Bauer AG, 
Switzerland). The power consumption is converted into an electric potential signal between 
0 and 10V, 10V corresponding to 2 kW and sampled by an I/O Multifunction DAQ-Card 
connected to a laptop computer and displayed graphically by the Recorder Software 
(produced in co-operation with Pharmatronic Ltd, Switzerland) (Betz et al., 2003). 
 
7.2.4 Granules characterization 
 
Samples were taken at predetermined time intervals and its residual moisture was 
immediately determined thermogravimetrically (Mettler-Toledo LP16M balance, Mettler 
Instruments). The loss of moisture was calculated in percent by weight. The drawn samples 
were dried in a dish dryer at 40°C for around 10 hours before sieve analysis, which was 
carried out in ISO-norm sieve oscillator type equipment (Rietsch, Germany). The eight 
selected sieves ranged from 1000 µm to 90 µm mesh. The particle-size distribution 
percentage was calculated by the ratio of cumulative sieves and total sample weight. In this 
study, the desired granules particle size, also called target granules (T.G.), was set between 
125µm and 710µm, i.e., cumulative weight from sieves 125µm to 500µm. 
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7.2.5 Calculations of Liquid Saturation and Power Number 
 
The formulations studied differ in composition and batch size and as a consequence also 
vary in the amount of granulating liquid required. In order to facilitate the comparison 
between measurements, three ways to calculate the liquid saturation were investigated and 
compared. 
A dimensionless amount of granulating liquid pi, which can be defined as the degree of 
saturation of the interparticulate void space between the solid materials (Leuenberger and 
Imanidis, 1986):  
 
pi = (S – S2) / (S5 – S2)             (Equation 1) 
 
where S is the amount of granulating liquid (in liters) to a desired point, S2 the amount of 
granulating liquid (in liters) necessary, which corresponds to a moisture equilibrium at 
approximately 100% relative humidity (the end of phase I in power consumption profile), 
and S5 is the complete saturation of interparticulate void space before a slurry is formed, 
corresponding to MAX in the profile (amount of liters). Power consumption measurements 
are used as an analytical tool to define S values for different compositions. Thus, the 
granule formation and granule size distribution can be analyzed as a function of the 
dimensionless amount of granulation liquid pi.  
 
The moist agglomerates can exist in the following three states, based on the amount of the 
liquid they contain: the pendular state, the funicular state, and the capillary state, as 
described before (see item 6.1). The three states can be distinguished by the relative liquid 
saturation of the pores S, which is the ratio of pore volume occupied by the liquid to the total 
volume of the pores available in the agglomerate. Agglomerates are in the pendular state 
when the liquid saturation of the pores S<25%; in the funicular state when S is between 
25% and 80%; and in the capillary state when S>80% (Gokhale, 2005). Following this 
thought, the liquid saturation S is determined by the amount of binder solution and the 
intragranular porosity, which can be calculated based on the following equation (Kristensen 
et al., 1984): 
                                         (Equation 2) 
 
where H is the ratio of the mass of liquid binder to the mass of solid particles, ε is the 
intragranular porosity, and ρ is the particle density of the feed material.  
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Also the dimensionless group pi2, specific amount of granulation liquid, according to 
Buckingham’s theorem (Buckingham, 1914), was calculated: 
 
  pi2= q.t / V.ρ                              (Equation 3) 
 
Where ρ is specific density of the particles, q is the mass (kg) of granulating liquid added 
per unit time, t is the process time, and V the volume loaded with particles (Leuenberger, 
2001). 
 
For better understanding of the process the dimensionless Power Number (pi1), that is 
applied to analyze process similarities between different scales and represents a measure 
of power requirement to overcome friction in fluid flow in a stirred reactor, was calculated 
according to the following equation (Leuenberger, 1979): 
 
pi1= P / r5.ω3.ρ                                              (Equation 4)             . 
 
where P is the power consumption (kg m2/s3), r is the radius of the impeller blade (m), ω is 
the angular velocity (rad/s)* and ρ is the specific density of the particles (kg/m3). In a first 
approximation, it was neglected the effect of the addition of granulating liquid on the bulk 
density of the powder mixture. Thus the bulk density of the dry mixture was used in the 
calculation. 
 
*(ω= 2.pi.ƒ where ƒ is the frequency in revolutions/s) 
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8 Results and discussion 
8.1 Characterization of starting material 
 
The physical properties of the compounds are compiled in Table 8.1.1. The mean particle 
size of PCM was smaller than other compounds. The hydrophobic property of PCM was 
confirmed by the very low residual moisture, 0.08% by loss on drying. The residual moisture 
content of MCC was 4.23%. The true density of PCM was much smaller than MCC, but the 
bulk and tapped densities were bigger. The porosity of PCM was also smaller compared to 
MCC, 64% and 78%, respectively. 
The Compressibility Index showed that the mixture of 90%-wt. PCM had a very poor ability 
to flow. The 50%-wt. PCM formulation presented a poor flowability and the 10%-wt. drug a 
passable one. For poorer flowing materials, there are frequently greater interparticle 
interactions, that is calculated when a greater difference between the bulk and tapped 
densities is observed (USP 31, 2009). 
 
Table 8.1.1:  Characterization of MCC, PCM, HPMC and the three dry mixtures in % w/w 
(drug/excipients). 
  
 
The percentage by volume of each compound in each formulation is shown in table 8.1.2. 
 
Table 8.1.2: Percentage by volume of each compound. 
  
MCC  
(% v/v) 
PCM 
(% v/v) 
HPMC 
(% v/v) 
Mix 1 (10% drug w/w) 85.95 11.76 2.27 
Mix 2 (50% drug w/w) 43.41 54.47 2.10 
Mix 3 (90% drug w/w) 6.73 91.30 1.96 
 
 
From the Scanning Electron Microscopy images (see Figures 8.1a e 8.1.b) could be more 
clearly seen the morphology difference between PCM and MCC particles; the long porous 
fibres that awards a high superficial area to MCC particles in contrast with the very smooth 
surface of the more regular shaped particles of paracetamol.  
 
Mean 
particle 
size (µm) 
Residual 
Moisture 
(%) 
True 
Density 
(g/cm3) 
Bulk 
Density 
(g/cm3) 
Tapped 
Density 
(g/cm3) 
Powder 
Porosity 
(%) 
Other Properties 
(Rowe et al., 2006; WHO, 
2005)
 
MCC 101 81.88 4.23 1.5385 0.344 0.417 78 hygroscopic 
Paracetamol 79.66 0.08 1.2769 0.463 0.560 64 hydrophobic (1:70) 
HPMC 113.33 5.9 1.3217 0.341 0.557 74 hygroscopic 
              
Compressibility Index 
Mix 1 (10% drug) - 4.09 1.5028 0.340 0.439 77 22.62 
Mix 2 (50% drug) - 2.17 1.3914 0.354 0.485 75 27.06 
Mix 3 (90% drug) - 0.62 1.2954 0.367 0.568 72 35.37 
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      Figure 8.1.a: SEM of MCC 101  Figure 8.1.b: SEM of Paracetamol 
 
8.2 Liquid Saturation 
 
As demonstrated by Gokhale (2005), the relative liquid saturation of the pores S shows that 
only the target granules from mixtures of zero and 10% (w/w) drug content were in the 
funicular state when sampled. For the other mixtures, the desired granules were found at 
pendular state (i.e., S<25%). The intragranular porosity varies during granulation; and the 
porosity of the dry mixture was used for the calculation of S, what can lead to an imprecise 
calculation. When the powder dissolves partly or totally in the liquid, the relation becomes 
invalid because the porosity of the particles, the intra granular void space and hence its 
density, change. However, it is valid to conclude that the agglomeration of high load 
paracetamol formulations began at very low liquid saturations in contrast to the 
agglomeration of high MCC content mixtures (See table 8.2). 
 
The physical properties of the powder strongly affect the liquid saturation, influencing the 
amount of liquid penetration and the free surface liquid which is necessary for the 
coalescence of primary particles and/or agglomerates. The relation between the median 
diameter of the agglomerates of the four formulations and the amount of granulating liquid pi 
is plotted in Figure 8.2. Evidently the regression lines shift to smaller pi values with 
increasing percentage of paracetamol. While formulations with 10% (w/w) drug requires a 
dimensionless amount of granulating liquid pi of about 59% for significant granule growth, for 
90% (w/w) drug content it proceeds at less than 25% liquid saturations.  
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Granule median diameter as a function of the granulating liquid
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  Figure 8.2: Granule median diameter as a function of the granulating liquid pi. 
 
 
Looking at Table 8.2, the ratio Liquid/Solid (H) in the moment of maximum power 
consumption (MAX) was found in the range of 1.21 - 1.35 for the formulations containing 
10% drug, 0.78 - 0.85 for 50% drug and 0.26 - 0.38 for 90% drug formulations, revealing a 
big difference in the total amount of water used to fully saturate the three systems. The 
liquid saturation S at MAX was in the range of 0.53 - 0.59, 0.37 - 0.40 and 0.14 - 0.19 for 
formulations of 10, 50 and 90% (w/w) drug, respectively. For the specific amount of 
granulation liquid, pi2, the values at MAX ranged from 0.28-0.32, 0.21-0.25 and 0.06-0.11 for 
the formulations of 10, 50 and 90% (w/w) drug, respectively. 
 
Interestingly, the ratio H/S at was found to be constant for all experiments with same 
formulation; being 2.3 for 10% drug, 2.1 for 50% drug and 2.0 for 90% drug formulations. 
The ratio was independent of the batch size or liquid addition rate. 
 
At the moment of the target granules (T.G.) the relative liquid saturation of the pores S drew 
small values ranging from 0.33-0.41, 0.18-0.25 and 0.05-0.09; pi and pi2 were 0.50-0.63 and 
0.16-0.21, 0.43-0.51 and 0.10-0.14, 0.13-0.36 and 0.03-0.05, respectively for the 
formulations with 10, 50 and 90%-wt. drug.  
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Table 8.2: Summary of experiments and its liquid saturation calculations at the relevant points: 
Target Granules (T.G.) and maximum power consumption (MAX). 
 
% drug  
in the 
formulatio
n (w/w) 
batch 
size 
[kg] 
liquid 
addition 
rate 
[g/min] 
water at 
moisture 
equilibriu
m S2 
[liters] 
 
H (mass 
Liq/Solid) 
at T.G. 
S (Liquid 
Saturatio
n) at T.G. 
pi
  
(at T.G.) 
pi2  
(at T. G.) 
H (mass 
Liq/Solid) 
at MAX 
S (Liq 
Saturatio
n) at 
MAX. 
pi2        
(at MAX) 
0 0.50 25 0.18  1.00 0.53 0.43 0.29 2.20 1.03 0.54 
0 1.20 38 0.34  0.65 0.30 0.30 0.16 1.48 0.69 0.39 
0 2.00 38 0.49  0.97 0.45 0.47 0.24 1.79 0.83 0.47 
                       
10 1.20 38 0.38  0.80 0.35 0.50 0.18 1.30 0.57 0.32 
10 2.00 38 0.46  0.93 0.41 0.63 0.21 1.35 0.59 0.32 
10 2.40 38 0.46  0.86 0.38 0.59 0.19 1.31 0.58 0.30 
10 2.00 50 0.35  0.84 0.37 0.59 0.18 1.30 0.57 0.31 
10 2.40 50 0.50  0.76 0.33 0.55 0.16 1.21 0.53 0.28 
                       
50 1.20 38 0.23  0.52 0.25 0.51 0.14 0.84 0.40 0.25 
50 2.00 38 0.23  0.43 0.20 0.43 0.11 0.84 0.40 0.21 
50 2.40 38 0.15  0.38 0.18 0.44 0.10 0.78 0.37 0.22 
50 2.40 50 0.20  0.46 0.22 0.49 0.11 0.85 0.40 0.22 
                       
90 1.20 25 0.11  0.17 0.09 0.32 0.05 0.36 0.18 0.11 
90 1.20 12.5 0.10  0.15 0.08 0.21 0.04 0.38 0.19 0.11 
90 2.00 16 0.11  0.10 0.05 0.13 0.03 0.38 0.19 0.10 
90 2.40 16 0.11  0.15 0.08 0.36 0.04 0.34 0.18 0.08 
90 1.20 38 0.11  0.13 0.06 0.13 0.04 0.34 0.17 0.09 
90 2.00 38 0.15  0.13 0.07 0.23 0.04 0.30 0.15 0.09 
90 2.40 38 0.15  0.12 0.06 0.23 0.04 0.32 0.16 0.09 
90 2.40 50 0.15  0.13 0.06 0.31 0.04 0.26 0.14 0.06 
 
 
Considering MAX as 100% saturation of the entire particulate system (and also considering 
that the addition of the liquid was at constant rate) for the formulations containing 90% drug, 
the moisture equilibrium at 100% relative humidity (S2) was reached at 22.40% of system 
saturation and the target granules at 42.37%, in average. For the formulations with 50% 
drug the values were 12.54% and 50.64% for S2 and at the target granules point, 
respectively. As well as the system saturation value was 16.59% at S2 and 62.24% at target 
granules for 10% drug formulations. 
 
The rate of granule breakage is a consequence of the freshly formed granules strength, 
what is related to the liquid penetration, as showed by Dries and Vromans (2009). All values 
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calculated of liquid saturation confirm a smaller liquid penetration when increasing the 
amount of paracetamol; what was also shown by the values of residual moisture of the 
agglomerates when they were sampled. These values were in average 45.76%, 30.36% 
and 11.35%, in the moment of T.G., for the 10, 50 and 90 percent drug content mixture, 
respectively. 
 
8.3 Comparison of the power consumption profiles of three different 
formulation mixtures: the effect of a poor water soluble drug load 
 
The amount of drug in the formulation had a strong influence on how the power 
consumption profile looked like (Figures 8.3.1 and 8.3.2). In a concentration of 90% weight 
of the total formulation, the physicochemical properties of paracetamol were predominant in 
the mixture environment and in granules formation. The phase I of a typical profile could 
briefly be seen in these formulations, indicating a very fast saturation in the moisture 
content of the components, followed by a more accentuated and well-defined s-shaped 
ascent in phase II, compared with other formulations. The ascent slope represents the 
powder agglomeration and granule growth. 
 
The hydrophobic behaviour of paracetamol molecule (Log Pow: 0.49) probably permitted that 
the water molecules entering the system become more available for inter-particulate 
interactions (Omar et al., 2006). Another factor was that there aren’t significant internal 
pores in the primary particles to fill (attested by the low values of liquid used to reach the 
powder moisture equilibrium (S2): 0.10-0.15 liters). Therefore, agglomeration took place 
faster compared with low drug load formulations, even for bigger batches. The time for the 
entire system to change from a powder bed to an overwetted mass was shorter for 
formulations containing higher amounts of drug.  
 
Due to the PCM hydrophobicity, hence the elevated water available, both the total amount 
of water used in the granulation (look at the values of H, S and pi2 for MAX) and the granules 
residual moisture presented much smaller values compared with the others systems. It was 
overwetted at reduced liquid concentration (see section 8.2 and table 8.2). 
 
C H A P T E R  I I  –  R E S U L T S  A N D  D I S C U S S I O N  
 
Elaine Darronqui 
 
- 111 -
0
200
400
600
800
1000
1200
1400
1600
1800
2000
-0.20 0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00
Dimensionless amount of granulation liquid (pi)
Po
w
er
 
Co
n
su
m
pt
io
n
 
(w
at
ts
)
 98% MCC (w/w)
 10% drug (w/w)
 50% drug (w/w)
 90% drug (w/w)
 
Figure 8.3.1: Power Consumption measurement of four different mixture proportions at 
same batch size (2kg) and constant liquid addition rate (38 grams per minute). 
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Figure 8.3.2: Power Consumption measurement of tree different mixture proportions at 
same batch size (2.4kg) and constant liquid addition rate (38g per minute). 
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Reduced values were also found for the power consumption for formulations containing 
increased amounts of paracetamol. Considering that power consumption values are 
correlated with the cohesion of the powders inside the mixer vessel and also its contact with 
the vessel walls and impeller blade, the results showed that the higher drug load formulation 
presented weaker interparticle interactions, smaller cohesiveness and resistance to impeller 
movement. The plateau found in the phase III of the P.C. profile indicates that this 
formulation presented equilibrium between granule growth and breakage, maybe due to 
crumb behaviour (Iveson et al., 2001). Consequently, the power consumption did not 
increase but showed an almost constant level until overwetting was reached. 
 
In a granulation experiment using the high hydrophobic lubricant magnesium stearate, 
Pepin et al. (2001) observed in the P.C. profile only a very long phase I, until a very clear 
overwetting point was reached and the powder mass became a paste. 
 
On the other hand, by decreasing the amount of the poor water soluble drug and increasing 
the amount of the hygroscopic microcrystalline cellulose the total amount of water 
necessary to reach the desired granules size and for overwetting the system increased 
dramatically (values of H, S, pi and pi2 at table 2), as well as the granules residual moisture.  
 
MCC has the capacity of adsorbing water on its large and very porous surface area, making 
necessary the addition of more water to create the liquid bridges between particles that 
promote granules formation. What was confirmed by the higher values of liquid used to 
reach the powder moisture equilibrium (0.35-0.50 liters for mixtures with 10%-wt drug); and 
visualized by the more extended phase I in the PC profile. 
 
The constant increase in power consumption for formulations with high content of MCC is 
probably caused by a further coalescence of particles. The high liquid saturation generated 
by the continuous addition of liquid brings MCC into a degree of plasticity that facilitates 
successful collisions, then keeping the granule growth. The time to reach MAX was longer 
and the temperature inside the mixer also higher compared with other mixtures. 
 
For the formulations with a mixture of PCM/MCC 54.40/43.41 (% v/v) the power 
consumption profiles were more similar to formulations with 90%-wt excipients than for 
formulations of 90%-wt drug, showing the likely predominance of the MCC growth kinetics 
on the mixture agglomeration behaviour. Leuenberger and Usteri (1989) explained in a 
previous work the kinetics of binary mixtures agglomerate growth. Even that the MCC 
particles are surrounded by the PCM ones, it still dominating the granulation process at this 
concentration.  
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8.4 Influence of the mixer bowl filling (mixer load) in the power consumption 
profile: scale-up invariants. 
 
The mixer bowl filling strongly affects the particles’ flow pattern and how they collide and 
interact. In this study the possible interferences of wall adhesion and wall, lid or blade build-
up were neglected, although the applique of an anti-adherent material over the surfaces is 
recommended. 
 
The absolute power consumption values (watts) were directly proportional to the batch size, 
for all formulations. As the load increases, so does the current draw of the motor. 
 
Differences in the absolute MAX value could be noticed from batch to batch (Figure 8.4.1 
and 8.4.2). The reason probably lies on the differences in total wet mass volume and faster 
saturation of the powders for small batches, once that the liquid addition rate was kept 
constant. Nevertheless, the values found were very proportional to the scale up of the 
batches; and their profile phases are presented similarly. Also the granulation liquid 
requirement was linearly dependent of the mass loaded. In previous works of the research 
group in Basel, it was reported that the P.C. profile, as defined by the parameters S3, S4, 
S5 (Leuenberguer, 1983, 2001) or MAX (Betz et al., 2003, 2004), is independent of the 
batch size. 
 
When the batch size was changed but the liquid addition was kept constant for each 
formulation, similar profile phases could be found, but with a shift in time and absolute MAX 
value (Figures 8.4.1 and 8.4.2). However, when the rate of liquid addition was enhanced in 
proportion to the batch size, the characteristic phases I, II and III of the power profile 
appeared within the same range of time (Figure 8.4.3). That was an evidence of an invariant 
moment of the scale-up and could serve as an in-process control. 
 
For batches of 2000 grams, corresponding to approximately 60% of the equipment filling 
capacity, the typical Leuenberger phases of power consumption curves were easily 
visualized.  
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Figure 8.4.1: Power Consumption measurement of three batch sizes of the mixture 
containing 90% (w/w) drug and constant liquid addition rate (38 grams per minute). The 
percentual volume that the batch represents in the total filling of the working vessel is 
shown in brackets. 
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Figure 8.4.2: Power Consumption measurement of tree batch sizes of the mixture 
containing 50% (w/w) drug and constant liquid addition rate (38 grams per minute). The 
percental volume that the batch represents in the total filling of the working vessel is 
shown in brackets. 
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The batch size should not be too big in relation to the capacity of the mixer, so that powder 
particles can be properly fluidized by the impeller blades and an optimal mixing of the 
ingredients with binder can be achieved, neither so small that it can lead to high loss due to 
wall deposition, powder segregation during mixing, or the changes in powder cohesiveness, 
which are not easily measurable or reflected by the impeller movement. 
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Figure 8.4.3: Power Consumption measurement of tree batch sizes of the mixture 
containing 90% (w/w) drug and liquid addition rate (25, 38, 50 grams per minute) 
enhanced proportionally to batch size. The percental volume that the batch represents 
in the total filling of the working vessel is in brackets. 
 
As presented by Faure et al. (1999), there is a limit to scale-down that corresponds to the 
point where the wall adhesion and friction effects start to dominate. It is indeed impossible 
to scale-down while conserving both geometric similitude and a constant ratio of wall 
surface to bowl volume. Dynamic similitude did not occur since wall adhesion seriously 
affects the flow pattern of the wet mass (Faure et al., 1999).  
 
8.5 Effect of the liquid addition rate on the power consumption profile 
 
The liquid addition rate slightly influenced the total amount of water used in the process. As 
remarked by Holm et al. (1985b), it is necessary to keep in mind that liquid flow rate and 
process time are interrelated and that low liquid flow rate favours compaction and, hence, 
an increasing liquid saturation. 
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In most of the experiments, the amount of liquid necessary to reach the desired granules 
size and the maximum in power consumption was slightly higher with decreased rate 
addition. This was confirmed by the values of H shown in table 8.2. It could be due to more 
liquid binder droplets penetrating into the material structure by capillary flow and/or some 
water evaporation happening during longer processes. 
 
Liquid addition rate, as well as the impeller speed, influence linearly the granulate growth 
rate (Leuenberger, 1982; Leuenberger and Imanidis, 1986; Vonk et al., 1997). In the 
formulations containing 10 and 50 percent of drug with the increase in the liquid addition 
rate the plateau phase became less visible, sometimes disappearing for the higher addition 
rate. In the higher liquid addition rates the entire profile appears as a single ascent slope 
(Figure 8.5.1). In contrast, for the 90 percent drug formulations the ascent curve (in phase 
II) and the plateau (phase III) are very evident. In some experiments, specially the ones with 
bigger batch sizes, a non clear delimitation among the phases III, IV and V was present 
(Figure 8.5.2). Vide comments at section 8.3. 
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Figure 8.5.1: Power Consumption measurement of the mixture containing 50% (w/w) 
drug, batch size of 2.4 kg (67.79% in volume of the equipment filling capacity) and liquid 
addition rates of 38 and 50 grams per minute.  
 
In general, the more notable influence of the liquid addition rate on the P.C. profile was a 
shift in the process time, which became shorter for all formulations and batches with the 
increase in liquid addition rate. This is a relevant point to consider when taking the decision 
of using ‘time’ as a granulation end-point control.  
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Figure 8.5.2: Power Consumption measurement of the mixture containing 90% (w/w) drug, 
batch size of 2.4 kg (65.39% in volume of the equipment filling capacity), and liquid addition 
rates of 16, 38 and 50 grams per minute.  
 
 
The time necessary to reach the maximum power consumption, i.e., 100% saturation of the 
system was shorter for faster addition rates, as well as the absolute power value for some 
experiments. The maximum consumption of energy showed to be slightly smaller with the 
increase in liquid addition rate, probably because of a faster formation of liquid bridges 
between the particles and faster changes in the powder cohesiveness. This finding was 
similar to the one presented by Carius (1992), where he described that already during the 
significant longer spraying phase, agglomeration takes place besides distribution of the 
granulation liquid, and consequently the power consumption increases. 
 
However, when power (watts) is plotted as a function of the degree of saturation (pi) it can 
be seen that at the start of phase III the saturation was smaller for the slower rates of liquid 
addition (Figure 8.5.2). The particles moving inside the high shear mixer are suffering 
consolidation and compaction along the time, reducing the interparticles space to be filled 
up with liquid. 
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8.6 Granule size analysis 
 
The particle-size distribution analysis from specimens collected at different time points of 
the process made it possible to define in which moment of granulation and power 
consumption measurement a higher percentage of the desired particles was produced. The 
desired granules particle size was set between 125µm and 710µm, i.e., cumulative weight 
from sieves 125µm to 500µm, as described in the methods section. Most results are 
discussed but are not shown because of the higher number of experiments and samples 
analyzed. 
 
Microscopic examinations of the granules (Figure 8.6.1) showed that granules sampled 
from a 10% drug formulation had a more uniform texture, with a melted and merged 
appearance, while the 90% drug granules were composed of a number of minor particles 
bound together or immersed in a mass. 
 
   
   
 
Figure 8.6.1: SEM of granules composed of 98% MCC (top left), 10% PCM (top right), 50% 
PCM (bottom left) and 90% PCM (bottom right). 
 
In almost all situations, the median size of the agglomerates could be linearly related to the 
PC value. With increased amounts of PCM, however, the linearity was being lost (Figure 
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8.6.2). To produce similar particle size distribution among the formulations the amount of 
energy used was decreased with increasing drug content. 
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Figure 8.6.2: Absolute power consumption value as a function of the median granule 
diameter 
 
 
In the case of a fixed amount pi of granulating liquid (see Figure 8.6.3), it is interesting to 
note that the granules obtained from 50%-wt. PCM (equivalent to 54.48% of the formulation 
volume) lead to granule size distributions equivalent either to 10% or 0% PCM formulations. 
This can be interpreted based on the predominance of the MCC growth kinetics on the 
mixture agglomeration behaviour (Leuenberger and Usteri, 1989) and percolation theory 
(Leuenberger et al., 1989); i.e., the properties differ for compositions below or above a 
critical ratio pc (percolation threshold) of components between the MCC and PCM. The 
cumulative weight fractions of the binary mixtures at a fixed pi-value presented similarity, but 
it was dependent of the proportion of the compounds. In order to develop robust 
formulations, the theory of percolation should be taken into account and the critical ratios 
must be avoided (Leuenberger, 1999). 
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Cumulative particle size distribution at a fixed normalized amount pi (=0.50) of 
granulation liquid.
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Figure 8.6.3: Cumulative particle size distribution at a fixed normalized amount pi (=0.50) 
of granulation liquid. 
 
The ratio of the mass of liquid binder to the mass of solid particles, H, was in the range of 
0.10 to 0.17 for T.G., considering all experiments with 90%-wt. PCM, showing that a 
significant granule growth could happen at very low liquid saturation for this formulation 
(what can also be seen in figure 8.2 for pi values). In this formulation, capillary forces were 
also probably acting bringing particles together and promoting their adhesion. The values of 
H were higher for increased amounts of MCC in the formulation. In most experiments with 
10%-wt. and 50%-wt. drug formulations, the desired granules were found in the ascending 
slope of the profile. A non-visible well delimited plateau phase in most of those 
measurements could be an explanation for these findings. 
 
For the experiments with 90%-wt drug formulations in higher mixer loads, batches of 2000 
and 2400 grams, the desired granules were found in the ascent of the curve, i.e., in phase II 
of the profile. An exception was the experiment with higher mixer filling and a slowly liquid 
addition rate of 16g/min. For the smaller batch size experiments, the higher percentage of 
desired granules was found in the plateau phase of the P.C. profile, except for the 
experiment with faster liquid addition speed. For the last case, the fast addition of liquid in a 
small amount of powder probably promoted a premature granule agglomeration.  
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It is known that the coalescence of particles is characterized by the exponential growth of 
the mean particle size (Leuenberger and Imanidis 1986; Vonk et al., 1997), so it was 
expected that granules produced in the end of phase III or during phase IV would be bigger 
than the desired size range.  
 
More relevant than where in the profile curve the desired granules appeared is the fact that 
most of them were found in the same range of power consumption value, i.e., independently 
of the spraying rate, for the same formulation and not so different batch sizes, the power 
consumption values were similar in all experiments. It means that a reproducible granulate 
quality can be achieved by stopping the granulation process at a defined power 
consumption value. In another study of process monitoring, it was also concluded that at the 
end of spraying, identical power consumption levels are reached not influenced by spraying 
rates; questioning the conventional time-control (that usually leads to large deviations in 
terms of granulate quality) of granulation  (Carius, 1992). 
 
For reasons of particle size, primary agglomerates made from MCC would be more 
resistant to rupture or breakage than agglomerates made from PCM at the same liquid 
saturation because liquid bridges between particles inside the agglomerates are thicker for 
MCC compared with PCM. Therefore, submitted to the same stress, agglomerates made of 
finer powder will be more fragile, what was testified by the constant increase in P.C. 
measurement for high MCC content formulations opposed to the long plateau phase found 
for high PCM content formulations. 
 
8.7 Conclusion 
 
The drug load showed to be the most influential factor on power consumption measurement 
in this study. To saturate the components moisture content and to fill up the interparticulate 
void space with granulation liquid (reaching 100% saturation of the system) was faster with 
higher poor water soluble drug concentration. The powder properties are a key parameter in 
order to control, and predict, the process. 
 
The range of usable granules could be found in the same range of liquid added, but not 
exactly in the same location in the power consumption curve. When the addition of liquid 
was done faster, the usable granules not anymore appeared in the plateau phase, but 
instead they appeared in the ascent slope of the curve, during stage II. However, the power 
consumption value in the moment of desired granules size was similar among experiments. 
If a conventional time-controlled granulation had been carried out, experiments with an 
under-granulated mass or an over-granulated mass would be found.  
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The time determination of when, i.e., in which moment during granulation process, the 
usable granules are formed also depends on the desired final granules size selected. 
 
The S2 point (beginning of phase II), which is present in all profiles, indicates a well-defined, 
reproducible and invariant moment in the initiation of the agglomerates formation. The 
method of measuring the power consumption is also a useful and reliable analytical tool to 
define S values for different compositions, enabling the direct comparison of the 
agglomeration kinetics by the calculation of the dimensionless amount of granulating liquid 
pi.  
For a better P.C. measurement, the extremes, in all process parameters, should be 
avoided. It can be assumed that the prediction of a specific formulation P.C. profile can be 
done if enough data about the physico-chemical properties of the compounds in the 
formulation is available. A virtual library containing data about the physico-chemical 
properties of drug and excipients (as particle size, specific surface area, water affinity and 
uptake, residual moisture, and so on), and their interaction, could help in this process.  
 
The application of new technologies and sciences as Artificial Neural Network can be a 
useful tool in the studies of prediction of the powder agglomeration behaviour. Further 
experiments in this area are planned. The power consumption method is a valuable 
monitoring tool applicable into the Process Analytical Technology - PAT Initiative (FDA, 
2004) and helps to reach the “Quality by Design”.  
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Third Chapter 
Artificial Neural Networks applied to  
pharmaceutical wet granulation process. 
 
Abstract 
Pharmaceutical formulations are complex systems and are often developed empirically under a high 
time-pressure on the basis of ‘trial and error’ experiments. The situation is complicated further by the 
fact that many pharmaceutical processes are only poorly understood. Thus, the predictability of the 
manufacturing performance is suffering or completely absent. Predicting the future output of very 
complex systems is a difficult task. Adaptive systems however have shown themselves, trained on 
the right data, quite capable of producing good predictions. In this work, six formulation’ and process’ 
parameters were used as inputs, to feed an ANN, named Time, Drug concentration, MCC 
concentration, HPMC concentration, Batch Size and Granulation-Liquid Added. The goal was to 
predict the power consumption profile of a granulation process. Already in the preprocessing step, 
the artificial networks showed to be a helpful tool for data mining, data management and process 
understanding. After training trials, a network called Gamma-Recurrent Hybrid resulted in satisfactory 
predictions for formulations not containing high drug loads. When predicted outputs were plotted 
against the actual results the R2 values were 0.99, 0.95 and 0.26 for formulations of 10%, 50% and 
90% (w/w) of drug, respectively; with an absolute error of 76 (Manhattan error metric). As adaptive 
systems learn from data inputted, and the high drug load formulations presented more irregular 
experimental profiles, this could result in a difficult learning and thus the lack of network precision in 
predict the behaviour of that formulation. The R2 values were better (0.99, 0.98 and 0.99 for 
formulations of 10%, 50% and 90% (w/w) of drug, respectively) when the network (in these cases 
generalized two layer and one layer) was trained using as inputs drug and excipient concentration, 
bulk density, residual moisture, batch size, equipment filling fraction and the granulation liquid 
addition rate; and it was tested the system ability in predict the relevant S2, S3, S4 and S5 points of a 
typical Leuenberger power consumption profile. If an operator, based on the material and process 
properties, could predict those ‘moments’ he could adjust the amount of granulation liquid and stop 
the process at a more precise moment. However, there is simply no substitute for domain 
knowledge, as any result will always need to be interpreted properly. Adaptive systems may build the 
model, but if wrong data is inputted or an unqualified person interprets the output, then they are of 
little worth. 
 
 
 
Keywords 
Artificial networks, adaptive systems, wet granulation process, power consumption, process and 
formulation design, PAT. 
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10 Introduction 
Product development scientists are required to produce robust dosage forms, which may be 
manufactured over a range of scales with minimal time and cost. This need has encouraged 
the development of predictive techniques that may have benefits in reducing the time taken 
to develop suitable formulation and process parameters. Prediction may also have benefits 
in full-scale production if the causes of product variation can be identified and controlled. 
Predictive techniques have been used at many stages of the product development process, 
including selection and optimisation of formulations, prediction of process scale-up 
capability, control of process end-points and predicting the properties of processed material 
(Hardy and Cook, 2003). 
 
Control and optimization of wet granulation process by the pharmaceutical industry is a 
fundamental requirement to guarantee constant product quality but since long time it is still 
unsettled and troublesome. Granulation still remains more ‘an art’, employing operator 
practice, than a science-based approach. More accurate methods need to be developed in 
order to stop granulation when the higher percentage of desired granules size is reached, 
since the particle size distribution is usually wider than the one specified. 
 
Based on a series of investigations carried out by Leuenberger et al. (1979, 1982, 1986), 
granulation power consumption, liquid saturation level and granule particle size were inter-
related, which forms a technical basis to use power consumption as a monitoring tool for the 
characterization of particles within a high-shear mixer. For that is essential to measure the 
total power consumption profile till the state of a suspension is obtained. Then, from that 
profile five phases can be characterized and, defining the start points for each phase, the 
amount of granulation liquid can be calculated. A more detailed description of this control 
strategy is also provided in Leuenberger (1994). 
 
Many mathematical models had been used/created trying to explain the granulation process 
and consequently to model/predict its behaviour (Adetayo and Ennis, 2000; Gantt and 
Gatzke, 2005; Oullion et al., 2009; Tu et al., 2009; Cavinato et al., 2010), i.e. to predict 
powders agglomeration kinetics; a process that depends of many factors. A variety of 
approaches used for prediction and correlation of properties of solid dosage forms are 
reviewed by Hardy and Cook (2003). 
 
One of the major problems consists of the fact that pharmaceutical formulations are 
complex systems and that they are often developed empirically under a high time-pressure 
on the basis of ‘trial and error’ experiments. This procedure can easily lead to a non-robust 
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formulation. The situation is complicated by the fact that in addition many pharmaceutical 
processes are only poorly understood. Thus, the predictability of the manufacturing 
performance is suffering or completely absent (Leuenberger and Lanz, 2005). 
 
Predicting the future output of very complex systems is a difficult task. Adaptive systems 
however have shown themselves, trained on the right data, quite capable of producing good 
predictions. They are consistently better than more traditional methods. Adaptive systems 
can also be used to build a mathematical model that captures the functions and dynamics of 
a real-world system. Such models are very important for analysis, simulation, prediction, 
monitoring and control system design. The biggest difference between adaptive systems 
and traditional system identification methods are that adaptive systems are non-linear, 
giving them an order of magnitude more modelling power (Peltarion© Documentation). 
 
One of the first talks about the application of neural network in pharmaceutical product 
development was done by Hussain et al. (1994). In his report is introduced the concept of 
formulation expert system to predict the in vitro drug release profile from hydrophilic matrix 
tablets. Prediction of a model granulation and tablet system characteristics from the 
knowledge of material and process variables utilizing neural networks were also the basis of 
the work of Kesavan and Peck (1996). They reached satisfactory predictions.  
 
Watano et al. (1997) conducted with high accuracy a granulation scale-up using a 
backpropagation learning neural network, without constructing a mathematical model with a 
complicated non-linear relationship that use a vast amount of experimental scale-up data. 
 
An investigation to describe the degree of data fitting and robustness of an ANN compared 
to classical modelling technique was carried out by Bourquin et al. (1998). Comparable 
results were achieved using both methodologies for data fitting. However, the robustness of 
the models towards outliers was clearly better for the modelling technique. Kesavan and 
Peck (1996) also conducted a comparison between neural networks and regression 
analysis. They concluded that the neural network captured more efficiently the nonlinearity 
of the testing data. 
 
Other examples of using ANN in the pharmaceutical field are its application in the modelling 
of drug release from matrix tablets formulations (Petrovic et al., 2009), in predicting the in 
vivo behaviour of drugs (level A in vitro-in vivo correlation) (Parojcic et al., 2007) and also 
the prediction and/or optimization of microemulsion phase boundaries, in order to minimize 
experimental effort (Djekic et al., 2008). A generalized regression neural network was tested 
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and showed to be a reliable method to validate a fluid bed granulation (Behzadi et al., 
2005). 
 
The pharmaceutical formulation process is highly specialized and requires specific domain 
knowledge and often years of experience. Neural computing, machine learning, knowledge-
based systems and expert systems, derived from research into artificial intelligence, can 
assist in the efficient formulation of products and increase productivity, consistency and 
quality (Rowe and Roberts, 1998a). Those are approaches preconized in the Quality by 
Design initiative that is part of the FDA’s Process Analytical Technology - PAT framework. 
In another words, those new techniques can help companies in the understanding of the 
science behind its processes and demonstrate it. 
 
Prediction of power consumption curve, and an uncritical amount of granulation liquid, on 
the basis of knowledge of the starting materials and process variables has not yet been 
successfully done, and constitute the aim of this work.   
 
Artificial Neural Networks – ANNs 
 
ANNs are computer-based programs that attempt to simulate certain functions of the 
biological brain, such as learning, generalizing, or abstracting from experience. They have 
the ability to discern relationships or patterns in response to exposure to facts (“learning”). 
Adaptive systems, such as artificial neural networks, build models that find the relationship 
between the inputs and the wanted output. Instead of instructing the computer how to do 
something, examples of what need to be done are provided. Providing it with data on 
numeric inputs and informing what outputs are wanted the adaptive system builds the actual 
function autonomously. It follows the learning-by-example paradigm (Peltarion© 
Documentation). 
 
A neural network structure/architecture can be defined as a collection of parallel processors 
connected together in the form of a directed graph, organized such that the network 
structure lends itself to the problem being considered. The neurons in an ANN are arranged 
in a network architecture that may vary depending on the problem being modelled. The 
ANN typically consists of an input layer and output layer interconnected through one or 
more hidden layers, which perform the mapping functions. A typical network diagram is 
shown in figure 10.1. The weights of the various connections are modified through a 
process of training. The most common form of training used for formulation systems is 
supervised backpropagation training, which adjusts the weights of the connections between 
C H A P T E R  I I I  –  T H E O R E T I C A L  S E C T I O N  
 
Elaine Darronqui 
 
- 131 -
neurons by back propagation of errors to bring the predicted output closer to the 
experimental output. Once trained, the ANN can predict the outcome of a set of formulation 
or process variables on product performance and vice-versa (Freeman and Skapura, 1991; 
Hardy and Cook, 2003; Rowe and Roberts, 1998b; Hussain et al., 1994).  
 
 
 
 
Figure 10.1: A schematic representation of the character-recognition problem 
presented in this work. In this example, application of an input pattern on the 
left layer of processors can cause many of the hidden-layer units to activate. 
The activity on the hidden layer should then cause exactly one of the output-
layer units to activate – the one associated with the pattern being identified. 
 
The multivariate nature of pharmaceutical formulations can make ANNs a useful approach. 
 
Genetic Algorithms – GAs 
 
Holland (1975) proposed GAs as an optimization technique for minimizing multimodal 
functions. An optimizer is a batch processor that optimizes parameters of components such 
as blocks and update rules. Adaptation is the process of obtaining optimal weights while 
optimization is the process of finding the optimal configuration parameters for a system in 
order for it to be able to find a set of optimal weights.  
 
The GA draws inspiration from the process of natural selection as seen in nature where only 
the fittest individuals of a population survive. It uses three processes namely, selection, 
reproduction and mutation. These processes work to transform one population (generation) 
into the next, as figure 10.2 shows. Any implementation of a GA begins with the generation 
of an initial population of points inside the given search space. Each point is referred to as a 
chromosome. Then, each chromosome is evaluated independently of other chromosomes 
using a fitness function. This function, which is equivalent to a cost function, assigns fitness 
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values to each chromosome such that the “healthiest” ones have larger values. The next 
step of the algorithm, called Selection, creates an intermediate population by selecting the 
fittest chromosomes of the current population. Once the intermediate population has been 
formed, reproduction takes place. Reproduction mimics biological mating by randomly 
selecting members of the intermediate population and exchanging information between 
them. Next, mutation takes place. The process serves to add small perturbations to the 
newly generated strings and ensure that all parts of the search space are reached. It also 
helps the algorithm escape from local minima (Ocloo and Edmonson, 2008). 
 
GAs work best for large, unknown, search spaces. Although GA has the advantage of being 
able to search large domains and escaping local minimas, its primary disadvantage is its 
high computational cost, due the need to compute 
fitness values for all chromosomes in the population 
during each and every iteration (Ocloo and 
Edmonson, 2008). 
 
GAs can be applied alone. It is an artificial 
intelligence technique itself, and may be more 
effective than ANNs in finding solutions for certain 
problems. Turkoglu et al (1999) predicted the effect 
of formulation and process variables on tablets 
produced using a roll compaction process.  
 
Nevertheless, in this work it was only applied as an 
optimizer batch processor.  
 
  
Figure 10.2: Flow of a Genetic Algorithm (extracted from Ocloo and Edmonson, 2008). 
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11 Materials and Methods 
11.1 Granulation materials 
Microcrystalline Cellulose (MCC101, Pharmatrans Sanaq AG), Paracetamol (Mallinckrodt 
Pharmaceuticals) and Hydroxypropylmethylcellulose (Methocel K100, Dow Chemical) were 
used to prepare three different mixtures (different ratios of drug/MCC) in different batch 
sizes.  
 
11.2 Characterization of starting material 
The particle size distribution of the starting materials was analyzed by laser diffraction 
(MasterSizer X Long Bed, Malvern Instruments, UK). The measurement was performed 
using the Manual Dry Powder Feeder, and the obscurity was set around 20%. For the 
moisture content, ‘loss on drying’ was determined thermogravimetrically (Mettler-Toledo 
LP16M, Mettler Instruments, Switzerland). Before and after granulation, specimens of 1 to 2 
g were heated up at 105°C for 20 minutes. The loss of moisture was calculated in percent 
by weight. True density ρt was determined using a Helium Pycnometer (AccuPyc 1330, 
Micromeritics Instruments Corporation, USA). Bulk and Tapped Densities (ρbulk and ρtap, 
respectively) were determined according to U.S. Pharmacopeia 31, using the apparatus 
Type STAV 2003, Engelsmann AG, Germany. Powder porosity (ε) was calculated using the 
true and bulk densities, according to the formula ε = 1 - ρbulk/ρt. (More detailed explanation 
about the methods is given in the first chapter of this thesis) 
 
11.3 Granulation Design and Procedure 
Three main formulations containing Microcrystalline Cellulose (MCC) and Paracetamol 
(PCM) in different proportions were produced. The percentage of drug in the total 
formulation was zero, 10%, 50% and 90% (by weight). In all formulations 2% of 
Hydroxypropylmethylcellulose (HPMC) was added as a dry binder into the mixture, and the 
granulation liquid was distilled water. A lab scale Diosna® P10 high-shear mixer (Dierks & 
Söhne, Osnabrück, Germany) with a volume of 10L was used. Three batch sizes were 
chosen: approximately 30, 50 and 70% in volume of the filling capacity of the mixer working 
vessel. The granulation liquid was added using a peristaltic pump under constant addition 
speeds, two main ones set at 38 and 50 g.min-1. The total amount of blend was mixed for 5 
minutes inside the mixer with an impeller speed of 452 rpm. After the mixing time, the liquid 
addition and the power consumption measurement were started simultaneously. During the 
whole process the main impeller and chopper speeds were kept constant at 430 and 3000 
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rpm, respectively. The temperature inside the mixing vessel in the moment of sampling was 
also measured. 
 
11.4 Power consumption profile recording 
An “in process” computer calculation program was used to record the power consumption 
(PC) during all granulation experiments. The power consumption of the mixer motor (i.e. 
main impeller) is determined by the electric current consumption of the motor according to 
the equation P = U x I, where P is the power (W), U the electric potential (V), and I is the 
electric current (A). The product of electric potential (V) times electric current (A) is 
measured by a measuring transducer (Sineax Type PQ 502, 0–2kW, Camille Bauer AG, 
Switzerland). The power consumption is converted into an electric potential signal between 
0 and 10V, 10V corresponding to 2 kW and sampled by an I/O Multifunction DAQ-Card, to a 
laptop computer and displayed graphically by the Recorder Software (produced in co-
operation with Pharmatronic Ltd, Switzerland) (Betz et al., 2003). 
 
11.5 Characterization of collected samples 
Samples were taken at predetermined time intervals and its residual moisture was 
immediately determined thermo-gravimetrically. The loss of moisture was calculated in 
percent by weight. The drawn samples were dried in a dish dryer at 40°C for around 10 
hours before sieve analysis being carried out in ISO-norm sieve oscillator type equipment 
(Rietsch, Germany). The eight selected sieves ranged from 1000 µm to 90 µm mesh. A 
percentage in the particle-size distribution was calculated by the ratio of sieves cumulative 
and total sample weight. In this study, the desired granules particle size, also called target 
granules (T.G.), was set between 125µm and 710µm, i.e., cumulative weight from sieves 
125µm to 500µm. 
 
11.6 Computation Methods 
From the Synapse© software library different networks were tested and a dynamic snippet 
called Gamma Recurrent Hybrid showed to be the best option (with reduced error) to 
construct the topology of the network for the PC prediction. Suitable for simple dynamic 
problems it is a dynamic neural network that combines gamma and infinite impulse 
response (IIR) memories. The gamma memory block is used in dynamic systems to 
remember past signals. It enables the usage of past information to predict current and 
future states. IIR is infinite and used for applications where linear characteristics are not of 
concern, it operates on current and past input values and current and past output values. 
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Dynamic snippets use memory structures and are for processing time series. It follows a 
supervised learning rule. In supervised learning, each example is a pair consisting of an 
input object and a desired output value (also called the supervisory signal). A supervised 
learning algorithm analyzes the training data and produces an inferred function. As 
mentioned in the introduction, a supervised training adjusts the weights of the connections 
between neurons by back propagation of errors to bring the predicted output closer to the 
experimental output. 
 
The steps implicated in a network design until its deployment are described in the figure 11.6.1. 
  
 
 
 
Figure 11.6.1: Steps of network construction (From 
http://www.peltarion.com/doc/images/ModesChart.png). 
 
As inputs, six formulation properties and process parameters had been used, namely Time 
(minutes), Drug (paracetamol) concentration (% by weight of total formulation), MCC 
concentration (% by weight of total formulation), HPMC concentration (% by weight of total 
formulation), Batch Size (grams) and Granulation-Liquid Added (grams). The output was the 
absolute power value itself (watts). Each feature represents one column and the 
data/values were arranged in the rows and sorted in an ascending order (time sequence). 
As the experimental values were a time series, i.e. they are in time sequence, the order of 
the data is important to avoid that the software when taking a value doesn’t break the 
sequence, leading to a misunderstanding/misinterpretation of the data. Consequently the 
obtained network architecture consisted of six units in the input layer and one output unit.  
 
All experiments were collated in a single excel sheet and converted to a CVS file. From the 
overall data (20 experiments) an amount equivalent to 14.25% was selected for validation of 
the system, it corresponded to 3 experiments. Other 3 experiments (one for each 
formulation) were kept out of the inputted data set in order to be used to test the trained 
system. 
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The presented network was trained by the software Peltarion Synapse© Version 1.3.5 
(Peltarion© Corporation, 2010). It is very important for the training how many samples to 
take in to account for each update of the system parameters, i.e. the batch length; as well 
as the amount of times that the collection of all available samples (rows) enter the system, 
called epoch or iteration (repetition). Preferably the batch length should be chosen so that 
the full length is a multiple of the batch length. Failing to have it can result in samples being 
cropped. Many epochs are usually required to fully train the system. However, for small 
amount of samples the system can become over-trained easily and hence not being able to 
execute reliable generalizations. 
   
The final network topology/architecture is shown in the figure 11.6.2. After conclusion of 
designing step the model was optimized using a Genetic Algorithm optimizer followed by 
further training.  
 
Figure 11.6.2: Gamma-Recurrent Hybrid network topology/architecture (before training). 
 
 
On a second moment, other static networks were tested submitting as inputs formulation 
properties and process parameters such as drug concentration, excipient concentration, 
bulk density and residual moisture of the power mixture, batch size and equipment filling 
fraction as well as the granulation liquid addition rate. It was tested the ability of an adaptive 
system to predict the relevant S2, S3, S4 and S5 points of a typical Leuenberger power 
consumption profile (Leuenberger and Usteri, 1989; Leuenberger and Betz, 2007). The 
networks that resulted in higher values in the R2 coefficient are shown. 
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12 Results and Discussion 
The power consumption profiles, of all 20 experiments, are not shown here (some of them 
can be seen in the chapter II of this thesis). However, as their absolute values were used as 
outputs in this study, it is relevant to mention that for formulations containing 90% (w/w) 
drug the PC curves exhibited wider variation among the experiments compared with other 
formulations.  
 
During the preprocessing step, the correlation visualizer showed the linear correlation 
between features. The correlation between the output and input features is shown in the 
Figure 12.1. This procedure can be seen as a triage stage to see what features affect the 
desired output, as well as to get an overview of the system general behaviour. 
 
 
Figure 12.1: Correlation between the output (absolute power consumption) and 
the inputs (all six features). The higher the bar goes, the more the features are 
correlated. Blue bars indicate a positive correlation while red bars indicate a 
negative correlation. 
 
As can be seen in the figure 12.1 the HPMC concentration has zero relevance over the 
output. That happened due its constant value in all experiments; for that reason it was 
removed from the inputted features since it can only slow down the system. The MCC and 
PCM concentrations had the same level of correlation with the output (PC) but the drug 
concentration was the only feature that affects the output negatively. 
  
  
Figure 12.2: Correlation between the applied amount of liquid and other features (left). And 
correlation between the expended time and other features (right). 
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In both cases shown in the figure 12.2, the MCC and PCM concentrations had the same 
level of correlation with the amount of granulation liquid and the experiment time; however 
the amount of drug presented an inverse correlation with them, as experimentally 
measured. Time was the feature more correlated with the amount of liquid and vice versa.  
 
After optimization and training (batch length of 1 and short training time, resulting in a Mse 
of 3.84e-002), the system was tested and the predicted values for the power consumption are 
plotted in the figures 12.3.a, b and c together with the respective experimental values. 
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Figure 12.3.a) Predicted and Experimental values of power 
consumption versus time for a wet granulation process of a 
formulation containing 10% (w/w) of drug. 
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Figure 12.3.b) Predicted and Experimental values of power 
consumption versus time for a wet granulation process of a 
formulation containing 50% (w/w) of drug. 
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Figure 12.3.c) Predicted and Experimental values of power 
consumption versus time for a wet granulation process of a 
formulation containing 90% (w/w) of drug. 
 
The neural network model produced smoother curves compared with the experimental 
measured ones, what is not so good or intended. As it ‘learns’ from the data supplied, it did 
better prediction for the formulations containing higher amounts of MCC (the ones that were 
more robust during granulation and resulted in more similar energy consumption profiles). It 
was not possible to predict the accentuated slope, plateau and faster drop in the power 
consumption for the higher dose of paracetamol formulations (which ones presented more 
irregular measured profiles what could result in a difficult learning). However, the network 
did predict the decreased absolute values of power for this formulation. The non-linear 
prediction of power consumption could be better if there were other sets of data in the 
training set to indicate such tendency of fast overwetting with the increase in PCM 
concentration, i.e. for a better learning other experiments with additional/intermediate drug 
loads would enclose the design space. 
 
It could also be noticed that extended training times led to an over-trained network (over-
training was identified when the errors of training set and validation set starts to diverge in 
the error visualizer window). An over-trained network loses its ability to make 
generalizations and leads to a bad prediction. Another observation was that bigger batch 
lengths tend to produce smaller errors but not better predictions. 
 
The R2 correlation coefficients between the experimentally measured and the network 
predicted output values are depicted on the figure 12.4.  
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Figure 12.4: Predicted output values plotted against the 
experimentally measured (actual) values. The three different 
formulations used in the prediction studies are shown in the legend.  
 
From the R2 values it is observed that the predicted values for the formulations of 10% and 
50% (w/w) drug were in good agreement with the actual measured values. When 
predictions inside the domain of 90% (w/w) drug formulation where attempted, network 
performance was poor, as shown in the figures 12.3.c and 12.4 (low R2 value). As 
commented above the granulation process for that formulation generated more irregular 
power consumption curves/profiles and that wide variability among the input samples can 
be the reason for the lack of network precision in predict the behaviour of this formulation. 
However, it must be highlighted that a different network, properly trained, may be more 
successful in the power consumption prediction for that formulation. 
 
To test the performance of the trained adaptive system (its statistical validity) the ‘Error 
Analyzer Postprocessor’ tool was used. It also provides a connection to preprocessing 
allowing you to use the information gained by training a system to better understand the 
data. The error has been measured using the Manhattan error metric. Whereby the mean 
absolute error is an average of the absolute errors E = abs (S2 − S1), where S2 is the 
prediction and S1 the true value. The absolute error for the prediction of the power 
consumption value was 76,35 when the system was trained with a batch length of 1 for 
1500 epochs (itineration). The output prediction accuracy of +/- 201.34 (the smallest among 
all networks tested) was within the desired 95% confidence, as shown in the figure 12.5. 
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Figure 12.5: Confidence plot. The purple line is the output of the system; the black line 
is the desired output. The two other lines that enclose the shaded area are the 
confidence limits. 
 
 
The exact resulted values will vary depending on the random order of data and initial 
weights. As systems are initialized with random values they converge to different solutions. 
And problem space not covered by the data can result in great variance in output between 
models (Peltarion© Documentation, 2010). 
 
So the values looked nearly as good as the theoretical limit. Hence the system was quite 
acceptable for its purposes (to predict as the PC profile looks like) with the confidence level 
set to 95% (it means that 95% of the desired outputs should be within the gray area). As it 
starts with random weights when the training starts, it is expected the results will vary.  
 
The measurement of how important a feature is at a certain level is given by a ‘sensitivity 
analyses’. In another words this means that it is possible to see how much the output 
changes if an input feature is changed at certain percentage. In the Figure 12.6.a can be 
seen that a 10% increase in the paracetamol concentration can give a stronger output 
change than a 10% of MCC increase; and the output change is even stronger (quote y-
scale) if the parameters are changed 25% (figure 12.6.b) and 50% (figure 12.6.c).  
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Figure 12.6.a: Sensitivity of the output (power consumption) when the 
inputs (features) are dithered in 10%. The height of the bars is the absolute 
value of the difference between Errororiginal – Errordither. 
 
 
Figure 12.6.b: Sensitivity of the output (power consumption) when the 
inputs (features) are dithered in 25%. The height of the bars is the absolute 
value of the difference between Errororiginal – Errordither. 
 
  
Figure 12.6.c: Sensitivity of the output (power consumption) when the 
inputs (features) are dithered in 50%. The height of the bars is the absolute 
value of the difference between Errororiginal – Errordither. 
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Being careful with the interpretation, sensitivity analysis can give a lot of information about 
the model. Higher sensitivity differences lead to increased error. For example, a change 
from 10 to 25% in MCC concentration did not show a big relevance as a change from 25 to 
50%. Considering the applied liquid variable in this model, the sensitivity analysis states that 
if the changing in concentration is 10% it does not make a big difference, but if it is 25% or 
50% does and so on.   
 
It is important to understand that sensitivity is per model as long as input variables are 
correlated (and in this case, inputs are complex and non-linear). A neural net can choose 
which information it wishes to extract from what features, and that depends on many 
factors, the initial random weights in the network being a major one. This directly impacts 
the sensitivity and two models trained on the same data are unlikely to have equal 
sensitivity (Peltarion© Documentation). In such a way, it would be incorrect to state that 
PCM variable is more important than MCC variable, because this system is non-linear.  
 
 
Another way to work with the granulation power consumption using an ANN was tested. 
Submitting as inputs some formulation properties as drug concentration, excipient 
concentration, bulk density and residual moisture of the power mixture, batch size and 
equipment filling fraction as well as the granulation liquid addition rate, it was tested the 
ability of an adaptive system to predict the relevant S2, S3, S4 and S5 points of a typical 
Leuenberger power consumption profile. Those points were characterized from the 
experimental PC profiles by its respective time values (in minutes).  
 
As these points/values do not represent a long time series, static networks were tested 
once they are less complex and faster. The ones that gave the higher values in the R2 
coefficient are shown in the table 1. They are the generalized one layer and generalized two 
layer. They are extensions of the standard Multi-Layer Perceptron (MLP), a basic static 
feedforward backpropagation neural network. The systems were trained for a very short 
time and using small batches. No optimization was necessary.  
 
The experimental values and their corresponding predicted values are given in Table 12.1.  
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Table 12.1: Powder properties and/or process parameters used as inputs and their 
corresponding experimental measured and predicted results [(time points (in minutes)]. 
 
outputs inputs formulation* S2 S3 S4 S5 R
2
 
network 
[drug] 8 18 29 54 -- experimental 
results 
[MCC] 
A 
8 18 33 57 0.995 Generalized  Two Layer 
bulk density 4 30 45 54 -- experimental 
results 
residual 
moisture 
B 
  6 27 43 57 0.982 Generalized  Two Layer 
batch size 7 14 26 44 -- experimental 
results 
filling 
fraction 
C 
  9 14 24 39 0.999 Generalized  One Layer 
 
*Formulation A, B and C correspond to formulations containing 10%, 50% and 90% (w/w) of drug, respectively. 
 
 
From the R2 values it could be concluded that the prediction of important points (ones that 
represent moments of changes in the agglomeration process) in the power consumption 
curve can be reasonably done. If an operator could predict these moments he could adjust 
the granulation liquid amount to them and to stop the process in a more precise moment. A 
prediction of time moments means a prediction in the amount of liquid to add, if the liquid is 
added at constant rates.  
 
Finalizing, a word of caution should be highlighted. If a person is not qualified to evaluate 
the input variables and to interpret the output variables, then chances of making a mistake 
are big. If not enough domain knowledge about the studied subject is present, can be 
difficult to spot some probe combinations that could never happen in the real world and for 
which the model will give out nonsense. The results for impossible combinations vary 
greatly from model to model. There is simply no substitute for domain knowledge, as the 
results need to be interpreted properly. Adaptive systems may build the model, but if wrong 
data is inputted or an unqualified person interprets the output, then they are of little worth. 
  
13 Conclusion 
 
Predicting the future output of very complex systems is a difficult task. Adaptive systems 
however have shown themselves, trained on the right data, quite capable of producing good 
predictions. They are consistently better than more traditional methods. 
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The optimum structure/topology of the neural network was chosen by its error convergence 
behaviour and its correlation factor with the data obtained by laboratory experiments. The 
prediction of the non-linear curve of power consumption could have been better for the high 
drug load formulation if there were available more sets of data in the training set, i.e. 
experiments with broader ratios of drug concentration. ANN effectiveness is limited by the 
training data selected as well as how the data is introduced to the system and trained. 
Training parameters as batch length and number of epochs makes a big influence in the 
network capacity of generalization. 
 
Another limitation is that, in most of cases, ANNs lack explanation capability and there is 
difficulty in obtaining justification for results. However, such systems can shorten 
development time, simplify formulations, provide the rationale for decisions taken in arriving 
at a formulation, serve as excellent teaching tools for novices, and accumulate and 
preserve the knowledge and experience of experts (Augsburger and Zellhofer, 2007). 
ANN’s are valuable tools that fulfil into the PAT framework, helping in data mining, data 
management and process understanding. 
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15 Thesis Outlook 
Regarding Chapter I, for a better assumption that cellulose type II can be used in pulsatile 
drug release systems further studies using more proportions of it in the core composition, 
being directly compressed or granulated, with different model drugs (including high water-
soluble drugs), as well as dissolution tests representing more precisely the environment of 
drug release, should be done. Stability tests could be realized to guarantee efficiency during 
product shelf-life. The disintegration efficiency/performance of cellulose type II after pass 
through a wet granulation process can also be deeper investigated, as well as its 
performance as a super-disintegrant in the presence of different types and amounts of 
binder, i.e. interactions with other embedding excipients. Experiments with increased 
number of ratios drug/excipients can also help in the investigation of the percolation 
thresholds for this new excipient. Furthermore, the influence of commercial available 
coating suspensions (with its chemical adjuvants) in the water permeation through the 
coating layer can become another study. To increase the accuracy of dissolution models, 
more data points in the first few minutes after coating rupture should be generated. 
 
At Chapter II, the high-shear mixer walls, lid and blade could have been covered with a 
teflon lining to guarantee no powder adhesion. The measurement of all sampled granules 
densities would have offered a more complete monitoring of the changes in density and 
porosity during the granulation process.  It was reinforced that the PC method is an efficient 
method of monitoring the agglomeration process. Powder physicochemical properties 
showed to be an intrinsic part of the PC method and deserve special attention. Inversely, 
measuring the PC can provide scientist with extra information about the powder properties. 
As much as information you collect from a material or process more you are able to 
understand it.  
 
Regarding the use of ANNs in granulation process, on chapter II, it was concluded that its 
functionality has a wide applicability, once that same data can be inputted in different ways 
and/or one can predict same output by using different inputs. For a better network learning 
further experiments with additional drug loads may enclose the entire design space. ANNs 
have some drawbacks such as the lack of explanations and different solutions can be 
generated as the system initialize with random values and weights (the last can be 
overcome, in a close future, by software optimization). ANNs are coming to pharmaceutical 
field to stay as it showed to be not only a tool for prediction but also an interesting and 
useful tool for storage and mining of data. 
